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Abstract 
 
Self-renewal and pluripotency, the hallmarks of human embryonic stem 
cells (hESC), confer these cells with the capacity to expand indefinitely 
while maintaining the ability to differentiate into any cell type of the 
human body; thus, making hESC a valuable source of functional 
differentiated cells suitable for applications in regenerative medicine, 
drug discovery, biotechnology, biopharmaceuticals and developmental 
biology. However, the large-scale production of clinical-grade hESC, 
required for such applications, has been hampered by the current culture 
conditions in which hESC still depend on the use of mouse embryonic 
fibroblast-conditioned medium (MEF-CM) for their efficient growth. 
Therefore, investigation of the factors provided by MEFs is of the utmost 
importance to discover which components of MEF-CM allow the long-term 
expansion of undifferentiated hESC. 
While considerable progress has been made on the identification of the 
protein components of MEF-CM, very little is known about the small 
molecules (metabolites) secreted by MEFs. In this context, an untargeted 
metabolomics method was developed for the investigation of potential 
bioactive metabolites present in MEF-CM implicated in the proliferation 
and/or maintenance of pluripotency of hESC in vitro. 
A metabolomics method was applied and successfully identified a number 
of metabolites which were later confirmed in their identities with the use 
of authentic standards, to be further investigated for their effect on hESC 
culture. Interestingly, the addition of PGE2, 6-keto-PGF1α, 9, 12, 13-
TriHOME, 7-Ketocholesterol and stearidonic acid (the metabolites found 
in MEF-CM) to the unconditioned medium (UM), a medium incapable of 
the maintenance of hESC, showed a delay in apoptosis when compared to 
the negative control UM; thus, suggesting that these metabolites could 
help with the proliferation of hESC. 
Increasing evidence that hESC secrete factors into their 
microenvironment that can also help them to proliferate or to maintain an 
undifferentiated state prompted the application of the same 
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metabolomics method to the analysis of hESC spent culture media. The 
results identified lysophospholipids (LPLs) as potential molecules 
mediating some biological activities; however, the precise role of these 
LPLs still remains to be determined. 
Overall, the results of this thesis are expected to impact and add 
knowledge to the field of stem cell biology providing useful information 
for the creation and development of more efficient and defined culture 
conditions for the propagation of hESC with the appropriate quality to 
realise their widespread application in clinic and other research areas. 
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CHAPTER 1 
General Introduction 
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1 General introduction 
1.1 Human embryonic stem cells 
Approximately 5 to 6 days after fertilisation, the early human embryo 
develops into a hollow sphere of cells known as the blastocyst. The 
blastocyst is formed by an outer layer of cells (the trophoblasts) which 
contains inside a cluster of cells called the inner cell mass (ICM) (Figure 
1-1). Human embryonic stem cells (hESC) are derived from the ICM of 
the blastocyst and have the ability to self-renew in vitro for extensive 
periods of time while retaining their pluripotency (Thomson et al., 1998, 
Amit et al., 2000, Odorico et al., 2001).  
 
 
Figure 1-1 Derivation of human embryonic stem cells. 
 
Self-renewal (the process by which stem cells divide to produce more 
stem cells) and pluripotency (the ability to differentiate into tissues from 
all three germ layers of the body: ectoderm, mesoderm and endoderm) 
are the two fundamental characteristics that make hESC so attractive for 
their application in drug discovery, drug testing, human developmental 
biology studies as well as in regenerative medicine because they 
represent a valuable source of numerous functional differentiated cells 
including neurons (Guan et al., 2001), cardiomyocytes (Gallo and 
Condorelli, 2006), endothelial cells (Levenberg et al., 2002) and 
pancreatic cells (Zhang et al., 2009a). However, the widespread 
morula
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application of hESC has been limited by 1) the undefined conditions in 
which they are grown, making difficult the expansion of the cells in a 
reproducible manner, and 2) the reliance on non-human culture 
components, raising issues regarding animal-pathogen transmission. 
 
1.2 Stem cell culture 
When hESC were derived for the first time from the ICM of the human 
blastocysts, they were cultured over mouse embryonic fibroblasts (MEFs) 
feeder layers using a culture medium supplemented with foetal bovine 
serum (FBS) (Thomson et al., 1998). Under such undefined conditions, 
the large-scale production of hESC, required for their clinical applications, 
becomes difficult to control as the culture components vary from batch to 
batch. Furthermore, the reliance on animal-derived products increases 
the risk of pathogen transmission such as retroviruses and xenoepitopes 
(for example, non-human sialic acid and N-glycolneuraminic acid 
(Neu5GC)) from the culture system to hESC (Martin et al., 2005). 
Therefore, to realize the potential of hESC in clinic, it will be necessary to 
find more defined and animal product-free conditions where hESC can 
proliferate while maintaining their self-renewal and pluripotency 
properties. In culture, hESC require a substrate (supportive matrix), to 
which they will attach and grow, and an environment (culture medium) 
that will provide the correct growth factors and nutrients to keep them in 
an undifferentiated state (Figure 1-2). Thus, in order to obtain a more 
defined culture system, both substrate and culture medium have to be 
optimised. 
 
 
 
 
 
Figure 1-2 In vitro culture requirements of hESC. 
 
Culture medium 
 
Substrate 
hESC 
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1.2.1 Towards definition of the culture system 
As shown in Figure 1-2, the substrate and the culture medium are the 
essential requirements for in vitro hESC growth. Thus, they have been 
the target in the optimisation and definition of the culture system. Since 
the derivation of hESC in 1998, a large number of publications have 
arisen addressing the issue of a more defined culture system. Table 1-1 
summarises the advances made in the field while the major 
breakthroughs are explained in the text below.  
 
1.2.1.1 Optimisation of the substrate 
 
Human feeder cells 
Alternative to MEFs, the use of human feeder layers as substrate was 
introduced by Richards et al. (Richards et al., 2002). They successfully 
cultured and maintained the undifferentiated growth of hESC on human 
foetal muscle, foetal skin and adult fallopian tubal epithelial cells 
(Richards et al., 2002). Additionally, they derived a new hESC line under 
complete animal-free conditions using human serum instead of FBS in the 
medium. Subsequently, other research groups reported the use of other 
human feeders such as human foreskin fibroblasts (Amit et al., 2003, 
Hovatta et al., 2003). The main benefit in the use of human feeders is 
the elimination of animal contamination; however, the culture system still 
remains with an undefined and complex composition and subject to lot-
to-lot variation.  
 
Extracellular matrix and protein-based substrates 
A significant progress in the definition of the substrate was the culture of 
hESC in feeder-free systems. Xu et al were the first to report the use of 
Matrigel, an extracellular matrix (ECM) derived from mouse Engelbreth-
Holm-Swarm sarcoma cells, which supported the cultivation of hESC for 
more than 130 population doublings (Xu et al., 2001). However, the 
system still required the use of medium conditioned by MEFs. This 
conditioned medium (CM) consists in the incubation of hES medium, 
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known as unconditioned medium (UM), with mitotically inactivated MEFs 
for 24 h, after which it is collected and ready to use for feeder-free 
culture, in this case with Matrigel (Figure 1-3), although other feeder-free 
matrices can be used. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Feeder-free culture system of hESC. 
 
Individual Matrigel components such as laminin and collagen IV 
(Kleinman and Martin, 2005) as well as other purified proteins like 
fibronectin and vitronectin have also been shown to support the feeder-
free growth of hESC; and as with Matrigel, these protein-based 
substrates also rely on mouse embryonic fibroblast-conditioned medium 
(MEF-CM) (Xu et al., 2001, Amit et al., 2004). However, there have also 
been reports of their successful use (either alone or in combination) with 
more defined culture media (Liu et al., 2006, Lu et al., 2006, Ludwig et 
al., 2006b, Wang et al., 2007). In spite of being relatively more defined 
and with a more consistent composition than the use of feeder cells, 
these feeder-free substrates still lack a complete chemical definition, 
show chemical variability and their relatively high production costs make 
them unsuitable for the large-scale expansion of hESC (Villa-Diaz et al., 
2013, Celiz et al., 2014). 
hES medium 
inactivated 
feeders (MEFs) 
hESC  
colonies 
Matrigel 
coated plate 
conditioned medium 
after 24 h incubation with feeders  
medium is transferred to hESC in culture 
incubate 
24 h 
incubate 
24 h 
basic fibroblast 
growth factor 
basic fibroblast 
growth factor 
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Table 1-1 Summary of the optimisation of the hESC culture system. 
Substrate Basal medium Supplements Cell lines Reference 
Mouse embryonic fibroblasts DMEM, Gln, BME, NEAA 20% FBS H1, H7, H9, H13 & H14 (Thomson et al., 1998) 
Mouse embryonic fibroblasts KO-DMEM, Gln, BME, NEAA 20% KOSR, bFGF H9.1 & H9.2 (Amit et al., 2000) 
Matrigel & laminin MEF-CM: KO-DMEM, Gln, 
BME, NEAA 
20% KOSR, bFGF H1, H7, H9 & H14 (Xu et al., 2001) 
Human fetal muscle, fetal 
skin, AFT epithelial cells 
DMEM, Gln, Penicillin-
Streptomycin, BME, NEAA 
20% HS, hITS HS-3 & HS-4 (Richards et al., 2002) 
Human foreskin fibroblasts KO-DMEM, Gln, BME, NEAA 15% SR, bFGF H9, I6 & I3 (Amit et al., 2003) 
Human foreskin fibroblasts KO-DMEM, Gln, BME, NEAA 20% FCS, hLIF Isolation from ICM (Hovatta et al., 2003) 
Fibronectin KO-DMEM, Gln, BME, NEAA 15% SR, TGFβ1, LIF, bFGF H9, I6 & I3 (Amit et al., 2004) 
Human foreskin fibroblasts KO-DEME, Gln, Penicillin-
Streptomycin, BME, NEAA, 
20% SR, ITS, bFGF HS293, HS306 & 10 new 
lines 
(Inzunza et al., 2005) 
Matrigel & fibronectin DMEM/F12 bFGF, Wnt3a, April/BAFF, 
albumin, cholesterol, insulin, 
transferrin 
H9 & BG01 (Lu et al., 2006) 
Matrigel, fibronectin, 
laminin, vitronectin & 
collagen IV 
DMEM/F12, Gln, BME, NEAA N2: ITS, progesterone, 
putrescine. B27 supplement, 
bFGF 
H1 & H9 (Liu et al., 2006) 
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Table 1-1 continued 
    
Substrate Basal medium Supplements Cell lines Reference 
Matrigel DMEM/F12, Gln, BME, NEAA N2 or N2/B27 supplement H1 & HSF6 (Yao et al., 2006) 
Matrigel & combination of 
collagen IV, fibronectin, 
vitronectin and laminin 
mTeSR1™: DMEM/F12 BSA, human insulin, human 
holo transferring, bFGF, LiCl, 
TGFβ1, GABA, pipecolic acid 
H1, H7, H9 & H14 (Ludwig et al., 2006a) 
Matrigel  StemPro™: DMEM/F12, 
penicillin, streptomycin, 
BME, NEAA 
BSA, transferrin, ascorbic acid, 
heregulin 1β, bFGF, Activin A, 
LR3-IGF1 
BG01 & BG02 (Wang et al., 2007) 
Laminin-derived peptide MEF-CM  H1 & H9 (Derda et al., 2007) 
Plastic hEL-CM: KO-DMEM, Gln, 
BME, NEAA 
20% KOSR SA167 & AS034 (Bigdeli et al., 2008) 
PE-TCPS MEF-CM: DMEM/F12, BME, 
NEAA, GlutaMAX 
15% KOSR, bFGF HUES7 & NOTT1 (Mahlstedt et al., 2010) 
PMEDSAH MEF-CM, mTESR1™ & 
StemPro™ 
 BG01 & H9 (Villa-Diaz et al., 2010) 
Conjugated heparin-binding 
peptide GKKQRFRHRNRKG 
mTeSR1™ ROCK inhibitor H1, H7, H9, H13, H14 & 
IMR-90-1 
(Klim et al., 2010) 
APMAAm mTeSR1™  H1 & H9 (Irwin et al., 2011) 
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Table 1-1 continued 
    
Substrate Basal medium Supplements Cell lines Reference 
Vitronectin-NC E8™: DMEM/F12 ITS, L-ascorbic acid, bFGF, 
NaHCO3, TGFβ1 or NODAL 
hESC lines: H1 & H9;         
iPSC lines: iPS-imr90, 
iPS-foreskin & iPS-DF19 
(Chen et al., 2011) 
HG21 mTeSR1™  RH1 & H9 (Zhang et al., 2013) 
     
     
DMEM, Dulbecco’s Modified Eagle Medium; Gln, L-glutamine; BME, β-mercaptoethanol; NEAA, non-essential amino acids; FBS, foetal bovine serum; KOSR, Knock Out 
Serum Replacement; bFGF, basic fibroblast growth factor; MEF-CM, mouse embryonic fibroblast-conditioned medium; KO-DMEM, Knock Out DMEM; HS, human serum; AFT, 
adult fallopian tubes; hITS, human insulin-transferrin-selenium; SR, serum replacement; FCS, fetal calf serum; hLIF, human leukemia inhibitory factor; TGFβ1, transforming 
growth factor β1; April, a proliferation-inducing ligand; BAFF, B cell-activating factor belonging to TNF; BSA, bovine serum albumin; LiCl, lithium chloride; GABA, gamma 
aminobutyric acid; hEL-CM, human embryonic lung fibroblast conditioned medium; LR3-IGF1, Long R3-insulin-like growth factor 1; PE-TCPS, plasma etched tissue culture 
polystyrene; PMEDSAH, poly[2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide]; iPSC, induced-pluripotent SC; ROCK, rho-associated kinase; 
APMAAm, aminopropylmethacrylamide; HG, hydrogel. 
N2 supplements contain 1 mM human transferrin (Holo), 8.61 µM recombinant human insulin, 1 mM progesterone, 1 mM putrescine, and 1 mM selenite. The B27 
supplements contain D-biotin, BSA (fatty acid-free, fraction V), catalase, L-carnitine HCl, corticosterone, ethanolamine HCl, D-galactose (anhydrous), glutathione (reduced), 
insulin (human, recombinant), linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, superoxide dismutase, T-3_albumin complex, DL-α-tocopherol, DL-α-
tocopherol acetate, and transferrin (human, iron-poor).  
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Peptide-based substrates 
Following the use of protein-based substrates, polymers functionalized 
with biomolecules (i.e. peptides) have also been shown to support hESC. 
For example, Klim et al conjugated the heparin-binding peptide 
GKKQRFRHRNRKG to an alkanethiol self-assembled monolayer and found 
that hESC cultured on this substrate showed comparable growth rates 
with the Matrigel controls (Klim et al., 2010). Similarly, Derda and 
colleagues employed arrays of laminin-derived peptides which allowed 
hESC to attach and proliferate (Derda et al., 2007); however, the 
medium used in this case was MEF-CM thus resulting in a poorly defined 
system. 
 
Polymer-based substrates 
More recently, a huge improvement in substrate definition has been 
achieved with the use of synthetic polymers. Plasma etched tissue culture 
polystyrene (PE-TCPS) (Mahlstedt et al., 2010), poly[2-
(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl) ammonium hydroxide] 
(PMEDSAH) (Villa-Diaz et al., 2010) and aminopropylmethacrylamide 
(APMAAm) (Irwin et al., 2011) were all able to maintain the pluripotency 
and the long-term growth of hESC. Furthermore, their culture 
performance (growth rates and expression of pluripotency markers) was 
similar to those achieved with Matrigel controls. Although some of these 
substrates (PMEDSAH and APMAAm) demonstrated their utility with 
chemically defined culture media (StemPro and mTeSR1, respectively), 
some others like PMEDSAH and PE-TCPS showed better efficiencies when 
MEF-CM was used (Villa-Diaz et al., 2010, Mahlstedt et al., 2010). 
Nevertheless, synthetic substrates hold the most promising results as 
they are chemically defined, can be synthesised reproducibly, have longer 
stability than biological matrices and are more easily scalable for the 
large-scale production of hESC (Celiz et al., 2014).  
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1.2.1.2 Optimisation of the culture medium 
 
Serum-free medium 
A couple of years after the derivation of hESC using FBS supplementation 
in the medium (Thomson et al., 1998), Amit et al successfully cultivated 
clonally derived hESC cell lines with a substitute of serum commercially 
known as Knock-Out Serum Replacement (KOSR) (Price et al., (1998), 
Amit et al., 2000). This was the first serum-free hESC culture conditions 
reported in the literature. Further, a comparative study demonstrated 
that cells cultured in the presence of KOSR showed better proliferation 
rates when compared with FBS- and human serum-containing media 
(Koivisto et al., 2004). Subsequently, the use KOSR was adopted by 
other research groups as well (Xu et al., 2001, Amit et al., 2003, Amit et 
al., 2004, Inzunza et al., 2005). However, in spite of a relatively more 
defined and with a more consistent composition than FBS, KOSR still 
lacks a complete chemical definition. Furthermore, its animal-derived 
source (bovine plasma) (Price et al., (1998)) makes it incompatible with 
the clinical-grade hESC required in regenerative medicine.  
 
Chemically defined medium 
The development of chemically defined medium (CDM), as this group of 
culture media is called, represented a milestone in the definition of the 
hESC culture medium as they eliminated the use of KOSR and their 
components were chemically known and of high purity. The underlying 
success of CDM was the supplementation of a basal culture medium 
(Dulbecco’s Modified Eagle Medium, DMEM) with recently identified 
factors that promoted self-renewal and/or pluripotency. These factors 
included basic fibroblast growth factor (bFGF) (Xu et al., 2005a), 
transforming growth factor-β (TGF-β) (Amit et al., 2004, Beattie et al., 
2005) and Wnt3a (Sato et al., 2004). In this context several CDM media 
were developed (Lu et al., 2006, Liu et al., 2006, Ludwig et al., 2006b, 
Wang et al., 2007, Yao et al., 2006). However, when tested for their 
ability to maintain a set of 10 different hESC cell lines, only mTeSR1™ 
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(Ludwig et al., 2006a) and StemPro™ (Wang et al., 2007) supported the 
maintenance of most cell lines and produced comparable results with the 
positive control (bFGF- and KOSR-containing medium on MEFs feeder 
cells) (Akopian et al., 2010). For comparison, Table 1-2 provides a list of 
the known components of mTeSR1, StemPro and MEF-CM. 
 
BSA-free medium 
Common to all CDMs listed in Table 1-1 was the use of bovine serum 
albumin (BSA) which, amongst the rest of components, is the only one 
whose composition is not fully defined. Furthermore, its animal origin 
also impedes the use of hESC (cultured with BSA-containing CDM) in 
transplantation therapies. In 2011, the same group that developed 
mTeSR1 medium, by a systematic pairwise re-examination of its 
components, discovered that BSA was no longer necessary when β-
mercaptoethanol (BME), another component of the medium, was also 
excluded (Chen et al., 2011). The resulting BSA-free medium, named 
E8™, supported the undifferentiated proliferation of hESC at comparable 
levels to its predecessor mTeSR1. However, the applicability of E8 was 
only demonstrated with vitronectin VTN-NC variant (Chen et al., 2011) 
which being a biological matrix, makes it prone to batch-to-batch 
variability, less stable than synthetic surfaces and expensive for large-
scale hESC expansion (Villa-Diaz et al., 2013). Nevertheless, E8 is the 
most and truly defined medium of its kind and holds promising results for 
the transfer of hESC from basic research to the clinic. 
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Table 1-2 List of known components of MEF-CM and the two most widely used chemically defined media, mTeSR1 and StemPro. 
 
mTeSR1™ StemPro™ MEF-CM 
  
mTeSR1™ StemPro™ MEF-CM 
Amino acids 
    
Vitamins  
   Glycine    

Ascorbic acid   
L-Alanine    

Biotin    
L-Alanyl-L-glutamine 
 
 

Choline chloride    
L-Arginine   

D-Ca pantothenate    
L-Asparagine   

Folic Acid    
L-Aspartic acid    

i-Inositol    
L-Cysteine   

Niacinamide    
L-Cystine   

Pyridoxal 
 

 L-Glutamic Acid    

Pyridoxine   
L-Histidine   

Riboflavin    
L-Hydroxyproline 
  


Thiamine   
L-Isoleucine    

Vitamin B12    
L-Leucine    

Lipids 
   L-Lysine   

Arachidonic acid 
  L-Methionine    

Cholesterol 
  L-Phenylalanine    

DL-alpha tocopherol acetate 
  L-Proline    

Linolenic acid 
  L-Serine    

Myristic acid 
  L-Threonine    

Oleic acid 
  L-Tryptophan    

Palmitic acid 
  L-Tyrosine   

Palmitoleic acid 
  L-Valine    

Stearic acid 
  
     
Linoleic Acid    
     
Lipoic Acid    
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Table 1-2 continued 
         
 
mTeSR1™ StemPro™ MEF-CM 
  
mTeSR1™ StemPro™ MEF-CM 
Growth Factors 
    
Other Components  
  Heregulin-1b EGF domain 
 

  
D-Glucose (Dextrose)    
Activin A 
 

  
Hypoxanthine Na    
LR3-IGF1 
 

  
Phenol Red    
FGF2  
  
Putrescine 2HCl    
Bovine or Human Transferrin   

Sodium Pyruvate    
BSA: fatty acid free Cohn's fraction V 
  
Thymidine    
GABA 
   
2-Mecaptoethanol   
Lithium chloride 
   
Penicillin 
 

 Pipecolic acid 
   
Streptomycin 
 

 TGF-B 
   
HEPES 
  BSA 
   
Pluronic F-68 
  Insulin 
 


Tween 80 
  AlbuMAX 
  


Reduced glutathione 
 

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In spite of the significant progress made in defining the culture 
conditions, a complete chemically defined culture system (comprising 
both substrate and culture medium) has not been attained. On the one 
hand, the most defined substrates still depend on the use of MEF-CM. On 
the other hand, the most defined culture media still require extracellular 
matrices subject to batch-to-batch variability. Both scenarios indicate a 
lack of understanding of the molecular mechanisms regulating cell 
adhesion, proliferation, self-renewal and differentiation. Furthermore, the 
intracellular and extracellular factors that activate such mechanisms 
remain largely unknown. Therefore, identification of the factors that 
influence hESC behaviour will be pivotal to the development of the 
appropriate combination of substrate and culture medium, with known 
chemistries, that will enable the massive propagation of clinical-grade 
hESC as well as the controlled differentiation of hESC into specified 
lineages, thus providing sufficient functional differentiated cells suitable 
for therapeutics and other applications. 
 
 
1.3 Identification of the factors involved in hESC regulation 
Under feeder-free conditions, hESC depend largely on the use of medium 
conditioned by the feeders; otherwise, they readily undergo 
differentiation (Xu et al., 2001). This indicates that feeders (either 
murine or human) secrete a plethora of factors to the conditioned 
medium that are essential for the long-term expansion of undifferentiated 
hESC. Therefore, investigation of these factors is of utmost importance to 
understanding stem cell biology which ultimately will lead to the creation 
of more defined and controlled conditions for the culture of hESC. 
Several studies have reported the identification of the factors released by 
the feeders; however, most of them have focused on the protein 
components of the CM, as it will be detailed below, while very little 
attention has been paid to the low-molecular weight factors. Because 
small molecules can also activate signalling pathways in hESC (Pebay et 
al., 2005, Kumagai et al., 2013), it will be of equal importance to 
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investigate which small-molecule components are also present in the 
conditioned medium. 
 
1.3.1 Investigation of protein components in CM 
The first MS-based analysis pursuing the discovery of the factors secreted 
by the feeders was carried out by Lim and Bodnar. Conditioned medium 
from MEFs (STO cell line) was analysed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and matrix-assisted laser 
desorption/ionisation-time of flight mass spectrometry (MALDI-ToF-MS). 
Of the 828 proteins that were subjected to mass spectrometry analysis, 
136 were successfully identified and from these only three were 
associated to differentiation and cell growth. The 3 relevant proteins 
identified were insulin-like growth factor binding protein 4 (IGFBP-4), 
pigment epithelium derived factor (PEDF) and secreted protein, acidic 
and rich in cysteine (SPARC) (Lim and Bodnar, 2002). 
A few years later, Buhr et al in addition to analysing the CM from CD1 
MEFs, also investigated the proteome profiles of the MEFs and gelatine, 
the basement on which MEFs were grown (Buhr et al., 2007). By two-
dimensional (2D) SDS-PAGE followed by MALDI-ToF-MS and nano-liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), they identified 
110 unique proteins in MEFs, 23 in the CM and none in gelatine due to 
technical problems. Of the 110 proteins identified in MEFs, only 1% was 
related to signal transduction and another 1% with cell adhesion. The 
rest of the proteins were related to other kind of functions. Comparison of 
the 2D gel patterns of unconditioned and conditioned medium did not 
present any significant differences; therefore, it was not possible to 
distinguish protein candidates that may be able to regulate self-renewal 
or pluripotency. 
Another study analysing the proteins of CM was that of Chin and co-
workers. They compared the serum-free conditioned medium obtained 
from primary MEFs with that from ΔE-MEFs, an immortalised MEF line 
that did not support the undifferentiated growth of hESC (Chin et al., 
2007). Six growth factors (monocyte chemoattractant protein-1, 
interleukine-6, plasminogen activator inhibitor, pigment epithelium 
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derived factor, insulin-like growth factor binding protein (IGFBP)-2, and 
IGFBP-7) were identified in the CM of the supporting feeder cells (primary 
MEFs) which were further tested to investigate their relevance in hESC 
culture. It was found that the addition of the six growth factors to the UM 
delayed the loss of pluripotency; however, they were insufficient to 
maintain the long-term hESC expansion when compared with the positive 
control MEF-CM (Chin et al., 2007). This indicated that other secreted 
factors or components present in the serum supplement were also 
necessary.  
In 2005 Prowse et al published the protein analysis of the medium 
conditioned by human neonatal fibroblasts (Prowse et al., 2005) which 
they further expanded in 2007 with the additional analysis of the CM 
from human foreskin fibroblasts and MEFs (Prowse et al., 2007). The 
comparative study of the CM from the three feeder cell lines identified 34 
proteins in common and significantly increased the number of proteins 
associated with cell growth, differentiation and pluripotency. Some of the 
proteins identified included IGFBP-3, -6 and -7, inhibin β A/activin A, 
follistatin-related protein-1, and SPARC. Amongst these, activin A had 
already documented information of its implication in the maintenance of 
hESC pluripotency (Beattie et al., 2005). 
Bendall and colleagues, by employing an enhanced mass-spectrometry 
approach, increased 10-12 fold the number of proteins previously 
detected in MEF-CM (Bendall et al., 2009). Their iterative exclusion 
methodology which consisted in the repetitive analysis of individual 
samples using successive mass (m/z) and retention time-directed 
exclusion, so that the same peptide ion was not sampled twice for MS/MS 
analysis, allowed the identification of low abundant proteins that were 
usually masked by the high abundant ones and that used to go 
unidentified. As a result, they found 29 growth factor-like proteins in 
MEF-CM which represented approximately 10 times more proteins than 
the 3 previously identified by Lim and Bodnar (Lim and Bodnar, 2002). 
Platelet derived growth factor (PDGF)-α, basic fibroblast growth factor 
(bFGF), hepatoma derived growth factor, glia maturation factor β and 
thymic stromal lymphopoietin were some of the newly identified 
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differentiation and growth factors that had not been previously reported 
by Lim and Bodnar (Lim and Bodnar, 2002) or by Prowse et al (Prowse et 
al., 2007). 
Unlike the proteomics studies discussed thus far that employed mass 
spectrometry for the identification of the proteins in MEF-CM, Talbot et al 
performed a quantitative and semiquantitative immunoassay of the 
growth factors and cytokines produced by STO and CF1 mouse feeder 
cells (Talbot et al., 2012). In pure terms, this immunoassay could not be 
considered a discovery study since Talbot et al targeted proteins that had 
been previously described in the literature (Xu et al., 2005b, Greber et 
al., 2007, Eiselleova et al., 2008). However, the quantitative aspect 
added a deeper understanding of the medium conditioning process and 
provided possible explanations to the varying culture efficiencies 
observed when hESC are grown with CM of different mouse strains (Xu et 
al., 2001). The quantitative antibody-based analysis of Talbot et al found 
that CF1 cells expressed 10 times more activin A than STO cells and also 
produced larger quantities of interleukin-6, IGFBP-2, -3, -4 and -5. On 
the contrary, STO produced more hepatocyte growth factor and stem cell 
factor than CF1 cells (Talbot et al., 2012). These results demonstrated 
that each strain of mouse feeders had different capabilities to condition 
the medium which might be critical for the efficient growth of hESC (Xu 
et al., 2001). 
 
1.3.2 Investigation of small-molecule components in CM 
While the previously described studies have contributed to the 
identification of the protein components of CM, very few reports have 
addressed the identification of the small molecules (metabolites) secreted 
by the feeders which could also be involved in the maintenance of hESC. 
In fact, many of the feeder-secreted metabolites remain largely 
unknown, likely because of the lack of methods focused on their analysis. 
In the current literature only two publications have aimed at the 
identification of the metabolites secreted by mouse and/or human 
fibroblasts during the medium conditioning process. The first one, 
published in 2011, aimed to characterise the metabolites in a medium 
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conditioned by human foreskin fibroblasts (HFFs) (MacIntyre et al., 
2011). The authors in that publication employed a 1H-nuclear magnetic 
resonance (1H-NMR) method to compare the metabolite profile of the 
chemically defined TeSR1™ medium (Ludwig et al., 2006b) before and 
after incubation with HFFs. They found that HFF-CM contained higher 
levels of lactate, pyruvate and alanine than the TeSR1™ medium without 
conditioning (MacIntyre et al., 2011). These increased metabolites 
secreted by HFFs are by-products of glycolysis but their effects on hESC 
proliferation or pluripotency are still unknown. Interestingly, these and 
other less significantly increased metabolites found in HFF-CM were 
mostly those present at higher concentrations, this is one of the 
limitations of NMR methods which lack enough sensitivity to detect low 
abundant analytes. It might be possible that other known bioactive 
compounds are present in CM at levels below the detection limits of NMR; 
therefore, more sensitive analytical methods like mass spectrometry may 
be required. 
The second study that investigated the metabolites secreted by feeders 
was that carried out by Gupta et al. In their report the authors analysed 
the consumption of glucose and the production of lactate by mouse 
embryonic fibroblasts over a period of 72 h (Gupta et al., 2012). At 
regular intervals they measured the concentrations of glucose and lactate 
present in MEF-CM and fitted mathematical models to the data in order to 
predict the trends of glucose consumption and lactate production beyond 
the 72 h experimental time. Given the specific analysis of glucose and 
lactate, information regarding other secreted metabolites was neglected; 
therefore, making this method unsuitable for identification of unknown 
metabolites. 
Other methods analysing the culture medium of hESC have targeted their 
investigations to the discovery of drugs’ toxicity biomarkers (Cezar et al., 
2007, West et al., 2010). As these protocols have perturbed the system 
with the addition of drugs to the hESC culture, the investigation of the 
factors secreted by MEFs or any other feeder cells cannot directly be 
assessed. As a consequence, there is still a lack of protocols pointing to 
the investigation and identification of the metabolites present in the 
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conditioned medium. Furthermore, in spite of its widespread use as 
feeder cells, at present, there is no report of the comprehensive analysis 
of the metabolites secreted by MEFs. Metabolomics methods offer the 
appropriate tool for such kind of studies and will be described in more 
detail in the following sections. 
 
1.4 Metabolomics 
Metabolomics comprise the identification as well as the qualitative and 
quantitative measurement of all the metabolites (compounds with 
molecular mass lower than 1000 Da) present in a biological system 
(Fiehn, 2002). The related term, metabonomics, was coined by Nicholson 
et al and defined as the quantitative measurement of the dynamic 
multiparametric response of a living system to pathophysiological stimuli 
or genetic modification (Nicholson et al., 1999). Because in practice both 
terms overlap by a large degree, they are frequently used 
interchangeably; however, throughout this thesis the term metabolomics 
will be used. The whole set of intracellular and extracellular metabolites 
produced by a living cell is known as the metabolome (Oliver et al., 
1998). As metabolites are the downstream products of other ‘-omics’ 
such as transcriptomics and proteomics, metabolomics provide 
complementary information for a better understanding of the cellular 
processes occurring in the biological system under study (Villas-Boas et 
al., 2005).  
Metabolomics analyses are mainly undertaken by two major approaches: 
targeted and untargeted methods. A targeted metabolomics approach 
aims to quantify a pre-determined number of metabolites belonging to a 
certain class of compounds (e.g. lipids, amino acids, carbohydrates) or to 
a specific metabolic pathway (e.g. glycolysis) (Roberts et al., 2012). This 
targeted approach is usually hypothesis-driven and requires a priori 
knowledge of the biological system under study. An example of this 
approach was the analysis of 22 amino acids in Pichia pastoris cell 
extracts (Guerrasio et al., 2014). Because investigators focused on the 
measurement of the amino acids, other metabolites present in the cell 
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extracts were neglected. The advantage of targeted methods is that they 
provide quantitative information; however, because they are biased 
towards a selected number (or group) of metabolites, information about 
other components remains unknown.  
On the other hand, untargeted metabolomics methods (also known as 
global metabolomics or metabolite profiling) aim to detect all the 
metabolites in a biological sample, including the unknowns. Untargeted 
approaches usually compare the metabolite profile of a control group with 
that of an altered group allowing the identification of the metabolites of 
interest which could be further quantified with a targeted approach (Leon 
et al., 2013). Therefore, targeted and untargeted metabolomics are 
complementary approaches that if used in combination can provide more 
in-depth insights of the metabolic events occurring in the biological 
system. Untargeted metabolomics has found application in the discovery 
of potential biomarkers in cancer (Lin et al., 2011, Xie et al., 2012), 
Alzheimer’s disease (Li et al., 2010), onchocerciasis (Denery et al., 2010) 
and metabolic disorders such as diabetes and obesity (Zhang et al., 
2009b, Kim et al., 2010), amongst other conditions. However, this type 
of approach risks the identification of artefacts as markers; thus, the 
results should be properly validated. For this, it is recommended that 
metabolomics analyses are repeated with different sample sets to verify 
the legitimacy of the potential biomarkers; and finally, carry out absolute 
quantification using validated methods to confirm that test and control 
samples show concentrations significantly different. Other limitations in 
the application of untargeted metabolomics methods include the lack of 
standardised protocols in analytical performance, data mining and data 
reporting which, so far, have not been completely established yet. 
Given the complexity of untargeted methods, they can be sub-divided 
into: a) metabolomics fingerprinting (Fiehn, 2001), if the aim is to 
analyse all the intracellular metabolites (endo-metabolome) and b) 
metabolomics footprinting (Allen et al., 2003), if the aim is to analyse all 
the extracellular metabolites (exo-metabolome) (Figure 1-4). 
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Figure 1-4 Metabolomics strategies for the analysis of the metabolome. 
Untargeted metabolomics comprising fingerprinting and footprinting aim to 
identify all the intracellular and extracellular metabolites, respectively, whereas 
targeted approaches focus only on a selected number of metabolites that can be 
intracellular or extracellular. Diamond, circle and triangle shapes represent 
metabolites. 
 
 
Footprinting analyses are relatively straightforward when compared to 
metabolomics fingerprinting. Metabolomics footprinting requires minimal 
sample preparation, usually filtration or centrifugation to separate the 
cells from the culture medium. In contrast, metabolomics fingerprinting 
requires more elaborate procedures to extract the metabolites from the 
cells and the protocols are also extensively optimised in order to obtain 
good metabolite recoveries (Leon et al., 2013). An example of these 
metabolic strategies is the study of the intracellular and extracellular 
metabolites of Chinese hamster ovary (CHO) cells (Dietmair et al., 2012). 
Dietmair et al compared the metabolome of CHO cells cultivated in three 
different media and identified metabolites that correlated with differences 
observed in growth rate and cell viability. They centrifuged the culture 
medium to analyse the extracellular metabolites but employed a series of 
solvent addition, centrifugation, freeze-drying and reconstitution steps to 
extract the intracellular metabolites (Dietmair et al., 2012). 
Because untargeted methods (more specifically metabolomics 
footprinting) suit better the objective of identifying the metabolites 
secreted by MEFs, the following sections will focus on the instrumentation 
and data processes required by untargeted metabolomics. 
 
Fingerprinting 
Intracellular metabolites 
Footprinting 
Extracellular metabolites 
Target analysis 
Nucleus 
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1.4.1 Analytical platforms for metabolomics 
Amongst the analytical platforms applied in metabolomics, the most 
commonly used are nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry (MS) (Dunn et al., 2005). The latter usually coupled 
to a separation technique such as liquid chromatography (LC), gas 
chromatography (GC) and, less often, with capillary electrophoresis. 
NMR has been extensively used in metabolomics (Smolinska et al., 2012) 
and is particularly an advantageous technique since it requires minimal 
sample preparation, produces signals that correlate with the 
concentrations of the analytes in the samples and its non-destructive 
nature allows the recovery of the samples after analysis (Sotelo and 
Slupsky, 2013). However, NMR faces some limitations in terms of 
sensitivity; only the most abundant analytes in a given sample are 
detected. This limitation is overcome by MS which provides greater 
sensitivity than NMR and therefore enables the detection of low abundant 
metabolites that usually go undetected with NMR methods. 
Direct infusion MS (DIMS) offers a rapid way to analyse hundreds of 
samples per day due to its short analysis times, usually 1–2 min long. 
However, because all the analytes enter simultaneously to the mass 
spectrometer, DIMS can suffer from extensive ion suppression, a type of 
matrix effect where the signal of a particular ion can be suppressed or 
enhanced due to the presence of another co-eluting ion. Another 
limitation of DIMS is that it cannot distinguish between isobaric and 
isomeric compounds. Nevertheless, DIMS has proven to be successful in 
metabolomics, for example, it was able to identify biomarkers in a serum 
metabolomics study of kidney cancer (Lin et al., 2010).  
Hyphenated MS approaches (e.g. LC-MS, GC-MS) have several 
advantages over DIMS although at the expense of longer analysis times. 
For example, chromatographic separation of the analytes prior to 
detection reduces ion suppression effects, creates a retention-time 
identifier that will support the investigator at the time of metabolite 
identification and also produces better MS data quality due to reduced 
background noise (Patti, 2011). 
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The use of GC-MS in metabolomics is restricted to the analysis of volatile 
and semi-volatile compounds or to some extent it employs chemical 
derivatisation to make non-volatile analytes suitable for analysis. 
However, derivatisation requires extensive sample preparation times and 
not all sorts of molecules can be derivatised (Kopka et al., 2004). As a 
result, only a limited number of metabolites can be analysed by GC-MS. 
In contrast, LC-MS allows the separation of compounds of a wide range 
of polarity with little effort in sample preparation which makes it, 
probably, the most versatile separation method. LC-MS will be discussed 
in more detail in the next section.  
 
 
1.4.2 LC-MS-based metabolomics 
The highly complex samples used in metabolomics require that the 
tools/instruments used for the study of the metabolome perform at the 
highest resolution possible in order to increase metabolome coverage and 
facilitate metabolite identification. 
 
1.4.2.1 Liquid chromatography 
Although conventional high performance liquid chromatography (HPLC) is 
well suited to metabolomics analysis, the introduction of ultra 
performance liquid chromatography (UPLC), with its greatly enhanced 
chromatographic efficiency, has improved sensitivity, resolution and 
analysis time, resulting in the detection of an even greater number of 
metabolites (Swartz, 2005). Because of this, the use of UPLC is preferred 
over conventional HPLC as it increases metabolome coverage (Wilson et 
al., 2005). 
Reversed-phase liquid chromatography (RPLC) is by far the most widely 
used separation mode in metabolomics because of the wide range of 
metabolites that can be analysed. Furthermore, RPLC provides the most 
reliable, robust and sophisticated stationary phases than any other 
separation mode (Gika et al., 2014). However, there are some limitations 
with the use of RPLC, polar and/or ionic compounds are poorly retained 
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and cannot be effectively analysed with RPLC (Theodoridis et al., 2011). 
Hydrophilic liquid chromatography (HILIC) is an alternative separation 
mode suitable for the analysis of polar compounds although it sacrifices 
the retention of hydrophobic molecules (the ones retained with RPLC). 
Therefore, RPLC and HILIC are complementary approaches that if used in 
combination, provide a greater coverage of the metabolome (Zhou et al., 
2012). However, a compromise between metabolome coverage and high-
throughput analysis has to be met as the use of both types of 
chromatography implies that samples are analysed twice therefore 
increasing analysis times. Some examples of LC-MS-based metabolomics 
in cell culture include the metabolite profiling of Arabidopsis thaliana 
plant leaves (t'Kindt et al., 2008), the RPLC analysis of the extracellular 
metabolites of CHO (Chong et al., 2009) and the HILIC analysis of 
Escherichia coli extracts (Bajad et al., 2006). 
 
 
1.4.2.2 Mass spectrometry 
Because untargeted metabolomics deals with samples of unknown 
composition, one of the objectives is to identify the metabolites of 
interest that distinguish the conditions under study (usually, altered vs. 
control group). Therefore, untargeted metabolomics requires the use of 
mass spectrometers with high mass accuracy in order to determine more 
precisely the elemental composition of the unknown metabolites and to 
reduce the number of candidate identities when searched against 
metabolomics databases. Time of flight (TOF) mass spectrometers have 
extensively been used in untargeted metabolomics mainly due to its 
excellent sensitivity, rapid data acquisition and high mass accuracy 
(typically < 5ppm) (Wikoff et al., 2007, Want et al., 2010, Loftus et al., 
2011). Fourier transformed (FT) mass spectrometers such as ion 
cyclotron resonance (FT-ICR) and Orbitrap have also been used. 
Furthermore, they provide higher resolution and better mass accuracy 
than TOF instruments, although at lower scan rates. Therefore, with FT 
instruments there is usually a trade-off between high resolution and scan 
speed in order to obtain good resolution with enough data points per 
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chromatographic peak. The resolving power of FT-ICR is 1,000,000 full 
width at half maximum (FWHM) whereas that of Orbitrap is 140,000 
FWHM, both values calculated at m/z 400. The mass accuracy of these 
instruments is sub-ppm for FT-ICR and 1–2 ppm for Orbitrap (Zhou et 
al., 2012). 
Selection of the ionisation mode used in LC-MS also plays a major role in 
the metabolite profile that will be obtained (Theodoridis et al., 2012). 
Although various atmospheric pressure ionisation methods exist, the 
majority of experiments utilize electrospray ionisation (ESI) due to its 
soft ionisation and the capability of forming intact molecular ions that 
help in the identification process. Atmospheric pressure chemical 
ionisation (APCI) and atmospheric pressure photoionisation are 
complementary to ESI but they are preferred for the analysis of more 
non-polar and thermally stable analytes (Xiao et al., 2012).  
 
 
1.4.3 Data analysis 
LC-MS untargeted metabolomics analyses result in complex data sets of a 
large number of variables (ions) monitored simultaneously during the 
experiments. Therefore, data scrutiny requires the use of advanced 
statistical tools such as multivariate analysis (MVA) to extract information 
from the raw data files.  
However, prior to MVA, a series of pre-processing steps including noise 
filtering, peak picking, alignment and normalisation (Katajamaa and 
Oresic, 2007, Hendriks et al., 2011) are required in order to reduce the 
three-dimensionality (mass-to-charge ratio (m/z), retention time and 
signal intensity) of LC-MS data into a two dimensional data matrix that 
will be further manipulated with MVA software. Data pre-processing may 
be performed with the MS manufacturer’s software (e.g. Markerlynx, 
Sieve) or with freely available software like MZmine (Pluskal et al., 
2010), MetAlign (Lommen, 2009) or XCMS (Smith et al., 2006).  
Once data pre-processing has been completed and the data matrix 
generated, then MVA analysis begins. Initial MVA analysis involves the 
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use of unsupervised methods such as hierarchical cluster analysis (HCA) 
or principal components analysis (PCA). These methods do not require a 
priori information about the samples class (Sumner et al., 2007b) and 
are used to reduce data dimensionality and to provide an overview of 
class separation, groupings and outliers. 
Unsupervised methods are usually followed by supervised approaches 
such as partial least squares-discriminant analysis (PLS-DA) or 
orthogonal-PLS-DA (OPLS-DA). Supervised methods enhance the 
separation between classes and allow the identification of the variables 
(metabolites) responsible for the class separation. Sometimes the use of 
OPLS-DA is preferred to PLS-DA because it facilitates data interpretation. 
OPLS-DA, but not PLS-DA, can separate the between-class variation and 
the within-class variation which results in a more straightforward 
interpretation of the model and consequently of the data (Trygg et al., 
2007). The discriminating metabolites that result from supervised 
methods are subjected to classical univariate statistics (e.g. Student’s t-
tests, analysis of variance (ANOVA)) to test their significance and the 
most significant ones are finally identified for biological interpretation.  
 
1.4.4 Metabolite identification 
Initial metabolite identification in LC-MS-based metabolomics starts by 
searching the accurate masses obtained in the experiments against in-
house or web-based databases such as the Human Metabolome Database 
(www.hmdb.ca) (Wishart et al., 2009), Lipid Maps (www.lipidmaps.org) 
(Fahy et al., 2007) and/or METLIN Metabolomics Database 
(www.metlin.scripps.edu) (Smith et al., 2005) to obtain a list of possible 
candidates that can be further reduced by investigating the biological 
relevance of the putative identities. For a higher level of confidence in the 
identification of the metabolites MS/MS experiments can be performed 
and the MS/MS spectra likewise compared with spectral libraries. In the 
end, the unambiguous identification of the metabolites will only be 
achieved with the use of reference standards by comparing retention 
times, full scans and MS/MS spectra (Gika et al., 2014). 
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1.5 Aims and objectives 
In this thesis, the low-molecular weight factors (metabolites) secreted by 
MEFs during the medium conditioning process will be investigated with 
the use of untargeted metabolomics methods. The methodology will also 
be extended to the analysis of hESC spent culture medium based on 
recent evidence that hESC also secrete factors that help them to maintain 
their self-renewal and pluripotency properties.  
 
 To develop an untargeted LC-MS-based metabolomics method for 
the identification of the metabolites secreted by MEFs. 
 
 To identify potential small-molecule factors released by MEFs that 
could be implicated in the pluripotency maintenance and/or 
proliferation of hESC. 
 
 To investigate the effect on hESC in culture of potential small 
molecules identified in MEF-CM. 
 
 
 
 
CHAPTER 2 
Development of an LC-MS-
based metabolomics 
approach for metabolite 
profiling of culture media 
used in hESC culture 
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2 Development of an LC-MS-based metabolomics 
approach for metabolite profiling of culture media 
used in hESC culture 
2.1 Introduction 
2.1.1 Metabolomics methods for the analysis of mammalian cell 
cultures 
The application of metabolomics in the area of mammalian cell culture is 
relatively undeveloped as compared to the number of publications 
focused on the study of body fluids (e.g. serum, plasma, urine) 
(Cuperlovic-Culf et al., 2010). Nevertheless, there have been published a 
considerable number of reports applying cell culture metabolomics in 
several research fields including toxicology (Cezar et al., 2007, Palmer et 
al., 2013), drug testing (Croixmarie et al., 2009), cell-culture monitoring 
(Chong et al., 2009, Chong et al., 2010, Dietmair et al., 2012, McNamara 
et al., 2012), medium optimisation (Selvarasu et al., 2010), physiological 
cellular status monitoring (Chrysanthopoulos et al., 2010) and 
biopharmaceutical production (Fernandez et al., 2008, Mohmad-Saberi et 
al., 2013).  
The metabolomics methods applied in cell culture can be divided in two 
groups: 1) those interested in the analysis of the intracellular metabolites 
(metabolomics fingerprinting) and 2) those focused on the profile of 
extracellular metabolites (metabolomics footprinting). Either type of 
methodology requires the immediate stop of all metabolic activity 
(quenching) to provide representative metabolic profiles of the 
physiological status of the cells at the time of sampling (Leon et al., 
2013).  
For metabolomics footprinting, separation of the culture medium from 
cells in suspension is achieved by cold centrifugation or by filtration. In 
the case of adherent cells, the medium is simply collected by pipetting 
and subsequently centrifuged to eliminate cell debris. For metabolomics 
fingerprinting, a metabolite extraction procedure is necessary in addition 
to the quenching step. After removal of the culture medium, cell 
quenching is generally performed by freezing in liquid nitrogen, acid 
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treatment or addition of cold buffered methanol (Sellick et al., 2010); 
however, these techniques are more suitable when working with cells in 
suspension. Adherent cells on the other hand have first to be detached 
from the flask, washed and finally quenched with liquid nitrogen or cold 
organic mixtures. Conventionally, cell detachment is achieved by using 
trypsin/ethylenediaminetetraacetic acid (EDTA) solutions or by cell 
scraping (Dettmer et al., 2011). This process is time consuming and 
requires multiple wash/centrifuge cycles; alternatively, quenching and 
extraction can be carried out at once by adding a solvent mixture directly 
to the culture dish (Ritter et al., 2008). The choice of the experimental 
protocol will depend on the study objective. 
Because the objective of this thesis is to investigate the metabolites 
secreted by mouse embryonic fibroblasts to the conditioned medium, the 
methodology to be considered for method development will be 
metabolomics footprinting of the cultured medium (MEF-CM) used to 
grow hESC in vitro. 
 
2.1.2 Metabolomics footprinting of hESC 
Current LC-MS-based metabolomics methods analysing hESC culture 
media have been designed more properly to the discovery of toxicity 
biomarkers rather than characterising the medium itself. Furthermore, 
these methods have relied on long sample preparation times and long 
chromatographic analysis times making them unsuitable for high-
throughput analysis. Typically, these protocols pass spent culture media 
through molecular weight cut-off (MWCO) filters by centrifuging the 
samples for approximately 180 min (Cezar et al., 2007) and then 
concentrating the filtrate for several hours to finally reconstitute them in 
a water/solvent mixture before analysis (West et al., 2010). Although 
initial methods required 90-min chromatographic runs per sample (Cezar 
et al., 2007), more recent protocols have significantly decreased the 
analysis time to approximately 20 min (Kleinstreuer et al., 2011, Palmer 
et al., 2013) (Table 2-1 and Table 2-2). Nevertheless, they still rely on 
long sample preparation times. With such long sample preparation 
methods the stability of the metabolites could be compromised and the 
31 
 
metabolite profile obtained might not be representative of the cellular 
status. Therefore, a method with reduced sample preparation times 
would be ideal. In this chapter, the development of a high-throughput 
LC-MS method will be pursued. 
 
Table 2-1. Sample preparation protocols of methods analysing hESC culture 
media. 
Culture 
medium 
MWCO Centrifugation time Drying time Reference 
MEF-CM 3 KDa 180 min 0 min (Cezar et al., 2007) 
mTeSR1 3 KDa 200 min Several hours (West et al., 2010) 
mTeSR1 10 KDa 240 min Dried overnight (Kleinstreuer et al., 
2011) 
mTeSR1 10 KDa 200 min Dried overnight (Palmer et al., 2013) 
 
 
Table 2-2. Liquid chromatography conditions of methods analysing hESC culture 
media. 
Type of 
column 
Column 
dimensions 
Organic modifier Analysis time Reference 
C18 2.1x200 mm 0.1% formic acid 90 min (Cezar et al., 2007) 
HILIC 3x100 mm 0.1% formic acid 30 min (West et al., 2010) 
HILIC 3x100 mm 0.1% formic acid 22 min (Kleinstreuer et al., 
2011) 
HILIC 3x100 mm 0.1% formic acid 17 min (Palmer et al., 2013) 
 
 
2.1.3 Analytical strategy adopted for method development 
The LC-MS method development undertaken in this chapter will be based 
on the chromatographic and mass spectrometry response optimisation of 
the components of unconditioned medium (UM). UM was chosen because 
it is the medium used to obtain MEF-CM (as explained in chapter 1) 
whose mutual comparison will allow the identification of the small-
molecule factors secreted by MEFs.  
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The known components of UM are listed in Table 2-3. Although it seems 
that UM is composed of polar molecules (amino acids and vitamins), it 
contains AlbuMAX® I, a lipid-rich bovine serum albumin, whose 
composition is not completely defined yet and that has been reported to 
contain different classes of lipids (Garcia-Gonzalo and Izpisua Belmonte, 
2008), although these lipids have not been assigned a singular identity. 
 
Table 2-3. Known composition of the ingredients of unconditioned medium. 
DMEM/F12 (1:1) 
   Amino Acids 
  Glycine L-Glutamic Acid L-Phenylalanine 
L-Alanine L-Glutamine L-Proline 
L-Arginine L-Histidine L-Serine 
L-Asparagine L-Isoleucine L-Threonine 
L-Aspartic acid L-Leucine L-Tryptophan 
L-Cysteine L-Lysine L-Tyrosine 
L-Cystine L-Methionine L-Valine 
   Vitamins Other Components Inorganic Salts 
Biotin D-Glucose (Dextrose) Calcium chloride 
Choline chloride Hypoxanthine Na Cupric sulfate 
D-Calcium pantothenate Linoleic Acid Ferric nitrate 
Folic Acid Lipoic Acid Ferric sulfate 
Niacinamide Phenol Red Magnesium chloride 
Pyridoxine hydrochloride Putrescine 2HCl Magnesium sulfate 
Riboflavin Sodium Pyruvate Potassium chloride 
Thiamine hydrochloride Thymidine Sodium bicarbonate 
Vitamin B12 
 
Sodium chloride 
i-Inositol 
 
Sodium phosphate dibasic 
 
 
Sodium phosphate monobasic 
 
 
Zinc sulfate 
   KnockOut™ Serum Replacement 
   Glycine L-Hydroxyproline Thiamine 
L-Histidine L-Serine Reduced glutathione 
L-Isoleucine L-Threonine L-ascorbic acid-2-phosphate 
L-Methionine L-Tryptophan Transferrin (iron saturated) 
L-Phenylalanine L-Tyrosine Insulin 
L-Proline L-Valine AlbuMAX® I 
 
   Non-essential amino acids 
   Glycine L-Glutamic Acid  
L-Alanine L-Proline 
 
L-Asparagine L-Serine 
 
L-Aspartic acid 
  
   GlutaMAX™ Supplement 
   L-Alanyl-L-Glutamine   
Note. Besides the ingredients stated here, β-mercaptoethanol and bFGF are added 
separately before incubation with mouse embryonic fibroblasts. 
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To optimise the chromatographic separation, the experiments carried out 
in this chapter will monitor the retention times of amino acids and fatty 
acids as representative polar and non-polar compounds contained in UM. 
As the lipidic part of UM is still unclear, the fatty acids monitored in these 
experiments were the known lipids present in mTeSR1™ medium (Ludwig 
et al., 2006a) (Table 1-2, chapter 1), assuming that to some extent these 
media share a certain number of components. 
 
 
 
2.1.4 Aims and objectives 
 Employ LC-MS technology to develop a comprehensive, high-
throughput untargeted method for metabolite profiling of human 
embryonic stem cell culture media. 
 
 Apply the developed method to characterise the components of 
unconditioned medium (the medium to be conditioned by mouse 
embryonic fibroblasts) used in hESC culture. 
 
 Make use of metabolomics databases to assign putative identities 
to the unknown components of unconditioned medium. 
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2.2 Materials and methods 
2.2.1 Chemicals 
HPLC-grade acetonitrile (ACN) and methanol (MeOH) were obtained from 
Fischer Scientific (Loughborough, UK). Deionized water (18.2 MΩ) was 
prepared using an ELGA USF-Maxima water purification system (Marlow, 
UK). Ammonium acetate and ammonium carbonate were supplied by 
Merck (Darmstadt, Germany). MS-grade formic acid, DL-amino acid 
standards and leucine-enkephalin were purchased from Sigma-Aldrich 
(Gillingham, UK). Tissue culture reagents were purchased from 
Invitrogen.  
 
2.2.2 Samples and sample preparation 
100 mL of unconditioned medium (UM) were prepared using 83% v/v 
DMEM/F12 (1:1), 15% v/v KnockOut™ serum replacement, 1% v/v of 
GlutaMAX™, 1% v/v Non-essential amino acids, 10 µL of 1M β-
mercaptoethanol and 100 µL of basic fibroblast growth factor at 4 ng/mL. 
Unconditioned medium was kept at -80⁰C until analysis, and thawed over 
ice prior to sample preparation. 
For each sample preparation method, samples were prepared three times 
and injected in triplicate to provide analytical replicates. Water blanks 
were prepared in exactly the same manner as the test samples. 
2.2.2.1 Centrifugation method 
In 1.5 mL Eppendorf tubes, 500 µL of UM were centrifuged at 17000 rpm 
for 10 min in a precooled (4⁰C) centrifuge. Then, the supernatant was 
transferred into LC vials for analysis. 
2.2.2.2 Ultrafiltration method 
For the ultrafiltration method, 200 µL of sample were passed through 
Amicon Ultra filters (Millipore) with molecular weight cut-off (MWCO) of 
10 kDa. Samples were dispensed into the filter device either alone or as a 
pre-mixed sample containing 10% of ACN. Afterwards, they were 
centrifuged at 14000 rpm for 15 min at 4⁰C and the filtrate transferred 
into LC vials. 
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2.2.2.3 Solvent precipitation method 
Based on a modification of (Pereira et al., 2010), aliquots of 250 µL of UM 
were mixed with 750 µL of cold solvent (MeOH or ACN kept at -20⁰C), 
vortexed for 1 min to precipitate the proteins and stored at -20⁰C for 20 
min. After the cold storage period, samples were vortexed again for 15 s 
prior to centrifugation (17000 rpm, 10 min, 4⁰C). The supernatants were 
transferred into LC vials for analysis. 
 
2.2.3 Preparation of amino acids standards 
A solution of 19 amino acids was prepared by weighing ~10 mg of each 
amino acid and transferring them into a 250 mL beaker, stirred with 80 
mL of purified water and heated at ~70⁰C to dissolve the amino acids 
thoroughly. The solution was let cool down and diluted to 100 mL in a 
100-mL volumetric flask. The solution comprised the following amino 
acids: DL-alanine, DL-arginine, DL-asparagine, DL-aspartic acid, DL-
cystine, DL-glutamic acid, glycine, DL-histidine, DL-isoleucine, DL-
leucine, DL-lysine, DL-methionine, DL-phenylalanine, DL-proline, DL-
serine, DL-threonine, DL-tryptophan, DL-tyrosine and DL-valine. The 
solution was further diluted 1:10 to obtain a working concentration of 
~10 µg/mL for each amino acid. 
 
2.2.4 Liquid chromatography 
Unconditioned medium samples were analysed under each of the 12 
different chromatography conditions listed in Table 2-4. Mobile phase 
composition comprised solvent A: aqueous buffer and solvent B: 
acetonitrile with the respective pH modifier: 0.1% v/v formic acid (pH 
3.0), 10 mM ammonium acetate (pH 6.9) and 10 mM ammonium 
carbonate (pH 8.5). 
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Table 2-4. Chromatography columns and conditions tested. 
Column name 
(supplier) 
Column type Dimensions, 
particle size 
Chromatogra-
phy mode 
pH stability 
of column 
pH 
tested 
Hypersil Gold 
(ThermoScientific) 
C18 2.1x50mm, 
1.9 µm 
RP 1 – 11 3.0 
Hypersil Gold 
(ThermoScientific) 
C18 2.1x150mm, 
1.9 µm 
RP 1 – 11 3.0 
Zorbax Eclipse Plus 
(Agilent Technologies) 
C18 2.1x100mm, 
1.8 µm 
RP 2 – 9 3.0 
Zorbax Eclipse Plus 
(Agilent Technologies) 
C18 2.1x150mm, 
1.8 µm 
RP 2 – 9 3.0; 
6.9; 
8.5 
Synergi Polar-RP 
(Phenomenex) 
Ether linked 
Phenyl (PH) 
2.0x100mm, 
2.5 µm 
RP 1.5 – 7 3.0; 
6.9 
Acquity BEH Amide 
(Waters) 
Ethylene 
Bridge Hybrid 
2.1x150mm, 
1.7 µm 
HILIC 2 – 11 3.0; 
6.9; 
8.5 
SeQuant ZIC-HILIC 
(Merck) 
Zwitterion, 
Sulfobetaine 
2.1x150mm, 
5 µm 
HILIC 3 – 8 6.9 
 
For reversed-phase liquid chromatography (RPLC), the gradient used a 
linear increase from 10% B to 90% B in 10 min, held these conditions for 
11 min, and returned to 10% B within 1 min. Then, three minutes of 
column re-equilibration were allowed. For hydrophilic interaction 
chromatography (HILIC), a 15-min gradient started with 80% B which 
was held for 1 min and then decreased to 50% B in 11 min. Initial mobile 
phase conditions were achieved again in 0.1 min, followed by 2.9 min of 
re-equilibration. 
The chromatographic separations were performed on an Accela U-HPLC 
system (Thermo Fisher Scientific, USA) with a flow rate of 300 µL/min. 
The autosampler and column oven temperatures were set at 4⁰C and 
40⁰C, respectively. The injection sample volume was 7 µL.  
 
2.2.5 Mass spectrometry 
The LC system was coupled online to an Exactive Orbitrap mass 
spectrometer (Thermo Fischer Scientific, USA) equipped with a heated 
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electrospray interface (HESI-II) operating in positive and negative ion 
modes to provide the most comprehensive MS profile possible. A 50 
µg/mL solution of leucine-enkephalin (dissolved in 0.1% formic acid 
ACN/H2O 50/50) was used to optimise MS parameters. The parameters at 
which the highest signal was achieved were: spray voltage, 3 kV; heated 
capillary temperature, 350⁰C; heater temperature, 300⁰C; sheath, 
auxiliary and sweep gas flow rates were 35, 10 and 5 arbitrary units, 
respectively. Data were acquired in full scan mode from m/z 70–1000 at 
50,000 FWHM resolving power at 2 Hz. 
 
2.2.6 Optimised LC-MS conditions for ZORBAX Eclipse Plus C18 
column (2.1x100mm) 
The final LC method that provided a good compromise between 
separation and analysis time is detailed next. The mobile phase consisted 
of A: 0.01% formic acid in water and B: 0.01% formic acid in acetonitrile. 
A step gradient programme was used, starting with 10% B, 0-0.3 min; 
50% B, 5-6 min; 70% B, 7-8 min; 90% B, 9-10 min; 98% B, 11-16 min; 
and coming back to the re-equilibration mobile phase composition of 10% 
B, 16.5-18 min. The flow rate was kept at 300 µL/min with the exception 
of minute 9 to 11 which was increased to 400 µL/min. Before each 
sample injection of 7 µL in no-waste mode, the needle was washed with 
400 µL of 75% methanol. 
 
2.2.7 LC-MS/MS data dependent analysis 
Experiments were carried out on an Accela U-HPLC system hyphenated 
with an LTQ Velos mass spectrometer (all from Thermo Fischer Scientific, 
USA) using the data dependent scanning mode with 35 eV collision 
energy. The LC conditions were the same as those described in section 
2.2.6. The MS/MS method was fed with the list of parent ions –retrieved 
from the Exactive analyses– and the expected retention times of the 
analytes. 
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2.2.8 Data analysis 
Positive and negative data sets were processed using Tox ID 2.1.1 
Software to extract the retention times of the analytes, and QuanBrowser 
Xcalibur 2.2 software (both from Thermo Fischer Scientific, USA) to 
obtain the peak areas. When a compound was detected in +ve and –ve 
mode, the polarity at which it provided better sensitivity was chosen for 
quantification. Plots were created with GraphPad Prism version 6.03 
(GraphPad Software Inc., California, USA). 
Unknown compounds present in the UM were assigned a putative identity 
after searching their m/z values against web-based databases such as 
the Human Metabolome Database (www.hmdb.ca) (Wishart et al., 2009), 
Lipid Maps (www.lipidmaps.org) (Fahy et al., 2007) and METLIN 
Metabolomics Database (www.metlin.scripps.edu) (Smith et al., 2005). 
Confirmation of their identities was performed by means of tandem mass 
spectrometry (section 2.2.7). The MS/MS spectra of the possible 
compounds were compared with those in the databases aforementioned. 
 
2.3 Results and discussion 
2.3.1 Effect of pH and type of chromatography on separation 
Initial scouting gradients were performed on the Hypersil Gold (2.1x50 
mm) column, but polar compounds –amino acids, especially– were poorly 
retained (data not shown). Therefore, longer columns (2.1x150 mm) with 
the same stationary phase chemistry were tested. These longer columns 
included the Zorbax Eclipse Plus in addition to the Hypersil Gold. To keep 
the LC-MS method as simple as possible, the UM was injected directly 
into the LC columns using the centrifugation method (see materials and 
methods). 
During HPLC method development, the mobile phase pH should be 1.5 
units below or above the pKa of the analyte of interest in order to have 
the analyte either in the ionized or non-ionized form which will produce a 
decent retention time and a good peak shape (Snyder et al., 1997). In 
metabolomics, however, with hundreds of metabolites, it is practically 
impossible to meet this criterion for all the analytes present in the 
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sample. As a result, a common practice is to explore different mobile 
phase pHs. 
Retention times of amino acids and lipids run with mobile phase pH 3.0, 
6.9 and 8.5 are shown in Figure 2-1. Amino acids represent a challenge 
in terms of chromatographic separation as this group of chemicals have 
at least two pKa values, one for the carboxyl- and other for the amino- 
group; some amino acids even have a third pKa. Consequently, a mobile 
phase with a single pH will not suit the best chromatographic conditions 
for all of them. Exploring an acidic, a basic and a neutral pH 
demonstrated that major separation is achieved when using pH 3.0 
(0.1% v/v formic acid). 
L-Tryptophan, L-isoleucine and L-phenylalanine seemed to be less 
affected by change in the pH. On the other hand, L-glutamic acid, L-
cysteine, L-cystine, glycine and L-aspartic acid retention times dropped 
drastically while the mobile phase pH increased. The reason for this is 
that acidic amino acids lose their proton at higher pH, ionizing them and 
making them more polar; hence, eluting faster from the C18 column 
(Snyder et al., 1997). 
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Figure 2-1 Retention times of a) amino acids and b) fatty acids with the Zorbax 
Eclipse Plus (2.1x150 mm) column under acidic (pH 3.0), neutral (pH 6.9) and 
basic (pH 8.5) conditions. 
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Figure 2-2 Retention times of a) amino acids and b) fatty acids with the Acquity 
BEH Amide column under acidic (pH 3.0), neutral (pH 6.9) and basic (pH 8.5) 
conditions. 
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In contrast to the amino acids, lipids (like the fatty acids shown in Figure 
2-1b) were well retained and separated; again, mobile phase pH 3.0 
provided better retention times. Short and unsaturated fatty acids eluted 
earlier than long and saturated fatty acids. This is explained by the fact 
that long and saturated fatty acids interact more with the stationary 
phase (octadodecylsilane also known as C18) making them elute at the 
end of the gradient (Snyder et al., 1997). Similar results were obtained 
with the Hypersil Gold (2.1x150 mm) column. 
In spite of the fact that increasing the length of the column increased the 
retention time of the polar compounds (amino acids and vitamins), some 
amino acids still eluted very closely at the void volume time. 
Derivatization (a chemical transformation process) (Sharma et al., 2014) 
or the use of ion-pairing agents (Piraud et al., 2005) could have 
enhanced the reversed-phase retention of these compounds; however, 
these strategies would complicate the already laborious analysis of 
metabolomics data, so they were not considered here. Instead, I decided 
to experiment with hydrophilic interaction chromatography (HILIC), a 
chromatography technique employed for retention of more polar 
compounds like sugars (Antonio et al., 2008), nucleosides (Guo et al., 
2013), nucleotides (Inoue et al., 2010), etc., including amino acids 
(Guerrasio et al., 2014, Guo et al., 2013). 
As with the Zorbax Eclipse Plus column, UM was injected into the Acquity 
BEH Amide column under the same conditions of mobile phase. Figure 
2-2 shows the retention times of amino acids and lipids obtained with this 
column. In this case, amino acids presented superior retention times at 
pH 8.5, but lipids –except for lipoic acid– were practically unretained at 
all pHs.  
Even though good retention was achieved for polar compounds with the 
HILIC column, some inconveniences were encountered with its usage. 
The column required longer equilibration times (Valette et al., 2004) and 
broad peaks were observed for certain amino acids in both Acquity BEH 
Amide and SeQuant ZIC-HILIC columns. The latter led to the decision of 
not taking further the analysis of UM with HILIC columns. 
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2.3.2 Optimising the chromatographic separation of amino acids 
A second alternative to improve the chromatography of polar compounds 
in RPLC is by increasing the initial percentage of the aqueous buffer; in 
other words, reducing as much as possible the percentage of organic 
phase in the initial conditions of the RP-gradient (Snyder et al., 1997). To 
explore this route, a column (Synergi Polar) capable of supporting 100% 
aqueous was tested. 
For this experiment, a solution containing 19 amino acid standards was 
injected into the Synergi Polar column. Series of injections from 0% to 
50% organic (acetonitrile or methanol, as starting gradient composition) 
were performed to monitor the retention times of the amino acids (Figure 
2-3). Notice that methanol was also used as mobile phase B as a way to 
change the selectivity and improve elution times, nonetheless, retention 
times did not change much, but column backpressure increased 
considerably; hence, methanol was discarded as an organic modifier. 
Mobile phase at pH 3.0 (0.1% v/v formic acid) and 6.9 (10 mM 
ammonium acetate) were also investigated. Consistently with 
experiments detailed so far, formic acid still accounted for longer 
retention times. 
Amino acids started to elute faster while increasing the starting 
percentage of organic. It was at 20% organic when amino acids began to 
co-elute more significantly. In the case of methanol, this event occurred 
at 40%. Certainly, 100% aqueous (or 0% organic) conditions improved 
the chromatography for few amino acids, but for the rest, it had little or 
no benefit (Figure 2-3). 
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Figure 2-3 Retention maps of amino acid standards on the Synergi-Polar column with different initial percentages of organic solvent (ACN 
and MeOH), using both formic acid (FA) and ammonium acetate (Am) as pH buffers.
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When comparing these results with those obtained with the Zorbax 
Eclipse Plus (2.1x150 mm) column at pH 3.0, the longer retention times 
observed with the Zorbax column could be explained by a) the length of 
the column, the longer the analytes travel, the slower the elution; b) the 
particle size, the smaller the particle size, the higher the number of 
theoretical plates, which means that the analytes interact more with the 
stationary phase (Swartz, 2005) and c) the stationary phase chemistry, 
Zorbax Eclipse Plus is a normal C18 column that has more affinity for 
carbon-chain compounds, while the Synergi Polar column possesses an 
ether-linked phenyl phase which explains the good retention of aromatic 
amino acids like L-Phenylalanine, L-Tryptophan and L-Tyrosine, and the 
insignificant retentivity of the others. Since not all RP columns can deal 
with high aqueous percentages, 10% starting organic was considered for 
optimising the method. 
 
2.3.3 MS parameters optimisation 
This section includes the optimisation of the MS acquisition parameters, 
but the ESI source parameters (see materials and methods) were kept 
the same throughout the experimental work. 
In metabolomics experiments, high-resolution high mass accuracy MS 
data are required for the correct assignment of analyte masses and their 
identification/confirmation (Kellmann et al., 2009). The Thermo Exactive 
Orbitrap mass spectrometer has features to control the resolution and 
accuracy of the MS measurements: ion injection time, automatic gain 
control (AGC) target, microscans and resolution power. All these are 
interrelated for the final resolution outcome and will be explained shortly. 
The AGC target regulates the amount of ions that enter into the C-trap 
whereas the injection time is the time in milliseconds that ions are 
allowed to accumulate in this trap. The AGC target settings in the 
Exactive are: ultimate mass accuracy (5x105 charges), balanced (1x106 
charges) and high dynamic range (3x106 charges). If the ion population 
is small, the instrument sensitivity decreases (Wong et al., 2011). On the 
other hand, big ion populations can cause space-charge effects that 
induce mass measurement errors due to electrostatic interactions 
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(Makarov et al., 2006). Because of this, AGC target was set into balanced 
and injection time, 100 ms. 
With respect to mass resolution, two settings were evaluated; enhanced 
(25,000 FWHM, 4Hz) and high (50,000 FWHM, 2Hz). Figure 2-4 
illustrates the effect of increasing the resolution power. At 25,000 FWHM, 
the instrument was incapable of resolving the interference peak m/z 
524.2996 from the true ion m/z 524.3357, a fact that could induce mass 
errors and unreliable peak assignment. 
 
 
Figure 2-4 Effect of resolving power on separation of the analyte m/z 524.3357 
from the interference m/z 524.2996. High-resolution mass spectra are a 
prerequisite for correct peak assignments. 
 
It was found that high (50,000 FWHM) resolution power was necessary 
for separating analytes from interferences that could affect the mass 
accuracy and lead to false negatives. Experiments with different number 
of microscans were also assessed; in the end, microscans were set at 1 
as increasing the number of them reduced the chromatographic sampling 
resulting in fewer data points per peak (data not shown).  
50,000 FWHM resolution power and 1 microscan were chosen and finally 
adopted by the method as they provided a good compromise between 
resolution, mass accuracy and number of chromatographic points.  
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2.3.4 Sample preparation: comparison of centrifugation, 
ultrafiltration and protein precipitation methods 
To keep the sample preparation methodology as simple as possible, UM 
was initially injected into the LC-MS system following centrifugation (as 
described in the materials and methods section). Although centrifuged 
samples provided valuable information during the development of the 
method, fast deterioration of the column  was observed possibly as a 
result of proteinaceous material sticking to the stationary phase 
(Chambers et al., 2007). For this reason, and the likely existence of 
unwanted ion-suppression effects, other methods for preparing the 
samples were investigated (Figure 2-5). 
Firstly, ultrafiltration (UF) of the unconditioned medium using a 10 kDa 
cut-off filter would allow small molecules (metabolites) to pass through 
the membrane whilst retaining proteins and high molecular weight 
compounds. Secondly, the same ultrafiltration method employing as 
sample a premixed solution of UM containing 10% ACN (UF-ACN) instead 
of UM alone. Finally, sample deproteinization carried out by solvent 
precipitation (PPT) with methanol and acetonitrile in a proportion 3:1 v/v 
solvent to sample (PPT-ACN and PPT-MeOH, respectively) (Lai et al., 
2010). The samples were chromatographically separated with the Zorbax 
Eclipse Plus (2.1x150 mm) column and formic acid in the mobile phase. 
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Figure 2-5 (A) Relative quantification of 44 identified metabolites in UM using 
four different preparation methods. Data points and error bars represent peak 
area means (n=9) and standard deviation. (B) Distribution of the coefficient of 
variation (CV) of the metabolites according to the methodology used. The dash 
line indicates the level of acceptance of reproducible results (<15%). 
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Ultrafiltration by molecular weight cut-off filters offers a rapid solution to 
remove proteins from samples; however, in these experiment, the cut-off 
filters not only retained the proteins, but also the non-polar (e.g. lipids) 
and semi-polar (i.e. phenol red) compounds present in the UM (Figure 
2-6). Amino acids and vitamins passed freely through the membrane. 
Compare the intensity levels (peak areas) of these polar compounds with 
those of the fatty acids in Figure 2-5a. 
In fact, permeation of phenol red served as an indicator of this 
phenomenon. The retentate fraction in the filter device remained red 
while the filtrate was almost clear. To overcome this issue, 900 µL of UM 
were mixed with 100 µL of ACN (UF-ACN) and then processed as it was 
done with the pure UM (UF). Other percentages of ACN were tried too, 
but did not make any significant difference (data not shown). In Figure 
2-5a it is observed that while this trick worked well for some vitamins 
and phenol red, it did not improve the permeation of the fatty acids. 
Furthermore, this attempt produced larger CV (coefficient of variation) 
percentages (Figure 2-5b). 
 
 
Figure 2-6 Total ion count (TIC) chromatograms of a) permeate and b) retentate 
fractions of unconditioned medium after ultrafiltration. 
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Because of the failure of UF as a sample preparation method in either of 
the two ways experimented here, the next step was to try solvent-
induced protein precipitation in order to eliminate the proteins in the 
samples. MeOH- and ACN-precipitated samples provided similar results 
with regard to the response of fatty acids, but amino acids and vitamins 
gave higher intensities when MeOH was used. What is more, amino acids 
like L-cystine and L-glutamic acid were only detected with this method. 
For the selection of the final sample preparation method, three important 
characteristics were taken into account: i) sensitivity, ii) number of 
compounds detected and iii) peak area reproducibility. Metabolites in the 
UM span a wide range of concentrations (Figure 2-5a), so it was desirable 
a method that could detect as many compounds as possible, including 
those at lower concentrations. Of the four sample preparation methods 
tested herein, MeOH-precipitated samples showed better sensitivity and 
the ability to detect more compounds than the other methods. 
Furthermore, MeOH-precipitated samples also generated more 
reproducible results. Figure 2-5b shows the distribution of the coefficients 
of variation of all the analytes monitored by the four sample preparation 
methods. While UF and UF-ACN had the highest number of metabolites 
with CV > 15%, PPT-MeOH had the fewest. Precipitation of proteins with 
methanol fulfilled the abovementioned criteria and it was decided to be 
the method of choice for the subsequent sample preparation of culture 
media in the next chapters. 
 
2.3.5 Finalization of LC-MS method 
After having identified the type of column (Zorbax Eclipse Plus), the 
mobile phase conditions (pH 3.0), MS parameters and the sample 
preparation method whereby the components of UM presented higher 
sensitivity and enhanced separation, there were two issues concerning 
the final LC-MS method. The first one was the length of the analytical run 
per sample. Metabolomics studies generally involve tens or even 
hundreds of samples, that if injected in a single analytical experiment, 
would create long analysis times and cause inconsistent results (retention 
time drifts and loss of sensitivity) as contaminants build up in the LC-MS 
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system over time (Zelena et al., 2009). The second issue was the known 
ability of higher concentrations of formic acid to cause ion suppression 
(Annesley, 2003) and thus reduce sensitivity. Reducing the concentration 
of formic acid in the mobile phase may further increase the sensitivity but 
possibly at the expense of a change in mobile phase pH which might 
affect separation.  
To tackle these problems, the length of the column was reduced from 
150 mm to 100 mm. Reducing the length of the column reduces the 
analysis time but also reduces the resolution of the peaks (Swartz, 
2005). Thus, instead of a linear gradient, a step gradient was 
implemented and this maximised the separation of the components. The 
final LC parameters are provided in section 2.2.6 of this chapter. 
For the ion suppression effect, the mobile phase concentration of formic 
acid was reduced from 0.1% to 0.01%. An increase in sensitivity was 
observed when 0.01% formic acid was used, noticed in the normalization 
level (NL) in the extracted ion chromatograms (EIC) of glucose and 
niacinamide (Figure 2-7). Reducing the concentration of formic acid 
increased slightly the pH of the mobile phase, so ionic compounds were 
more affected; in this example, basic compounds like niacinamide were 
less ionized and more retained (Snyder et al., 1997). Non-ionic analytes 
remained unaffected by the change of pH (i.e. glucose). These changes 
were beneficial overall so it was decided to implement the change to 
0.01% formic acid in the mobile phase. 
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Figure 2-7 Extracted ion chromatograms (EIC) of glucose m/z 203.0532 
([M+Na]+) and niacinamide m/z 123. 553 ([M+H]+). The ion suppression effect 
of formic acid is reduced when lowered its concentration in the mobile phase. 
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2.3.6 Characterisation of the unknown lipid components of 
unconditioned medium 
Once the final settings of the method were established, it was applied to 
characterise the components of the UM. Table 2-3 provides the 
composition of each of the known ingredients that constitute the UM; 
which are mainly amino acids and vitamins. Notice, however, that the 
KnockOut™ SR (Price et al., (1998)) contains AlbuMAX I (a lipid-rich 
bovine serum albumin) whose exact chemical composition is still unclear. 
Analysis of AlbuMAX I by means of thin layer chromatography (Frankland 
et al., 2007) and HPLC (Garcia-Gonzalo and Izpisua Belmonte, 2008) 
identified different classes of lipids (Table 2-5), but as far as the thesis 
author is aware, no LC-MS analysis has been done to characterise more 
specifically the components of AlbuMAX I.  
 
Table 2-5. HPLC analysis reveals the type of lipids present in AlbuMAX (Garcia-
Gonzalo and Izpisua Belmonte, 2008) 
Lipid species  mg/ml in 1% AlbuMAX 
Free fatty acids (FFAs) 35.29 
Lysophosphatidylcholine (LPC) 11.30 
Triacylglycerides (TAGs) 9.79 
Phosphatidylcholine (PC) 5.29 
Phosphatidic acid (PA) 2.07 
Cholesterol (CH) 0.88 
Sphingomyelin (SM) 0.80 
 
Herein, the final method demonstrates its potential to separate, identify, 
and ultimately, characterise the unknown components of UM. Figure 2-8 
shows typical base peak chromatograms of UM and KnockOut™ SR (15% 
v/v) in negative electrospray ionisation mode. It is observed that the 
lipidic part –compounds eluting after minute 6, 50% organic– of UM is 
due to AlbuMAX I present in KOSR. This area of the chromatogram 
contains peaks which form the fraction of UM not listed in Table 2-3 and 
in this section these unknown peaks are identified and characterised with 
a putative identity. 
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Figure 2-8 Typical base peak chromatograms of a) unconditioned medium and b) 
KOSR at 15% v/v. Albumax I is responsible for the lipidic part of UM. 
 
To illustrate the identification process used, the ion at m/z 329.2487 ([M-
H]–) is taken as an example. First, the EIC of the ion was generated to 
confirm that it was derived from an authentic peak and the mass 
spectrum scrutinised to discern amongst possible adducts. Second, the 
exact mass was searched against the databases of HMDB, Lipid Maps and 
METLIN with a pre-specified mass tolerance (0.5 mDa). Assignment of 
the possible metabolite was based on isotope peak patterns, use of the 
nitrogen rule, charge state, retention time and biological relevance. In 
this case, docosapentaenoic acid was found to be the most likely 
identification, though accurate mass alone was not considered sufficient 
to confirm the identity. To further assist in identification, a mass 
fragmentation experiment was conducted for the quasi-molecular ion and 
the MS/MS spectrum was compared with that of the standard registered 
in the databases (Figure 2-9). Putative identity confirmation by means of 
MS/MS increases the level of reliability but it is not definitive until pure 
authentic standards are injected along with the sample and compared 
their retention times and MS/MS spectra (Gika et al., 2014). Table 2-6 
summarises the compounds that were detected with this methodology. It 
is worth mentioning that metabolite assignments in this table remain 
tentative as no authentic standards were analysed.  
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According to the Chemical Analysis Working Group, a member of the 
Metabolomics Standard Initiative, the identity of the compounds shown in 
Table 2-6 corresponds to levels 2 and 4. Level 2 for those compounds 
which were assigned a putative identity and their MS/MS spectra 
matched those registered in the spectral libraries. And level 4 for those 
compounds which remain unidentified (unknowns) to which it was not 
possible to assign a putative identity but can still be differentiated and 
quantified based upon spectral data (Sumner et al., 2007a). In 
accordance with the proposed minimum reporting standards suggested 
by the Chemical Analysis Working Group, the MS/MS spectra of the level 
2 compounds listed in Table 2-6 are shown in Appendix A. 
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Figure 2-9 MS/MS spectrum comparison of ion m/z 329 in a) sample and b) standard registered in Lipid Maps database. Fragment ions in 
the sample (m/z 311, m/z 285 and m/z 231) match those present in the standard. MS/MS spectral matching increases the level of 
confidence in the confirmation of the putative identity of the ion at m/z 329.2487 (docosapentaenoic acid). 
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Table 2-6. Characterisation of UM by retention time, experimental monoisotopic mass and database accession numbers. 
PUTATIVE IDENTITY RT, min [M–H]– [M+H]+ Δ ppm HMDB ID Lipid Maps ID METLIN ID 
L-Histidine 0.80 154.0617 
 
3.2 HMDB00177 21 
L-Lysine 0.80 145.0978 
 
2.8 HMDB00182 25 
Glycine 0.83 74.0243 
 
5.4 HMDB00123 20 
L-Serine 0.83 104.0353 
 
0.0 HMDB00187 30 
L-Alanyl-L-glutamine 0.83 216.0983 
 
3.2 HMDB28685 85601 
Glucose 0.84 
 
203.0527 2.5 HMDB00122 133 
Choline chloride 0.87 
 
104.1078 -2.9 HMDB00097 56 
L-Threonine 0.89 118.0506 
 
3.4 HMDB00167 32 
Pyruvate 0.89 87.0085 
 
3.4 HMDB00243 117 
L-Arginine 0.93 
 
175.1182 4.0 HMDB00517 13 
L-Glutamine 0.93 
 
147.0758 4.1 HMDB00641 18 
L-Asparagine 0.95 
 
133.0603 3.8 HMDB00168 14 
L-Proline 0.95 
 
116.0706 0.0 HMDB00162 29 
Thiamine 0.95 
 
265.1105 1.9 HMDB00235 229 
L-Hydroxyproline 0.98 
 
132.0649 4.5 HMDB00725 58354 
L-Valine 0.98 
 
118.0858 4.2 HMDB00883 35 
L-Aspartic acid 1.06 
 
134.0442 4.5 HMDB00191 15 
L-Cystine 1.06 
 
241.0300 4.6 HMDB00192 17 
L-Glutamic acid 1.06 
 
148.0598 4.1 HMDB00148 19 
L-Methionine 1.17 
 
150.0576 4.7 HMDB00696 26 
L-Phenylalanine 1.17 
 
166.0855 4.8 HMDB00159 28 
Hypoxanthine 1.17 
 
137.0452 4.4 HMDB00157 83 
L-Tyrosine 1.18 180.0661 
 
2.8 HMDB00158 34 
Thymidine 1.18 241.0822 
 
3.3 HMDB00273 3375 
L-Alanine 1.19 
 
90.0548 2.2 HMDB00161 11 
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PUTATIVE IDENTITY RT, min [M–H]– [M+H]+ Δ ppm HMDB ID Lipid Maps ID METLIN ID 
L-Leucine/L-Isoleucine 1.19 
 
132.1013 4.5 HMDB00687 24 
Niacinamide 1.19 
 
123.0547 4.9 HMDB01406 1497 
Pyridoxine 1.19 
 
170.0804 4.7 HMDB00239 2202 
D-Calcium pantothenate 1.22 
 
220.1169 4.5 HMDB00210 241 
Folic acid 1.31 440.1314 
 
2.3 HMDB00121 246 
L-Tryptophan 1.37 203.0820 
 
3.0 HMDB00929 33 
Vitamin B12 1.70 
 
678.2894
a
 2.2 HMDB02274 245 
Unknown 1.78 
 
267.0424  
   Riboflavin 2.67 
 
377.1437 5.0 HMDB00244 233 
Unknown 2.80 277.0175 
 
 
   
4-Sulfobenzyl alcohol 3.54 187.0065 
 
2.7 
  
66489 
Unknown 4.00 371.0597 
 
 
  Biotin 4.03 
 
245.0952 0.8 HMDB00030 243 
Phenol red 4.24 353.0491 355.0632 -0.6 
  
69460 
Unknown 4.57 351.0333 353.0474  
   Unknown 4.79 473.1453 
 
 
   Unknown 4.92 213.0553 
 
 
   Unknown 5.28 377.0702 
 
 
   
Taurocholic acid or possible isomer 5.85 514.2844 516.2987
b
 0.0 HMDB00036 
 Unknown 5.93 462.2865 
 
 
   Unknown 6.39 631.3494 633.3633  
   
Glycocholic acid or possible isomer 6.44 464.3021 466.3163
b
 -0.9 HMDB00138 
 
Unknown 6.50 509.2394 
 
 
   
Unknown 6.63 633.3650 
 
 
   
Unknown 6.74 243.0695 
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PUTATIVE IDENTITY RT, min [M–H]– [M+H]+ Δ ppm HMDB ID Lipid Maps ID METLIN ID 
3-Oxocholic acid or possible isomer 6.82 405.2648 389.2685
c
 -0.5 HMDB00502 
 
Taurodeoxycholic acid or possible isomer 6.96 498.2898 500.3038 -0.6 HMDB00896 
 Unknown 7.06 
 
601.2656  
   
Lysophosphatidylserine (20:1(11Z)/0:0) 7.15 550.3152 552.3292 -0.4 
 
LMGP03050020 
Unknown 7.18 429.0801 431.0947  
   Unknown 7.21 312.1816 
 
 
   Unknown 7.26 433.2809 
 
 
   
C17 Sphinganine 7.52 
 
288.2893 1.4 
 
LMSP01040003 41558 
Cholic acid 7.64 407.2805 391.2842
c
 -0.5 HMDB00619 206 
Unknown 7.89 291.0698 
 
 
  
Deoxycholic acid glycine conjugate or possible isomer 8.02 448.3071 450.3214 -0.7 HMDB00631 
 Unknown 8.18 293.1760 
 
 
   
Lithocholyltaurine 8.43 482.2945 
 
0.0 HMDB00722 LMST05040003 
LysoPC(14:0) 8.65 452.2784* 468.3082 0.4 HMDB10379 
 
LysoPE(18:3(9Z,12Z,15Z)/0:0) or possible isomer 8.67 474.2626 476.2768 0.0 HMDB11509 
 
LysoPC(18:3(9Z,12Z,15Z)) 8.73 502.2941* 518.3239 0.4 HMDB10388 
 
LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) 8.76 526.2939* 542.3241 0.0 HMDB10397 LMGP01050050 
LysoPC(O-14:1(1E)/0:0) or possible isomer 8.84 436.2833* 452.3131 0.9 
 
LMGP01070001 
LysoPC(16:1(9Z)) 8.89 478.2939* 494.3238 0.6 HMDB10383 
 LysoPC(15:0/0:0) 9.05 466.2938* 482.3237 0.8 HMDB10381 LMGP01050016 
LysoPC(20:4(5Z,8Z,11Z,14Z)) or possible isomer 9.05 528.3098* 544.3392 0.9 HMDB10395 LMGP01050048 
Deoxycholic acid 9.11 391.2854 375.2894
c
 0.0 HMDB00626 265 
LysoPE(18:2(9Z,12Z)/0:0) or possible isomer 9.14 476.2785 478.2928 -0.6 HMDB11507 LMGP02050011 
LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0) or possible isomer 9.14 500.2788 502.2927 -1.2 HMDB11517 LMGP02050009 
LysoPC(18:2(9Z,12Z)) or possible isomer 9.19 504.3101* 520.3397 0.0 HMDB10386 LMGP01050035 
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PUTATIVE IDENTITY RT, min [M–H]– [M+H]+ Δ ppm HMDB ID Lipid Maps ID METLIN ID 
LysoPC(P-15:0/0:0) 9.24 450.2993* 466.3289 0.6 
 
LMGP01070003 
LysoPE(22:5(4Z,7Z,10Z,13Z,16Z)/0:0) or possible 
isomer 9.35 526.2939 528.3081 0.0 HMDB11524 
 
LysoPC(22:5(7Z,10Z,13Z,16Z,19Z)) or possible isomer 9.41 554.3252* 570.3549 0.9 HMDB10403 
 
LysoPE(16:0/0:0) 9.46 452.2784 454.2926 -0.4 HMDB11503 LMGP02050002 
LysoPC(16:0/0:0) 9.54 480.3094* 496.3393 0.8 HMDB10382 LMGP01050018 
LysoPC(20:3(8Z,11Z,14Z)) or possible isomer 9.57 530.3251* 546.3550 0.2 HMDB10394 LMGP01050133 
LysoPE(18:1(9Z)/0:0) or possible isomer 9.71 478.2939 480.3085 0.0 HMDB11506 LMGP02050004 
(4E,8E,10E-d18:3)sphingosine 9.75 
 
296.2582 0.7 
 
LMSP01080013 53913 
LysoPE(P-16:0e/0:0) 9.76 436.2833 438.2977 0.0 HMDB11152 
 
LysoPC(18:1(9Z)/0:0) or possible isomer 9.79 506.3252* 522.3553 0.2 HMDB02815 LMGP01050032 
LysoPC(P-16:0/0:0) or possible isomer 9.87 464.3149* 480.3447 0.2 HMDB10407 LMGP01070006 
3R-hydroxypalmitic acid 9.90 271.2278 
 
0.2 HMDB10734 LMFA01050366 
Octadecanedioic acid 9.95 313.2386 315.2527 -0.6 HMDB00782 
 
Unknown 9.99 
 
440.4093  
   
LysoPC(17:0) 10.01 494.3253* 510.3550 0.8 HMDB12108 LMGP01050024 
Unknown 10.06 337.2385 
 
 
   
Halaminol A 10.35 
 
228.2319 1.3 
 
LMSP01080034 
LysoPE(18:0/0:0) 10.36 480.3094 482.3237 0.8 HMDB11130 LMGP02050001 
Hydroxy stearic acid or possible isomer 10.36 299.2591 
 
0.3 
 
LMFA02000120 35432 
LysoPC(18:0) or possible isomer 10.50 508.3409* 524.3705 1.0 HMDB10384 LMGP01050026 
Palmitoleamide 10.54 
 
254.2475 1.2 
 
LMFA08010010 97431 
2-hydroxy-nonadecanoic acid or possible isomer 10.70 313.2750 
 
-0.6 
 
LMFA01050071 
Linoleamide 10.81 
 
280.2632 1.1 
 
LMFA08010008 43435 
LysoPC(20:0) 10.82 536.3726* 552.4021 0.4 HMDB10390 LMGP01050045 
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PUTATIVE IDENTITY RT, min [M–H]– [M+H]+ Δ ppm HMDB ID Lipid Maps ID METLIN ID 
Eicosapentaenoic acid 10.85 301.2174 
 
-0.3 HMDB01999 
 
Alpha-Linolenic acid 10.96 277.2172 
 
0.4 HMDB01388 LMFA01030152 192 
Myristic acid 11.12 227.2012 
 
1.8 HMDB00806 LMFA01010014 196 
Docosahexaenoic acid 11.20 327.2328 
 
0.3 HMDB02183 LMFA01030185 
Palmitamide 11.24 
 
256.2633 0.8 HMDB12273 LMFA08010009 62905 
Palmitoleic acid or possible isomer 11.31 253.2173 
 
0.0 HMDB03229 LMFA01030056 188 
Arachidonic acid 11.39 303.2331 
 
-0.7 HMDB01043 LMFA01030001 
Pentadecanoic acid or possible isomer 11.47 241.2171 
 
0.8 HMDB00826 LMFA01010015 4205 
Oleamide 11.49 
 
282.2789 0.7 HMDB02117 LMFA08010004 4115 
Docosapentaenoic acid 11.53 329.2487 
 
-0.3 HMDB06528 LMFA04000044 
Linoleic acid 11.56 279.2331 
 
-0.7 HMDB00673 LMFA01030120 
(Z)-9-Heptadecenoic acid or possible isomer 11.83 267.2331 
 
-0.7 HMDB31046 LMFA01030060 
Dihomo-γ-Linolenic Acid or possibly Mead acid 11.85 305.2485 
 
0.3 HMDB02925 LMFA01030158 
Palmitic acid 12.15 255.2329 301.2112
d
 0.0 HMDB00220 LMFA01010001 
Oleic acid 12.32 281.2485 327.2266
d
 0.4 HMDB00207 LMFA01030002 
Stearamide 12.38 
 
284.2943 1.8 HMDB34146 LMFA08010003 34494 
Oleoyl Ethyl Amide 12.55 
 
310.3100 1.3 
  
44905 
Heptadecanoic acid 12.75 269.2485 
 
0.4 HMDB02259 LMFA01010017 4206 
Stearic acid 13.49 283.2642 329.2422
d
 0.0 HMDB00827 LMFA01010018 
13Z-Docosenamide 14.07 
 
338.3412 1.5 
  
64926 
Arachidic acid 14.08 311.2955 
 
0.0 HMDB02212 LMFA01010020 401 
 
       
 * Loss of one methyl group from the choline moiety, [M-CH3–H]
–  RT, retention time 
a
 [M+2H]2+         LysoPC, lysophosphatidylcholine 
b
 Preferentially observed as [M-3H2O+H]
+     LysoPE, lysophosphatidylethanolamine 
c
 [M-H2O+H]
+         Δ ppm = mass error in parts per million 
d
 [M+2Na-H]+ 
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In general, UM lipids were better ionised in negative ESI mode. 
Depending on the class of lipids, some of them were observed in both 
polarities (e.g. phosphatidylcholines and phosphatidylethanolamines); 
others preferentially in negative mode (i.e. free fatty acids); while few 
species were only detected in positive mode (i.e. fatty acid amides). 
Although most of the components were identified, some metabolites still 
remained unknown simply because they were not found in any of the 
databases or the candidates retrieved were biologically irrelevant. Also, 
compounds with multiple double bonds resulted in a less precise 
identification due to the diverse conformations that the molecule can 
adopt (isomers); nonetheless, it was possible to specify the type of 
compound and a molecular structure. 
 
 
2.4 Conclusions 
The present LC-MS method takes advantage of technological advances in 
chromatography and mass spectrometry. While UPLC increases peak 
capacity and enhances sensitivity, high resolution MS allows a more 
precise peak annotation. These analytical tools are of paramount 
importance in untargeted metabolomics for the discovery and 
identification of metabolites of interest in the biological systems under 
investigation.  
Enhanced metabolome coverage was achieved by the optimisation of the 
sample preparation method, type of chromatography and the use of 
heated electrospray ionisation in both positive and negative modes. In 
the end, methanol-precipitated samples and reversed-phase LC provided 
the most sensitive and reproducible results. 
As with any other LC-ESI-MS approach only ionisable molecules were 
observed. Nevertheless, the current method was capable of the detection 
and relative quantification of a wide range of small molecules present in 
the unconditioned medium. Additionally it allowed a more specific 
identification (albeit tentative) of the lipid classes contained in AlbuMAX I. 
This has made considerable advances compared with previous 
62 
 
methodologies (Frankland et al., 2007, Garcia-Gonzalo and Izpisua 
Belmonte, 2008), and contributed to an improved chemical definition of a 
widely used culture medium.  
In summary, this is the first time that a method has been developed for 
the comprehensive characterisation of the small molecule inventory of 
human embryonic stem cell culture media. The novel method developed 
in this chapter has many potential applications in the field of 
metabolomics and stem cell biology. As shown in subsequent chapters of 
this thesis, the methodology has enabled the metabolomics analysis of 
not only the traditionally culture medium (mouse embryonic fibroblast-
conditioned medium), but also of more defined media such as StemPro 
(Wang et al., 2007). Other applications also include metabolomics 
footprinting (analysis of extracellular metabolites) of different culture 
systems. 
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3 Metabolite profiling of mouse embryonic fibroblast-
conditioned medium for identification of potential 
low-molecular weight factors involved in the 
maintenance of hESC 
3.1 Introduction 
As mentioned in chapter 1, progress in the definition of the human 
embryonic stem cell (hESC) culture system has allowed the cultivation of 
hESC in the absence of the initially required mouse embryonic fibroblasts 
(MEFs) feeder layers. However, under feeder-free conditions, using either 
Matrigel (Xu et al., 2001) or a synthetic polymer (Villa-Diaz et al., 2010) 
as substrate, hESC still require the use of mouse embryonic fibroblast-
conditioned medium (MEF-CM) to retain their pluripotency; otherwise, in 
the presence of the unconditioned medium, hESC start to differentiate 
(Xu et al., 2001) (Figure 3-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Feeder-dependent 
culture 
Feeder-free 
culture 
 
Proliferation of hESC 
Unconditioned medium 
(UM) 
MEF-conditioned medium 
(MEF-CM) 
Incubation with 
inactivated MEFs 
for 24 h 
X    
  
  
  
Inactivated MEFs Matrigel 
Figure 3-1 Dependence on the use of mouse embryonic fibroblasts (MEFs) 
either as feeder cells or as a means to produce conditioned medium (CM) for 
the successful proliferation of hESC. Under feeder-free conditions 
unconditioned medium is unable to maintain hESC in an undifferentiated 
state. 
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The strong dependence on the use of MEFs, either as feeder cells or as a 
means to produce CM, suggests that MEFs secret a number of factors 
that are critical for the maintenance of hESC in an undifferentiated state. 
Therefore, the study of the factors released by the feeders into the 
medium during the conditioning process would identify potential 
compounds responsible for maintaining hESC pluripotency which could 
subsequently be used in the formulation of more defined culture systems 
that ultimately will place hESC technology a step forward in realising 
potential clinical applications.  
 
3.1.1 Investigation of the factors released into the medium 
conditioned by feeders 
Over the last 12 years, most of the work done in the investigation of the 
factors secreted by feeders (mouse or human fibroblasts) has focused on 
the analysis of the protein components of the medium (Lim and Bodnar, 
2002, Xie et al., 2004, Prowse et al., 2005, Prowse et al., 2007, Bendall 
et al., 2009, Talbot et al., 2012). Although many proteins have been 
detected, only a small fraction of them is known to be secreted or related 
with hESC growth, differentiation and pluripotency (Lim and Bodnar, 
2002, Prowse et al., 2007). The rest of proteins identified were of 
intracellular origin (endoplasmic reticulum, nucleus and cytoplasm) (Lim 
and Bodnar, 2002, Bendall et al., 2009). Furthermore, the CM used for 
identification of the protein factors is typically obtained under conditions 
different from those normally used for its collection or hESC culture. For 
instance, the unconditioned medium incubated with MEFs is serum- or 
serum replacement-free (to ease identification of the proteins released by 
MEFs) and is required to be collected after 16 – 18 hours of incubation, 
instead of the usual 24 hour-conditioning time, as the lack of serum may 
introduce stress to the MEFs (Lim and Bodnar, 2002, Chin et al., 2007). 
Under these conditions cellular physiology might have been altered and 
as a consequence the measured protein profiles may not be 
representative of normal culture conditions; nonetheless, these 
experiments have provided a valuable insight into the secretome of MEFs. 
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With regards to the profiling of the small-molecule (non-protein) 
components of the CM, only one report has been published to date. In 
this report, the authors employed a nuclear magnetic resonance (NMR)-
based metabolomics approach. They compared the metabolic profile of 
TeSR1™ medium (Ludwig et al., 2006b) before and after incubation with 
human foreskin fibroblasts (HFFs) (MacIntyre et al., 2011). The 
metabolites identified as secreted by the fibroblasts were lactate, 
pyruvate, formate and alanine which were found at higher concentrations 
in the medium conditioned by HFFs (MacIntyre et al., 2011). However, 
the effects of these metabolites on hESC proliferation or pluripotency 
remain unknown. Although this NMR method offered a rapid way of 
analysing CM samples, as it required minimal sample preparation, the 
compounds detected were mainly those present at higher concentrations 
in the medium. This highlights the need for a more sensitive method (like 
mass spectrometry) for the detection of more bioactive compounds 
secreted by feeders that may be found at lower concentrations in the CM. 
 
3.1.2 Murine or human feeders?  
Feeder cells from human origin are also able to support the growth of 
hESC (Richards et al., 2002, Amit et al., 2003, Hovatta et al., 2003); 
nonetheless, amongst feeder layers, mouse embryonic fibroblasts 
surprisingly proved to be more efficient in maintaining undifferentiated 
hESC than human feeders (Eiselleova et al., 2008). The capacity of 
conditioned media to support hESC growth relies on the ability of the 
feeders to secrete growth factors. Whereas human feeders secreted 
higher levels of basic fibroblast growth factor (bFGF), MEFs produced 
higher levels of Activin A. Although both factors have been shown to play 
an important role in the maintenance of hESC pluripotency (Vallier et al., 
2005), comparison of the percentage of cells expressing pluripotency 
markers (i.e. stage specific embryonic antigen-3 (SSEA-3)) showed a 
higher proportion of undifferentiated cells when hESC were grown on 
MEFs than when human feeders were used (Eiselleova et al., 2008). 
Consequently, medium conditioned by MEFs offers a better model for the 
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study of the extracellular factors involved in the regulation of hESC 
pluripotency.  
 
Metabolites secreted by MEFs feeder layers offer an important unexplored 
complementary approach for identification of potential low-molecular 
weight factors involved in the maintenance of hESC. However, at present, 
there is a lack of metabolomics methods for the identification of bioactive 
compounds in MEF-CM. In this study, a novel LC-MS-based metabolomics 
method has been applied to the analysis of the small-molecule 
components of MEF-CM and represents, to the best of the author’s 
knowledge, the first LC-MS metabolomics study of the factors secreted by 
MEFs.  
 
3.1.3 Aims and objectives 
 Employ the LC-MS metabolomics method described in chapter 2 for 
the analysis of the metabolic differences between UM and MEF-CM. 
 
 Identify potential small-molecule components in MEF-CM involved 
in hESC growth and pluripotency. 
 
 Investigate metabolic variability between batches of MEF-CM as 
well as MEF-CM collected over a time course of ten days. 
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3.2 Materials and methods 
3.2.1 Chemicals 
HPLC-grade acetonitrile and methanol were obtained from Fischer 
Scientific (Loughborough, UK). Deionized water (18.2MΩ) was prepared 
using an ELGA USF-Maxima water purification system (Marlow, UK). Mass 
spectrometry-grade formic acid and dimethylsulfoxide (DMSO) were 
purchased from Sigma-Aldrich (Gillingham, UK) and tissue culture 
reagents were obtained from Invitrogen. Deuterated arachidonic acid [5, 
6, 8, 9, 11, 12, 14, 15-2H8] (AA-d8) was purchased from Qmx 
Laboratories (Essex, UK). 
 
3.2.2 Preparation of AA-d8 stock solutions 
Under sterile conditions, stock solutions of AA-d8 were prepared with 
DMSO at concentrations of 0.032, 3.2 and 32 mM. 
 
3.2.3 Preparation of conditioned media 
Conditioned medium (CM) was prepared as described elsewhere 
(Burridge et al., 2007). Briefly, MEFs (strain CD1, 13.5 days post coitum) 
were mitotically inactivated with mitomycin C (10 µg/mL, 2.5 h) and 
seeded at 6x104 cells/cm2 in T75 flasks. The next day, inactivated MEFs 
were washed with PBS and incubated with 25 mL of unconditioned 
medium (UM) for 24 h, at which time CM was collected and stored at –
80⁰C until analysis. Unconditioned medium composition consisted of 
DMEM-F12 supplemented with 15% KnockOut Serum Replacement, 100 
mM β-mercaptoethanol, 1% non-essential amino acids (NEAA), 2mM 
GlutaMAX, and 4 ng/mL bFGF. MEF-conditioned media were prepared by 
Mrs Penny Howick, Mrs Katarzyna Lis-Slimak, Mrs Maria Barbadillo-Munoz 
and Dr James Smith, Wolfson Centre for Stem Cells, Tissue Engineering & 
Modelling, Centre for Biomolecular Sciences, University of Nottingham. 
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3.2.3.1 Time course experiment 
For the time course experiment, MEF-CM was collected similarly for 10 
consecutive days by adding fresh UM to the same flask of MEFs after 
each day of CM collection. 
 
3.2.3.2 Isotope labelling flux experiment 
25 mL of UM were supplemented with deuterated arachidonic acid at 
1.29x10-5, 1.29x10-3 and 1.29x10-2 mM by addition of 10 µL of each AA-
d8 stock solution. As a control, 10 µL of DMSO were added to 25 mL of 
UM too. All the media were incubated with or without MEFs and collected 
after 24 h.  
 
3.2.4 Sample preparation 
Unconditioned and MEF-conditioned media samples were prepared by 
solvent precipitation as described in chapter 2. Briefly, 250 µL of sample 
were mixed with 750 µL of cold MeOH (kept at -20⁰C), vortexed for 1 min 
to precipitate the proteins and stored at -20⁰C for 20 min. After the cold 
storage period, samples were vortexed again for 15 s and centrifuged at 
17000 rpm for 10 min at 4⁰C. The supernatants were transferred into LC 
vials for analysis. 
The number of prepared samples and analytical replicates are detailed in 
section 3.2.5. As part of the system conditioning and quality control 
process, a pooled “quality control” (QC) sample was prepared by mixing 
equal volumes of the samples involved in each experiment (Gika et al., 
2007, Want et al., 2010). These QC samples were also prepared in 
exactly the same manner as the test samples. 
 
3.2.5 Sample analysis 
Ten QC samples were injected at the beginning of each experiment to 
condition the LC system and then intermittently once every 6 test 
samples to assess the stability of the analysis. All test samples were 
injected in a randomised order to eliminate any bias.  
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To avoid problems related with long analysis times (retention time drifts, 
built-up contamination, loss of sensitivity, etc) (Zelena et al., 2009), the 
number of samples to prepare and number of injections were adjusted in 
order to keep analysis times to a minimum but still with enough 
analytical replicates to enable good statistics at the end of the 
experiment. For this, the number of sample conditions to be analysed 
were considered allowing at least three analytical replicates for each time 
each sample condition was prepared in order not to exceed 25 hours of 
LC-MS analysis. 
 
3.2.5.1 Unconditioned medium versus MEF-conditioned medium 
experiment 
For the comparison of UM vs MEF-CM, samples were prepared six times 
for each type of medium and injected in triplicate into the LC-MS system. 
To assess the reproducibility and robustness of the method (inter-day 
variability), the whole experiment was repeated three times with the 
same samples but on different days. 
 
3.2.5.2 Analysis of CM obtained from different batches of MEFs 
Samples of UM and MEF-CM batches 107, 115, 116, 117, 118, 120, 121 
and 122 were prepared three times each and injected in triplicates into 
the column. 
 
3.2.5.3 Time course experiment 
UM and MEF-CM samples from day 1 to day 10 (CM-day1 to CM-day10) 
were prepared two times each and injected in triplicates into the LC-MS 
system. 
 
3.2.6 Liquid chromatography conditions 
The chromatographic separations were performed on an Accela U-HPLC 
system (Thermo Fisher Scientific, USA) using a ZORBAX Eclipse Plus C18 
column 1.8 µm (i.d. 2.1x100 mm) attached to a guard column (2.1x5 
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mm) of the same chemistry and particle size (Agilent Technologies, 
Cheadle, UK). The oven temperature was maintained at 40⁰C while the 
autosampler temperature set at 4⁰C. The mobile phase consisted of 
solvent A: 0.01% formic acid in water and solvent B: 0.01% formic acid 
in acetonitrile. A step gradient programme was used starting with 10% B, 
0-0.3 min; 50% B, 5-6 min; 70% B, 7-8 min; 90% B, 9-10 min; 98% B, 
11-16 min; and coming back to the re-equilibration mobile phase 
composition of 10% B, 16.5-18 min. The flow rate was kept at 300 
µL/min with the exception of minute 9 to 11 which was increased to 400 
µL/min. Before each sample injection of 7 µL in no-waste mode, the 
needle was washed with 400 µL of 75% methanol. 
 
3.2.7 Mass spectrometry instrumentation 
The LC system was coupled online to an Exactive Orbitrap mass 
spectrometer (Thermo Fischer Scientific, USA) equipped with a heated 
electrospray interface (HESI-II) operating in positive and negative ion 
mode. The working parameters were: spray voltage, 3 kV; heated 
capillary temperature, 350⁰C; heater temperature, 300⁰C; sheath, 
auxiliary and sweep gas flow rates were 35, 10 and 5 arbitrary units, 
respectively. Data were acquired in full scan mode from m/z 70 – 1000 at 
50,000 FWHM (2 Hz) resolving power. 
To provide a higher degree of confidence for metabolite identification 
data dependent MS/MS experiments were carried out on an LTQ Velos 
mass spectrometer (Thermo Fischer Scientific, USA) as detailed in section 
2.2.7. The collision energy used was adjustable from 35 to 45 eV. 
 
3.2.8 Data processing and analysis 
The LC-MS raw data files were imported to SIEVE software version 2.0 
(Thermo Fisher Scientific, USA) and analysed in an unbiased manner, 
using the non-differential single class analysis option, in order not to 
specify classes or groups. The positive and negative electrospray 
ionisation data were analysed separately with the following settings: ion 
intensity threshold, 10000; peak width, 10 ppm; frame time width, 2.50 
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min and normalised to the total ion current. SIEVE analysis resulted in a 
data matrix containing the detected peaks characterised by their 
retention time, m/z value, and integrated intensity. This data matrix was 
exported in the form of a spreadsheet (Microsoft Excel) to be further 
manipulated for multivariate and univariate statistical analyses. For 
multivariate analysis (MVA), the data were processed with SIMCA version 
13.0 (Umetrics AB, Umea, Sweden) to create PCA and OPLS-DA models 
using unit variance (UV)-scaling. Positive and negative data sets were 
merged together into one single file for MVA manipulation. 
The ions responsible for the class separation were selected by means of 
the OPLS-DA loadings plots and VIP (Variable Importance to the 
Projection) plots. The metabolites that increased in one condition and 
reduced in the other were verified as true peaks using Xcalibur 2.2 
software (Thermo Fischer Scientific, USA). After verification, the m/z 
values were searched against web-based databases such as the Human 
Metabolome Database (www.hmdb.ca) (Wishart et al., 2009), Lipid Maps 
(www.lipidmaps.org) (Fahy et al., 2007) and METLIN Metabolomics 
Database (www.metlin.scripps.edu) (Smith et al., 2005). The MS/MS 
spectra of the ions were also compared with those registered in the 
aforementioned databases. 
For univariate statistics, data were exported to GraphPad Prism version 
6.03 (GraphPad Software Inc., California, USA). One-way ANOVA (using 
Dunnett’s post hoc test) and t-tests with Welch’s correction were applied 
where appropriate. Prior to Student’s t-test, D’Agostino-Pearson omnibus 
normality test was performed. Accounting for multiple comparisons 
Bonferroni correction was applied (maintaining a type I error probability 
of 0.05) before considering any statistically significant difference. Data 
are reported as the mean ± standard deviation (SD). 
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3.3 Results and discussion 
3.3.1 Chromatography and mass spectrometry stability 
Typical base peak chromatograms of MEF-CM in positive and negative ion 
electrospray are shown in Figure 3-2. Compounds previously identified in 
the UM (described in chapter 2) were also found in MEF-CM samples in 
addition to new compounds resulting from the MEF conditioning. The 
different classes of metabolites eluted at different retention time windows 
which are depicted in Figure 3-2 with capital letters. The elution order of 
typical small molecules detected in the MEF-CM was as follows: amino 
acids and vitamins, cholic-acid derivatives, lysophosphatidylcholines and 
lysophosphatidylethanolamines, fatty-acid amides (detected only in 
positive mode) and free fatty acids. Representative compounds for each 
class of metabolites are displayed in Table 3-1. In the analysis, 1178 and 
846 individual ions were detected in positive and negative electrospray 
ion (ESI) modes, respectively. 
 
 
Figure 3-2 Base peak chromatograms of MEF-CM in a) negative and b) positive 
ionisation mode. The elution order of identified compounds was: A, amino acids 
and vitamins; B, cholic-acid derivatives; C, lysophosphatidylcholines and 
lysophosphatidylethanolamines; D, fatty-acid amides; and E, free fatty acids. 
 
 
RT: 0.00 - 18.50
0 2 4 6 8 10 12 14 16 18
Time (min)
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
4.24
353.0492
9.54
540.3309 12.29
381.1742
13.46
383.18981.32
164.0710 10.47
568.3622
7.61
407.28076.45
464.3021
14.08
311.2957
3.54
107.0493
14.98
99.9248 17.32
716.5765
9.53
496.3389
10.48
524.3702
11.43
282.2786
4.23
355.0628 9.18
520.3390 13.47
705.5816
7.60
355.2625
14.75
705.5811
15.92
705.5812
1.81
154.9899
4.39
154.9899
NL: 2.69E6
Base Peak F: FTMS 
{1,2}  - p ESI Full ms 
[70.00-1000.00]  MS 
130510-MEF-
CM_R1_03
NL: 3.00E6
Base Peak F: FTMS 
{1,1}  + p ESI Full ms 
[70.00-1000.00]  MS 
130510-MEF-
CM_R1_03
A B C E 
D 
a) 
b) 
RT: 0.00 - 18.50
0 2 4 6 8 10 12 14 16 18
Time (min)
0
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
0
20
40
60
80
10
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
4.24
353.0492
9.54
540.3309 12.29
381.1742
13.46
383.18981.32
164.0710 10.47
568.3622
7.61
407.28076.45
464.3021
14.08
311.2957
3.54
107.0493
14.98
99.9248 17.32
716.5765
9.53
496.3389
10.48
524.3702
11.43
282.2786
4.23
355.0628 9.18
520.3390 13.47
705.5816
7.60
355.262
14.75
705.5811
15.92
. 2
1.81
154.98 9
4.39
154.9899
NL: 2.69E6
Base Peak F: FTMS 
{1,2}  - p ESI Full ms 
[70.00-1000.00]  MS 
130510-MEF-
CM_R1_03
NL: 3.00E6
Base Peak F: FTMS 
{1,1}  + p ESI Full ms 
[70.00-1000.00]  MS 
130510-MEF-
CM_R1_03
74 
 
Table 3-1. Representative compounds for each class of metabolites found in 
MEF-CM. The capital letters represent the elution order of the metabolites 
depicted in Figure 3-2. From polar to non-polar compounds, A-E. 
Polarity Class Subclass name Examples 
High A 
Amino acids 
L-glutamine 
L-phenylalanine 
Vitamins 
Niacinamide 
Folic acid 
Intermediate 
B Cholic-acid derivatives 
Taurocholic acid 
Glycocholic acid 
3-Oxocholic acid 
C 
Lysophosphatidyl-
ethanolamines (LPE) 
LPE(16:0) 
LPE(18:2(9Z,12Z)) 
Lysophosphatidyl-
cholines (LPC) 
LPC (18:3(9Z,12Z,15Z)) 
LPC(20:4(5Z,8Z,11Z,14Z)) 
Low 
D Fatty-acid amides 
Palmitoleamide 
Linoleamide 
Oleamide 
E 
Polyunsaturated free 
fatty acids 
Arachidonic acid 
Dihomo-gamma-linolenic acid 
Saturated free fatty 
acids 
Palmitic acid 
Stearic acid 
 
 
Data quality in metabolomics experiments is of paramount importance 
since these experiments will provide biological insights of the systems 
under study. Therefore, the use of quality control (QC) samples (Gika et 
al., 2007) was adopted as a way of assessing the quality of the data 
obtained from the analysis of UM and MEF-CM samples. A small subset of 
peaks (6 in +ESI and 6 in –ESI), covering a range of retention times and 
signal intensities, were selected to monitor their retention time (RT) and 
intensity variability in the QCs injected throughout the LC-MS analysis, 
discarding the first 10 QCs used for equilibration. Table 3-2 reports the 
percentage of coefficient of variation (%CV) of RT and intensity of the 
selected peaks. The acceptance criteria suggested by the Food and Drug 
Administration (FDA) for bioanalysis and biomarker validation are <2% 
variation for RT and <30% variation for signal intensity (FDA, 2013). 
Good mass accuracy for these ions was also observed with variability 
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lower than 5 mDa. The observed repeatability in RT and intensity of the 
QC samples indicated satisfactory analytical stability, well within the FDA 
acceptance criteria and demonstrated that the metabolomics analysis of 
the samples was valid.  
 
Table 3-2. Variation in retention time and intensity for selected peaks in positive 
and negative ESI mode. 
Negative ESI mode 
 
Retention time, min 
 
Intensity (arbitrary units) 
Peak (m/z) mean ± SD %CV 
 
mean ± SD %CV 
164.0710 1.33 ± 0.01 1.06 
 
5572088 ± 263062 4.72 
277.0175 4.43 ± 0.02 0.35 
 
96995 ± 5248 5.41 
514.2845 5.88 ± 0.01 0.25 
 
1022065 ± 14068 1.38 
502.2944 8.75 ± 0.02 0.18 
 
980682 ± 23755 2.42 
327.2331 11.13 ± 0.01 0.12 
 
660063 ± 16378 2.48 
311.2957 14.03 ± 0.02 0.16 
 
2834680 ± 43181 1.52 
     
 
 Positive ESI mode 
 
Retention time, min 
 
Intensity (arbitrary units) 
Peak (m/z) mean ± SD %CV 
 
mean ± SD %CV 
146.0597 1.41 ± 0.01 0.96 
 
22666244 ± 1303675 5.75 
377.1450 2.45 ± 0.04 1.68 
 
188756 ± 16912 8.96 
218.2111 4.65 ± 0.01 0.27 
 
78636 ± 2538 3.23 
412.2841 6.46 ± 0.00 0.00 
 
630859 ± 15216 2.41 
522.3547 9.79 ± 0.01 0.11 
 
11016529 ± 183850 1.67 
284.2943 12.3 ± 0.01 0.11 
 
750636 ± 8974 1.20 
 
 
3.3.2 Multivariate analysis 
Datasets obtained from positive and negative ion electrospray were 
combined to perform multivariate analysis. Initially, PCA was applied to 
generate an overview of the data as well as for detecting groups, outliers 
and/or trends within the samples. Figure 3-3 shows the PCA scores plot 
of UM and MEF-CM samples using unit variance (UV)-scaling. For clarity 
purposes, only one of the three experimental replicates is shown here, 
however, similar results were obtained on the other two days that the 
experiment was repeated. PCA with Pareto-scaled data was also 
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evaluated. However, stronger outliers in the principal component 2 were 
observed hence it was decided not to be used any further. The reason of 
the stronger outliers with Pareto scaling will be explain later with Figure 
3-4a and b. 
 
 
Figure 3-3 PCA scores plot of unconditioned medium (triangles) and mouse 
embryonic fibroblasts-conditioned medium (circles) samples. The separation 
between the two types of culture media indicates metabolic differences. Stability 
of the system is indicated by the tight cluster of QC samples (squares). CM_S1, 
analytical replicates of one of the prepared MEF-CM samples. 
 
Whereas principal component 1 (t[1]) in Figure 3-3 showed a clear 
separation between unconditioned and MEF-conditioned media, indicating 
metabolic differences between the samples, principal component 2 (t[2]) 
displayed the analytical variability. It is observed that MEF-CM samples 
(circles) present better clustering on the right-hand side of the plot 
although three replicates appear apart from the group. As the deviated 
injections were all the replicates of one of the six MEF-CM prepared 
samples, the atypical behaviour was attributed to a bad manipulation 
during sample preparation; however, since they are still within the 95% 
confidence interval (indicated by the Hotelling’s T2 ellipse) they were 
kept in the model. On the other hand, UM samples (triangles) were more 
scattered in t[2]. Nonetheless, the analytical run demonstrated sufficient 
stability as described previously and also indicated here by the tight 
cluster of QC samples (squares) injected throughout the analysis. 52.4% 
of the data variation was explained by the first three principal 
components of the PCA model. 
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When PCA with Pareto-scaled data was performed, stronger outliers in 
the direction of the principal component 2 were observed (data not 
shown). Figure 3-4 shows the p[2] loadings plot of the UV- and Pareto-
scaled data. Notice that when Pareto scaling is used, the weight of 
particular variables (those depicted with an open red circle) in the p[2] 
loadings plot is increased (Figure 3-4b) when compared to the same 
variables in the UV-scaled data (Figure 3-4a). This signifies that these 
highlighted variables contribute largely to the scores (some of them 
outliers) in t[2] of the Pareto-scaled PCA (data not shown). Having 
examined these variables in more detail, it was noted that the outliers 
observed with the Pareto-scaled PCA showed lower levels of these 
variables which made them deviate from the rest of samples and appear 
outside of the Hotelling’s T2 ellipse. As a consequence, for the 
experiments carried out in this thesis, UV-scaling was preferred as it 
provided all the variables with an equal opportunity to influence the data 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4 p[2] loadings plot of a) UV- and b) Pareto-scaled data. The open red 
circles highlight the variables that contributed to the observation of outliers 
when Pareto-scaling was used. 
a) 
b) 
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3.3.2.1 OPLS-DA and OPLS-DA model validation 
To find out the metabolites that accounted for the difference between UM 
and MEF-CM, OPLS-DA was applied. Since OPLS-DA is a supervised 
method that maximises the separation between the groups and 
minimises within class variation (Bylesjo et al., 2006), it allows the 
identification of the important metabolites that contribute to the class 
separation. To build the model, 75% of the samples (n=27) were 
randomly selected and the 25% left (n=9) was used for model external 
validation (Figure 3-5). R2Y(cum) and Q2(cum) parameters were used for 
the evaluation of the model. R2 is a measure of how well the model fits 
the data while Q2 indicates how well the model predicts new data. Values 
above 0.4 are respectively indicative of good model fitting and good 
predictivity (Westerhuis et al., 2008). In this experiment, a good 
discriminating model was achieved. R2Y(cum) and Q2(cum) values were 
0.997 and 0.992, respectively. 
 
 
Figure 3-5 a) OPLS-DA model of UM versus MEF-CM. b) T-predicted plot as a 
result of the OPLS-DA model external validation.  UM,  MEF-CM,  UM 
prediction set, and  MEF-CM prediction set. Q2(cum) 0.992, R2X(cum) 0.467, 
R2Y(cum) 0.997. 
 
Classification models like OPLS-DA require validation to assess their 
predictive ability (Westerhuis et al., 2008); thus, cross-validation and 
external validation were used to validate the model. Initially, a cross-
validation-analysis of variance (CV-ANOVA) test ensured model validity 
with a resulting p-value of 2.56x10–33. This provided statistical 
verification that metabolites in MEF-CM were distinct from those found in 
UM. Additionally, external validation of the OPLS-DA model was 
a)                                                      b) 
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performed with an independent test set which consisted of 5 UM and 4 
MEF-CM samples (the 25% of the samples initially excluded). None of 
these samples had been previously included during the supervised model 
building, therefore allowed the evaluation of the predictivity of the model. 
As shown in Figure 3-5b, the OPLS-DA model correctly predicted all the 
UM- and MEF-CM-prediction set samples, demonstrating its feasibility for 
classifying new data. 
 
3.3.2.2 Discovery and identification of altered metabolites in MEF-CM 
The small molecules responsible for the separation (metabolic difference) 
between UM and MEF-CM were selected according to pq values (loading 
weights of the X (p) and Y (q) variables combined in one vector) obtained 
from the loadings plot. Variables (ions) with the lowest and the highest 
loading weights were chosen as long as their VIP (variable importance for 
the projection) values were above 1.5. Ions that fulfilled the criteria were 
subjected to Student’s t-tests. In metabolomics, the number of 
univariate-paralleled t-tests equals the number of ions detected. As the 
number of hypotheses tests increases so does the probability of rejecting 
a null hypothesis; that is, the chance of making a Type I error (false 
positive) (Vinaixa et al., 2012). Therefore, the p-value threshold at which 
a statistically significant difference is considered should be stricter. 
Bonferroni correction is applied to correct for multiple comparisons 
according to the following equation: 
α = FWER/k 
Where:  
α = pre-defined threshold of probability in each individual test. 
FWER = family wise error, the probability (0.05) of yielding one or 
more false positives out of all hypotheses tested. 
k = the number of hypothesis tests performed (number of ions 
detected). 
Therefore, in this experiment, only those ions with p-values ≤ 2.47x10–5 
were considered statistically significant as α = 0.05/2024 = 2.47x10–5. 
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Further, the ions that differed significantly were identified. The detailed 
method of compound identification has been described in section 2.3.6 
and in the same way was applied here. The list of significant metabolic 
changes are summarised in Table 3-3. To provide a more intuitive 
comparison, box and whiskers plots of some representative metabolites 
are shown in Figure 3-6. 
Owing to limitations of databases’ repositories some ions remained 
unknown; however, they were listed in Table 3-3 due to their 
importance, as they were only detected in MEF-CM. Other ions like those 
at m/z 329.2336, 333.2074, 247.1703, 249.1859 and 251.2017, 
although identified, lacked a more precise identification because of the 
high chemical structure similarity of their isomers. Furthermore, MS/MS 
data could not provide specific information to distinguish amongst them. 
For example, the m/z 333.2074 ion matched the exact [M–H2O–H]
– ion 
mass of the prostaglandins PGE2, PGD2 and PGH2. Then, when the MS/MS 
spectrum of the m/z 333.2074 ion in the samples was obtained and 
compared with the LipidMaps reference MS/MS spectra of PGE2, PGD2 and 
PGH2 (Figure 3-7), it was difficult to assign a unique identity because the 
MS/MS pattern of the sample was similar to the MS/MS patterns of the 
three prostaglandins. Therefore, to discern between isomers, the use of 
authentic standards will be required so that retention time can be used as 
discriminator when the three prostaglandins are injected into the LC-MS 
system. In the particular case of the ion at m/z 333.2074, it is very likely 
that PGE2 is the one present in the samples since it has been previously 
identified in MEF-CM (Jones et al., 2010). However, for the rest of ions, 
this is the first time that they have been reported in MEF-CM and their 
identity will be confirmed and described in more detail in chapter 4. In 
this chapter the metabolites will be discussed based on their putative 
identity (shown in Table 3-3) assigned with high degree of confidence 
after MS/MS analysis. 
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Table 3-3. Significant metabolic changes between unconditioned medium and MEF-conditioned medium. 
Accurate 
mass (m/z) 
Δ ppm RT 
(min) 
Ion Formula Putative Identification Fold 
change 
Database 
Reference 
Supporting 
Information 
147.0762 1.4 0.81 [M+H]+ C5H10N2O3 L-Glutamine -2.31 HMDB00641 MS2; 130; 101 
216.0986 1.9 0.89 [M–H]– C8H15N3O4 L-Alanyl-L-glutamine -2.66 HMDB28685  
308.8783  0.97 [M+H]+  Unknown Note 1   
89.0234 11.2 0.98 [M–H]– C3H6O3 Lactic acid 39.51 HMDB00190 MS2; 71; 61 
129.0548 7.0 1.71 [M–H]– C6H10O3 4-methyl-2-oxovalerate 27.35 HMDB00695 MS2; 111; 101; 85 
267.0422  1.71 [M+H]+  Unknown 66.31   
642.3073 -1.1 5.41 [M–H]– C30H49N3O10S S-(9 deoxy-delta12-PGD2)glutathione Note 1 HMDB13057  
369.2284 -0.5 5.51 [M–H]– C20H34O6 6-keto-PGF1α Note 1 LMFA03010001 MS2; 351; 333; 
315; 289 
329.2336 -0.9 6.39 [M–H]– C18H34O5 9,10,13-TriHOME or 9,12,13-TriHOME 14.86 HMDB04710, 
HMDB04708 
MS2; 311; 285 
333.2074 -0.9 6.59 [M–H2O–H]
– C20H32O5 PGE2 or PGD2 or PGH2 6.78 LMFA03010003, 
LMFA03010004, 
LMFA03010010 
MS2; 333; 315; 
271; 189 
586.3154 -1.5 8.76 [M+HCOO–]– C28H48NO7P LPC(20:5(5Z,8Z,11Z,14Z,17Z)) -1.53 LMGP01050050 MS2; 301; 257; 224 
588.3309 -1.4 9.19 [M+HCOO–]– C28H50NO7P LPC(20:4(5Z,8Z,11Z,14Z)) -1.69 LMGP01050048 MS2; 303; 259; 224 
614.3467 -1.5 9.40 [M+HCOO–]– C30H52NO7P LPC(22:5(7Z,10Z,13Z,16Z,19Z)) -1.41 HMDB10403 MS2; 329; 285; 242 
590.3470 -2.0 9.55 [M+HCOO–]– C28H52NO7P LPC(20:3(5Z,8Z,11Z)) or 
LPC(20:3(8Z,11Z,14Z)) 
-1.74 HMDB10393, 
LMGP01050133 
MS2; 305; 242; 224 
417.3357 1.4 9.90 [M+H]+ C27H44O3 1, 25-Dihydroxyvitamin D3 88.97 HMDB01903 MS2; 399; 381 
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Accurate 
mass (m/z) 
Δ ppm RT 
(min) 
Ion Formula Putative Identification Fold 
change 
Database 
Reference 
Supporting 
Information 
464.3131  9.96 [M+H]+  Unknown 2.49   
247.1703 0.0 10.05 [M–H]– C16H24O2 Hexadecatetraenoic acid 122.19 LMFA01030163
a MS2; 229; 203; 149 
249.1859 0.4 10.45 [M–H]– C16H26O2 Hexadecatrienoic acid 24.66 LMFA01030134
a MS2; 231; 205; 151 
345.2437 -0.6 10.51 [M–H]– C22H34O3 1alpha,22-dihydroxy-23,24,25,26,27-
pentanorvitamin D3  
2.95 LMST03020011  
275.2019 -1.1 10.54 [M–H]– C18H28O2 Stearidonic acid 4.70 LMFA01030357 MS2; 257; 231; 177 
251.2017 -0.4 10.95 [M–H]– C16H28O2 Hexadecadienoic acid 4.58 LMFA01030109
a  
623.4171  11.06 [M–H]–  Unknown Note 1   
303.2331 -0.7 11.39 [M–H]– C20H32O2 Arachidonic acid -1.86 LMFA01030001 MS2; 285; 259; 205 
305.2488 -0.7 11.83 [M–H]– C20H34O2 Dihomo-gamma-linolenic acid -2.52 LMFA01030158 MS2; 287; 261; 207 
331.2645 -0.9 12.15 [M–H]– C22H36O2 Adrenic acid -2.09 LMFA01030178 MS2; 313; 287; 233 
401.3407 1.7 13.78 [M+H]+ C27H44O2 7-Ketocholesterol 4.21 LMST01010049 MS2; 383; 365 
Fold changes were calculated as the ratio of the average peak area (n=18) of MEF-CM and UM, for decreased metabolites the ratio is inverted and the 
sign changed to indicate such decrease. 
a 
Used here only as an example as LipidMaps database provides a list of similar isomers.  
LPC, lysophosphatidylcholine; PGF1, prostaglandin F1; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGH2, prostaglandin H2; TriHOME, 
trihydroxyoctadecenoic acid. 
MS2 supporting information indicates the characteristic fragment ions of each molecule and whose MS/MS spectrum is shown in appendix B. 
Note 1: the ion was only detected in MEF-CM. 
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Figure 3-6 Upper panel, integrated intensities of representative metabolites whose concentrations increased in the CM after UM 
incubation with MEFs. Lower panel, integrated intensities of representative metabolites with decreased levels in CM. The boxes are drawn 
from the 25th to 75th percentiles in the intensity distribution. The median, or 50th percentile, is represented as a horizontal line inside the 
box. 
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Figure 3-7 Example showing identification by reference to library MS/MS 
spectra. Reference MS/MS spectra of a) PGD2, b) PGE2 and c) PGH2 obtained 
from LipidMaps database. d) experimental MS/MS spectrum of ion m/z 
333.2074 in MEF-CM samples. It is difficult to assign a more precise 
identification for this ion since the MS/MS data is insufficient to provide 
specific information to distinguish between isomers. 
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3.3.3 Identification of possible metabolic pathways occurring 
during the MEF-conditioning process 
As shown in Table 3-3, the compounds that decreased their concentration 
in the MEF-CM were, amongst others, lysophosphatidylcholines and 
arachidonic acid, while those that increased (secreted by MEFs) were 
mostly polyunsaturated fatty acids, including prostaglandins (PGs). 
Searching into the Kyoto Encyclopaedia of Genes and Genomes (KEGG, 
www.genome.jp/kegg), it was possible to identify different metabolic 
pathways relating both the increased and decreased metabolites (Figure 
3-8). Arachidonic acid (AA), linoleic acid (LA) and alpha-linolenic acid 
(ALA) metabolism pathways were found to be involved during the 
conditioning of the medium. 
AA can be released from phospholipids (i.e. lysophosphatidylcholines) via 
phospholipase A2 or formed by the elongation and desaturation of LA. 
Moreover, β-oxidation of adrenic acid can also lead to AA formation 
(Mann et al., 1986). Further, AA can be metabolised by a number of 
enzyme pathways including cyclooxygenase (COX), which gives rise to 
PGs; lipoxygenase (LOX), which forms leukotrienes, lipoxins and 
hydroxyeicosatetraenoic acids (HETEs); and cytochrome P-450 (CYP), 
which results in epoxyeicosatrienoic acids (EETs) (Wenzel, 1997). LA, on 
the other hand, can produce trihydroxyoctadecenoic acids (TriHOMEs) via 
9S-lipoxygenase and lastly, stearidonic acid results from the action of Δ6-
desaturase on alpha-linolenic acid (Guil-Guerrero, 2007). Due to the 
central importance of AA metabolism to produce bioactive oxylipins such 
as the observed here with increased levels of PGs, it was decided to 
investigate this area further as described below. 
3.3.3.1 Arachidonic acid metabolism 
To test the hypothesis that the prostaglandins observed in the CM are 
produced by MEFs using arachidonic acid as substrate, an isotope 
labelling flux experiment was carried out. UM was supplemented with AA-
d8 at three different concentrations; 1.29x10-5, 1.29x10-3 and 1.29x10-2 
mM. The UM+DMSO, used as a control, and the AA-d8-supplemented 
unconditioned media were incubated with and without MEFs for 24 h, 
after which the samples were analysed. 
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Figure 3-8 Metabolic pathways identified during the process of medium conditioning. One of the main pathways is arachidonic acid 
(AA) metabolism since it relates most of the decreased metabolites found in CM. Although AA can be metabolised by several enzyme 
pathways (cytochrome P-450 (CYP-450), lipoxygenase (LOX) and cyclooxygenase (COX)), only metabolites associated with COX 
activity (prostaglandins) were detected in the CM. Other increased metabolites can be explained by linoleic acid (LA) and α-linolenic 
acid (ALA) metabolism. LA oxidation by 9S-lipooxygenase leads to trihydroxyoctadecenoic acids (TriHOMEs), while desaturation of 
ALA produces stearidonic acid. Furthermore, LA and AA metabolism are interconnected as desaturation and elongation of LA can give 
rise to AA. Increased (blue) and decreased (red) metabolites of CM are coloured to ease interpretation. HETEs, hydroxyeicosa-
tetraenoic acids. 
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The peak areas of AA-d8 and the deuterated forms of PGE2 (or its 
isomers, PGD2 or PGH2) and 6-keto-PGF1a were taken from the extracted 
ion chromatograms of UM incubated with and without MEFs. Samples 
incubated without MEFs did not produce PGs (data not shown). On the 
contrary, those incubated with MEFs showed a decrease of AA-d8 and an 
increase of deuterated PGE2 (or isomers), 6-keto-PGF1a and S-(9 deoxy-
delta12-PGD2) glutathione (Figure 3-9). It is worth noting that during the 
transformation of AA-d8 to prostaglandins, there is a loss of one 
deuterium atom, hence, producing prostaglandins (PGE2-d7 and 6-keto-
PGF1a-d7) seven mass units different from the non-labelled ones (Figure 
3-9c, d). With this experiment, it was confirmed that arachidonic acid is 
used by mouse embryonic fibroblasts to produce prostaglandins; 
however, products from other enzymatic pathways (LOX or CYP-450) 
were not identified, suggesting a predominant COX activity in MEFs. 
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Figure 3-9 a) and b) peak areas of deuterated arachidonic acid (AA-d8) and 
deuterated prostaglandins, respectively. c) Starting AA-d8 (m/z 311.2828) 8 
amu heavier than non-labelled (m/z 303.2329) and producing d) prostaglandins 
(6-keto-PGF1α, as an example) 7 amu different between deuterated (m/z 
376.2722) and non-labelled (m/z 369.2280). Data represent mean ± SD (n=3).  
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3.3.3.2 Linoleic acid and α-linolenic acid metabolism 
As shown in Figure 3-8, TriHOMEs are the result of linoleic acid oxidation, 
thus, it was expected that LA would be reduced in the CM; however, no 
significant reduction was observed (Figure 3-10). This suggests that 
either LA levels are being replenished by other metabolic reaction(s) or 
that TriHOMEs are formed from other sources. Since there have not been 
reported sources of TriHOMEs other than LA (Funk and Powell, 1983, 
Nording et al., 2010), it is more likely that hydrolysis of 
lysophosphatidylcholines (LPCs) release more LA. 
Similarly, stearidonic acid is the main metabolite of α-linolenic acid (Guil-
Guerrero, 2007) and no other sources of stearidonic acid have been 
identified. However, in this case, not only ALA concentrations were 
maintained or decreased but, surprisingly, they increased (Figure 3-10). 
Likewise the high content of LPCs (a source of fatty acids) in UM could 
explain such results. 
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Figure 3-10 Peak areas of a) linoleic acid (LA) and b) α-linolenic acid (ALA) in 
unconditioned (UM) and conditioned medium (CM). No significant difference in 
LA levels was found in spite of being the only possible source of 
trihydroxyoctadecenoic acids (TriHOMEs) which are increased in CM. An 
unexpected significant increase of ALA was observed in CM when it would be 
expected to decrease as stearidonic acid (increased in CM) formation results 
mainly from ALA desaturation. The unexpected results could be explained by the 
lysophosphatidylcholines (source of fatty acids) present in UM. Data represent 
mean ± SD (n=18). Statistical analysis used was Student’s t-test. Significance: 
*p < 2.47x10–5. 
 
 
a) b) 
* 
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3.3.4 Analysis of a series of batches of MEF-CM obtained from 
separate batches of MEFs 
Initially, the analysis of conditioned media collected from different 
batches of MEFs was intended to investigate differences between 
supportive and non-supportive MEF-CM batches. It was expected that 
during isolation of MEFs some batches would fail to produce a suitable 
medium for hESC growth, hence, the difference between those batches 
that supported hESC proliferation from those that did not could be 
investigated. However, all the batches of MEF-CM were able to support 
hESC proliferation. Consequently, these batches were used to study the 
variability in small molecule composition of MEF-CM between batches.  
PCA was applied in the first instance to obtain an overview of the 
samples. As seen in Figure 3-11a there is a clear separation between UM 
and the batches of CM. UM replicates clustered far on the right-hand side 
of the plot while the conditioned medium batches appeared more 
scattered in the middle showing metabolic differences even amongst 
them. This illustrates the considerable batch-to-batch variability in the 
small molecule components and hence the incubation conditions to which 
hESC are subjected during culture. To further investigate the differences 
between the two types of media, the corresponding PCA loadings plot 
was analysed (Figure 3-11b). Consistent with the first findings, UM 
samples presented higher levels of L-alanyl-L-glutamine, arachidonic 
acid, LPC(20:5) and LPC(20:4) while CM samples contained higher 
concentrations of lactic acid, 6-keto-PGF1a, PGE2 (or PGD2 or PGH2), 9, 
10, 13 TriHOME (or 9, 12, 13 TriHOME) and stearidonic acid (Figure 
3-11b). 
The metabolic differences observed amongst the batches in the PCA 
scores plot indicate that each batch of MEFs possesses different 
capabilities of transforming UM into a suitable medium for hESC culture; 
in other words, of secreting potential factors required for long term 
expansion of hESC. For example, MEF-CM batch 117 in Figure 3-12 is the 
one that produces the lowest levels of lactic acid and 6-keto-PGF1a, and 
also the one that consumes less arachidonic acid and LPC(20:4). This 
behaviour is also reflected in the PCA scores plot as MEF-CM-117 appears 
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closer to UM. On the contrary, MEF-CM-107 and MEF-CM-120 produced 
more lactic acid and prostaglandins and consumed more nutrients from 
the UM than the rest of batches. In this case, MEF-CM-107 and MEF-CM-
120 appeared farther from UM.  
 
 
 
 
 
 
 
 
 
           
Figure 3-11 a) PCA scores plot and b) PCA loadings plot of MEF-CM obtained 
from different batches of MEFs. The position of an observation in a given 
direction in a scores plot is influenced by variables lying in the same direction in 
the loadings plot. Therefore, samples that appear on the right-hand side of the 
scores plot contain higher levels of the variables (metabolites) on the right-hand 
side of the loadings plot and vice versa. LPC, lysophosphatidylcholine. 
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Figure 3-12 Batch to batch variability observed during the conditioning process. Different batches of MEFs (107, 115, 116, 117, 118, 120, 
121 and 122) were used to condition the same batch of UM and the metabolic differences amongst batches are shown by selection of 
representative increased and decreased metabolites in CM. One-way ANOVA with Dunnett’s post hoc test indicates significant differences 
between the CM batches and UM (control). Data represents mean ± SD (n=9). Significance: ***p < 0.001. 
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The small-molecule composition differences observed amongst the MEF-
CM batches were also reflected in the efficacy in which each batch 
supported the expansion of hESC. Table 3-4 shows the hESC doubling 
times obtained with each batch of MEF-CM, doubling time is the period of 
time required by the hESC to double their population. According to this; 
the shorter the doubling time the greater the growth rate. In this case, 
batches 120, 121 and 122 showed the most efficient growth rates as they 
had the shortest doubling times. However, attributing this difference to 
solely observing changes in the small-molecule composition of the MEF-
CM media would be difficult since when the MEF-CM batches were tested 
no protein had been removed from the media. Therefore, it is fair to say 
that a combination of protein factors and small-molecule factors may 
contribute to the observation of short doubling times. Nevertheless, 
evaluation of the increased metabolites in MEF-CM would determine if 
these small molecules can also affect the efficiency in which MEF-CM can 
support the proliferation of hESC. Biological evaluation of selected 
metabolites found increased in MEF-CM will be carried out in chapter 4 
and will help to understand the effect of these small molecules on hESC 
proliferation. 
 
Table 3-4. Population doubling times of hESC tested with several batches of 
MEF-CM.  
hESC doubling times (days) 
MEF-CM-107 1.87 
MEF-CM-115 1.99 
MEF-CM-116 1.89 
MEF-CM-117 1.79 
MEF-CM-118 1.83 
MEF-CM-120 1.73 
MEF-CM-121 1.72 
MEF-CM-122 1.74 
Note: Data were kindly provided by Dr Maria Barbadillo-Munoz. 
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3.3.5 Investigating the effect of MEF age on CM small molecule 
composition 
Routinely, batches of MEFs are used to prepare CM every 24 h for a 
period of seven days (Burridge et al., 2007, Mahlstedt et al., 2010), after 
which MEFs are disposed of as they get old and the CM is stored at -20⁰C 
for future use. To investigate the effect of MEF age on the composition of 
MEF-CM, metabolite profiles of CM collected over a time course of ten 
days were analysed. PCA (Figure 3-13) revealed a time-effect trend in 
the collection of the media. The tendency observed from CM-day 2 to 
CM-day 8 could indicate two things: 1) that MEFs are producing more or 
less of certain metabolites every day or 2) that MEFs are consuming more 
or less nutrients from UM. In either case, this demonstrates that even 
with the same batch of MEFs, the CM produced and used in hESC culture 
varies greatly in its chemical composition, highlighting the need of a 
chemically defined medium for the reproducible expansion of hESC in 
order to realise their clinical use. Interestingly, CM-day 1, CM-day 9 and 
CM-day 10 appeared outside of the trend, suggesting that other 
metabolic changes are occurring when MEFs are used fresh (CM-day1) 
and when they get very old. A possible explanation is that MEFs coming 
from a different culture system (as the medium in which MEFs are 
derived is different from the medium used for conditioning) adjust to the 
new conditions (UM) to produce CM. To better understand these 
metabolic differences, peak areas from individual metabolites were 
examined. For illustration purposes, increased and decreased metabolites 
are presented as plots of metabolites present in low, medium and high 
concentration in MEF-CM (Figure 3-14 and Figure 3-15). 
 
 
 
 
 
 
 Figure 3-13 PCA scores plot of CM obtained every 24 h for 10 consecutive days 
(CM-day1 to CM-day10). A time-effect trend is observed during CM collection, 
indicating continuous increased or decreased metabolic changes. 
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Figure 3-14 Low, medium and high concentration plots of metabolites with 
increasing trends in MEF-CM collected for ten consecutive days. Each point 
represents the average peak area ± SD (n=6) of the metabolites on each day. 
Day 0 means UM.  
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Figure 3-15 Low, medium and high concentration plots of metabolites with 
decreasing trends in MEF-CM collected over a 10-day period. Each point 
represents the average peak area ± SD (n=6) of the metabolites on each day. 
Day 0 means UM. 
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A more careful inspection of the metabolic differences revealed several 
trends. For example, metabolites that steadily increased or decreased 
over time (e.g. lactic acid and LPC(20:4), respectively); metabolites that 
had a day of maximum secretion (PGs); and metabolites that increased 
or decreased and then were maintained constant (e.g. L-histidine and 4-
methyl-2-oxovalerate, respectively). This illustrates the metabolic 
changes caused by MEF ageing. 
As demonstrated before, AA is the substrate for the production of PGs; 
therefore, it would be expected that at the day of maximum 
prostaglandin secretion (day 5), AA levels would show a minimum on the 
same day; however, the levels of AA were almost constant. This suggests 
that other sources of AA might be being activated to maintain steady 
concentrations of AA. These sources could be LPC(20:4) (Wenzel, 1997), 
adrenic acid (Mann et al., 1986) and dihomo-gamma-linolenic acid (Wang 
et al., 2012) (Figure 3-8) which were observed to be constantly reducing 
over time; however this requires further investigation.  
The data also indicate that L-glutamine is highly needed when MEFs 
senesce as there is a large consumption of the dipeptide L-alanyl-L-
glutamine which results in increased levels of L-alanine but not of L-
glutamine. Other amino acids that seem to be essential in the diet of 
mice (MEFs in this case) (Bauer and Berg, 1943) were also reduced. 
These were L-valine, L-histidine, L-phenylalanine, L-threonine, L-lysine, 
L-leucine and L-isoleucine. 
As MEFs get older they also present higher glycolytic activity as indicated 
by the increase over time of glycolysis endpoints such as pyruvate and 
lactate. These results are in agreement with the constant lactic acid 
increase reported elsewhere (Gupta et al., 2012) although the CM 
collection was for a shorter period of time (3 days). It has been shown 
however that above certain concentration (1.5 g/L), lactic acid becomes 
detrimental for the cells as demonstrated by inhibition of mouse 
embryonic stem cell growth (Ouyang et al., 2007). These observations 
may, in part, explain the low efficiencies observed  when hESC are 
cultured with CM-day 7 when compared with those cultivated with CM 
from day 1 (Villa-Diaz et al., 2009). A lower percentage of 
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undifferentiated colonies were observed with CM-d7 (31.7%) whereas 
with CM-day 1 a higher proportion of hESC remained undifferentiated 
(78.6%) (Villa-Diaz et al., 2009). Together, these results indicate that 
MEFs’ senescence affects the production of efficient CM that supports 
hESC growth.  
In the same way as lactic acid, polyunsaturated fatty acids like 
hexadecatetraenoic acid, hexadecatrienoic acid, hexadecadienoic acid and 
stearidonic acid showed a continuous increase along the days of CM 
collection; however, there is lack of information about the possible 
beneficial or toxic effects on stem cells. 
 
 
3.3.6 Biological significance of altered metabolites 
Metabolites whose concentrations increased after the medium 
conditioning process include lactic acid, prostaglandins, polyunsaturated 
fatty acids (PUFAs), 7-ketocholesterol and vitamin D derivatives. On the 
other hand, metabolites that decreased or were used by MEFs during 
incubation were mainly lysophosphatidylcholines, some PUFAs (including 
arachidonic acid) and L-glutamine which was obtained directly from the 
medium or after in situ hydrolysis of the dipeptide L-alanyl-L-glutamine. 
Amongst the increased metabolites, prostaglandins and vitamin D 
derivatives have been shown elsewhere to be involved in the proliferation 
and pluripotency maintenance of stem cells. For example, prostaglandin 
E2 promotes cell proliferation (Kim and Han, 2008) and protects mouse 
embryonic stem cells from apoptosis (Liou et al., 2007). Additionally, 
PGE2 stimulates proliferation of human mesenchymal stem cells (Arikawa 
et al., 2004) and enhances both mouse and human hematopoietic stem 
cell survival (Hoggatt et al., 2009). On the other hand, 6-keto-
prostaglandin F1α (6-keto-PGF1α), a stable metabolite of prostaglandin 
I2, has been reported to be involved in inducing hESC to form 
cardiomyocytes (Xu et al., 2008b), although a more recent report has 
associated both 6-keto-PGF1α and PGE2 with hESC self-renewal (Jones et 
al., 2010). The biologically active form of vitamin D, 1, 25-
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dihydroxyvitamin D3, on the other hand, has been reported to maintain 
the multipotent capacity of human mesenchymal stem cells (Klotz et al., 
2012). To date, there is no direct evidence of their effect on hESC. 
Even though there have not been reports associating the increased PUFAs 
in CM with stem cells, 9, 10, 13-TriHOME and 9, 12, 13-TriHOME are 
believed to regulate prostaglandin synthesis (Funk and Powell, 1983), 
which suggests that they could modulate the synthesis of more active 
compounds implicated in stem cell proliferation. Stearidonic acid, on the 
contrary, has been characterized as a potent inhibitor of cancer cell 
growth (Cantrill et al., 1993) and may have undesirable effects on hESC, 
but there is still not sufficient information to support this idea. 
7-ketocholesterol (7-KC), another increased metabolite in the CM, has 
shown cytotoxic and pro-apoptotic effects on human adipose tissue 
mesenchymal stem cells (Levy et al., 2014). Nevertheless, oxysterols, 
the group of compounds to which 7-KC pertains, are known activators of 
the hedgehog signalling pathway (Dwyer et al., 2007) whose activation 
has stimulated the proliferation of mouse embryonic stem cells (Heo et 
al., 2007). Thus, in spite of the reported deleterious effects of 7-KC, it is 
likely that it can stimulate hESC growth by activation of the hedgehog 
pathway. 
With regards to the decreasing metabolites, the importance of 
arachidonic acid has been shown in the production of prostaglandins; 
although some prostaglandins can also be produced from dihomo-
gamma-linolenic acid (Wang et al., 2012) (Figure 3-8). Further, it has 
been pointed out previously that lysophosphatidylcholines, dihomo-
gamma-linolenic acid and adrenic acid could act as alternative sources of 
arachidonic acid and so maintain AA levels. 
Overall, whether or not the increased metabolites of MEF-CM have an 
effect on hESC proliferation and/or pluripotency maintenance they have 
to be tested in hESC culture. Such investigations will be described and 
discussed later in chapter 4. 
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3.4 Conclusions 
In an attempt to identify the small-molecule factors secreted by MEFs 
during the medium conditioning process, the LC-MS metabolomics 
method, described in chapter 2, was applied and successfully identified 
metabolic differences between UM and CM samples. The LC-MS approach 
showed excellent advantages for the study of conditioned medium as it 
could detect changes in levels of low abundance bioactive molecules with 
potential roles in hESC growth, survival and maintenance of pluripotency.  
Lactic acid, prostaglandins, polyunsaturated fatty acids, 7-ketocholesterol 
and vitamin D derivatives were found to be increased or were only 
detected in MEF-CM samples. However, their increased concentration in 
CM does not necessarily imply that the metabolites are involved in hESC 
growth or pluripotency as some of the increased metabolites have also 
been associated with deleterious effects (i.e. lactic acid, 7-KC) on other 
stem cell types. Therefore, to corroborate whether or not these 
metabolites exert a positive or negative effect on hESC proliferation, they 
need to be tested in in vitro hESC culture (investigated in chapter 4).  
It was demonstrated that arachidonic acid metabolism by cyclooxygenase 
is an enzyme pathway highly active during MEF-conditioning which led to 
the formation of prostaglandins (PGE2 and 6-keto-PGF1α) associated with 
stem cell proliferation. Nonetheless, this enzyme activity varies from 
batch to batch and even from day to day of collection as demonstrated by 
the analysis of CM obtained with different batches of MEFs and CM 
collected every 24 h from the same batch of MEFs. The chemical 
variability of these conditioned media points out the need of a culture 
medium with a more consistent composition for the reproducible 
expansion of pluripotent hESC required in clinical applications. The 
insights provided by the metabolic profiling results of these experiments 
may greatly contribute towards this end. 
 
 
 
 
CHAPTER 4 
The effect of small 
molecules found in MEF-CM 
on the maintenance of hESC 
cultures 
 
101 
 
4 The effect of small molecules found in MEF-CM on 
the maintenance of hESC cultures 
4.1 Introduction 
Following the successful identification of metabolites present in MEF-CM 
with potential implications in the proliferation of undifferentiated human 
embryonic stem cells, it was investigated whether or not these 
metabolites had a positive effect on hESC. For this, hESC were exposed 
to the compounds during in vitro hESC culture; however, prior to hESC 
culture testing, it was necessary to confirm the putative identity of the 
metabolites (assigned in chapter 3) so that only those successfully 
confirmed could then be tested. Additionally, the concentrations of the 
confirmed metabolites were measured in order to investigate their effects 
at levels similar to those at which they are normally found in MEF-CM.  
Amongst the increased metabolites found in MEF-CM (Table 3-3, chapter 
3), only those with potential biological activity in stem cell regulation 
were chosen for further identification/confirmation and subsequent test in 
hESC culture in this chapter. The selected metabolites were PGE2 (or its 
possible isomers PGD2 and PGH2), 6-keto-PGF1α, stearidonic acid, 9, 10, 
13-TriHOME (or its possible isomer 9, 12, 13-TriHOME), calcitriol and 7-
ketocholesterol. Confirmation of these metabolites was achieved by 
chromatography and mass spectrometry methods with the use of 
authentic standards as a means of unambiguous identification (Gika et 
al., 2014). 
 
4.1.1 Potential roles of selected metabolites in stem cell 
regulation 
From the selected metabolites, PGE2 is the compound that has been 
studied the most in stem cells. For example, it was found that when PGE2 
was added to the culture medium, it promoted the proliferation of both 
human mesenchymal stem cells (hMSC) and mouse embryonic stem cells 
(mESC) (Arikawa et al., 2004, Kim and Han, 2008). Furthermore, PGE2 
also showed the ability to protect mESC from apoptosis (Liou et al., 
2007) and enhance homing, survival and proliferation of hematopoietic 
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stem cells (Hoggatt et al., 2009). Contrary to the aforementioned, in the 
case of hESC, it was reported that PGE2 induced differentiation (Garcia-
Gonzalo and Izpisua Belmonte, 2008); however, it is probable that such 
an effect might have been caused by the relatively high concentration at 
which PGE2 was tested (20 µM). Therefore, for the benefits of PGE2 to 
other stem cells, it is possible that PGE2, at concentrations normally 
found in MEF-CM, may have survival and proliferation effects on hESC as 
it does with mESC and hMSC.  
7-ketocholesterol, one of the oxidation products of cholesterol (known as 
oxysterols) has been shown to exhibit cytotoxicity in mesenchymal stem 
cells (Levy et al., 2014); nonetheless, oxysterols have also shown novel 
biological activities in cell signalling (Olkkonen et al., 2012). For instance, 
it has been found that oxysterols are activators of the Hedgehog 
signalling pathway (Dwyer et al., 2007) whose activation has been 
demonstrated to stimulate mESC proliferation (Heo et al., 2007). 
Additionally, oxysterols can bind to members of the cytoplasmic 
oxysterol-binding protein (OSBP) family, a group of intracellular lipid 
receptors. In particular, it was found that 7-ketocholesterol can form a 
complex with OSBP proteins which interacts with the tyrosin kinase JAK-2 
which in turn leads to the activation of the signal transducers and 
activators of transcription 3 (STAT-3) (Romeo and Kazlauskas, 2008). 
Activation of STAT-3 pathway in mESC is known to maintain the cells in 
an undifferentiated state (Matsuda et al., 1999). Consequently, it seems 
likely that 7-ketocholesterol can mediate some biological functions in 
hESC by coupling to OSBP proteins or by activation of the Hedgehog 
signalling pathway.  
In the literature, 9, 10, 13-TriHOME and 9, 12, 13-TriHOME, lipoxygenase 
metabolites of linoleic acid, have not shown any biological activity related 
with stem cells; nevertheless, it has been shown that these hydroxylated 
fatty acids possess PGE-like activity (Claeys et al., 1986). Thus, it is 
possible that these lipids could further enhance the activities of PGE2 
already mentioned.  
6-keto-PGF1α and calcitriol have had relatively few reports associating 
their functions with stem cells. For example, when hESC were exposed as 
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embryoid bodies (EBs) to 6-keto-PGF1α in basic serum-free medium, a 
small percentage of cardiomyocytes were obtained (Xu et al., 2008b), 
demonstrating with this the cardiogenic activity of 6-keto-PGF1α. 
However, more recently, 6-keto-PGF1α has also been associated with the 
proliferation and pluripotency of hESC as its levels were found to be 
increased in MEF-conditioned medium supporting undifferentiated hESC 
(Jones et al., 2010). Calcitriol, has been shown to inhibit the proliferation 
rates of hMSC, but also inhibited apoptosis and maintained the 
multipotent capacity of the cells (Klotz et al., 2012). Apart from the 
above circumstantial evidence, to date, none of these metabolites have 
shown direct evidence of their functions in the maintenance of 
undifferentiated hESC. 
Finally, with regard to stearidonic acid no relevant study has linked its 
biological activities with hESC or any other type of stem cells. 
Nevertheless, due to the action of omega-3 fatty acids (like stearidonic 
acid) on cellular mechanisms associated with inflammation (Weylandt et 
al., 2012) and cell signalling (Kim et al., 2008) it is perhaps possible that 
stearidonic acid modulates some signalling pathways in hESC.  
 
4.1.2 Known functions of small molecules in hESC 
Most of the identified mechanisms that control hESC self-renewal, 
pluripotency and differentiation are known to be regulated by proteins, 
more specifically, growth factors (e.g. basic fibroblast growth factor 
(bFGF), transforming growth factor-β (TGFβ)) and cytokines (i.e. activin 
A) (Avery et al., 2006). However, small molecules have also been shown 
to play an important role in the maintenance of pluripotent hESC. For 
example, when cultured in medium supplemented with sphingosine-1-
phosphate (S1P), it was found that S1P enhanced survival and 
proliferation of hESC (Inniss and Moore, 2006). Furthermore, when S1P 
was used in combination with platelet-derived growth factor (PDGF), 
hESC also maintained an undifferentiated state (Pebay et al., 2005). 
More recently, evidence has emerged that synthetic small molecules may 
have relevance in modulating hESC self-renewal. Using high-throughput 
chemical screening approaches, Xu et al identified two small molecules, 
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thiazovivin (Tzv) and tyrintegin (Ptn), that promoted hESC survival and 
self-renewal (Xu et al., 2010). Interestingly, they discovered that the 
survival-promoting effect was due to the fact that Tzv and Ptn increased 
cell attachment following cell dissociation and seeding processes (Xu et 
al., 2010). A recent high-content screening also reported the 
identification of other synthetic small molecules, some of which were 
neurotransmitter antagonists (trimipramine and ethopropazine), that 
supported the long-term expansion of undifferentiated hESC without 
bFGF in the medium, however, the efficiency was lower than when cells 
were cultured in MEF-CM (Kumagai et al., 2013). All this highlights the 
notion that low-molecular weight factors can be of paramount importance 
during maintenance of pluripotent hESC.  
Therefore, given the increasing evidence that small molecules have 
important roles in the maintenance of undifferentiated hESC, it is possible 
that the selected metabolites generated in MEF-CM (previously identified 
in chapter 3) play key roles in the proliferation and pluripotency 
maintenance of hESC as they do in other type of stem cells. Such a 
possibility will be explored in this chapter. To the best of the author’s 
knowledge, this is the first time that metabolites identified in MEF-CM 
have been investigated for their effects on hESC.  
 
4.1.3 Aims and objectives 
 To confirm by liquid chromatography and mass spectrometry the 
identity of the selected metabolites found in MEF-CM that could 
potentially mediate some functions in hESC. 
 
 To develop a quantification method and measure the 
concentrations of the confirmed metabolites in several batches of 
MEF-CM. 
 
 To investigate the effects of selected and confirmed metabolites of 
MEF-CM on the proliferation of hESC in culture.  
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4.2 Materials and methods 
4.2.1 Chemicals 
Acetonitrile, methanol and chloroform were HPLC-grade and obtained 
from Fischer Scientific (Loughborough, UK). Deionized water (18.2MΩ) 
was prepared using an ELGA USF-Maxima water purification system 
(Marlow, UK). Mass spectrometry-grade formic acid, dimethylsulfoxide 
and 7-ketocholesterol (7-KC) were purchased from Sigma-Aldrich 
(Gillingham, UK). Prostaglandin D2 (PGD2), prostaglandin H2 (PGH2), 6-
keto-prostaglandin F1α (6-keto-PGF1α) and stearidonic acid (SA) were all 
obtained from Cambridge Bioscience (Cambridge, UK). Prostaglandin E2 
(PGE2) was purchased from BioVision (Bedfordshire, UK) whereas 1, 25-
dihydroxyvitamin D3 (calcitriol) was obtained from Tocris Bioscience 
(Bristol, UK). 9(S), 10(S), 13(S)-trihydroxy-11(E)-octadecenoic acid (9, 
10, 13-TriHOME) and 9(S), 12(S), 13(S)-trihydroxy-10(E)-octadecenoic 
acid (9, 12, 13-TriHOME) were both purchased from Larodan Fine 
Chemicals (Malmö, Sweden). All tissue culture reagents were obtained 
from Invitrogen.  
 
4.2.2 Preparation of standards 
Standards were prepared according to the purpose of the individual 
experiments as described in sections below. For identity confirmation of 
the increased metabolites of MEF-conditioned medium (previously 
reported in chapter 3), the standards were subjected to LC-MS and LC-
MS/MS analyses. The successfully confirmed analytes were then tested in 
hESC culture. 
 
4.2.2.1 Preparation of standards for LC-MS and LC-MS/MS analyses 
All standards stock solutions for LC-MS and LC-MS/MS analyses were 
prepared with 75% MeOH with the exception of 7-KC which, due to its 
lower polarity, was diluted in a 50:50 chloroform/MeOH mixture. To 
reach a final working concentration solution, further dilutions were made 
for all the standards with 75% MeOH. The working concentration for all 
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the standards was 20 ng/mL except for calcitriol whose final 
concentration was 1 µg/mL. The stock solutions were stored at -80⁰C. 
4.2.2.2 Preparation of standards for hESC culture 
Stock solutions of PGE2, 6-keto-PGF1α, 7-KC, SA and 9, 12, 13-TriHOME 
were prepared with DMSO under sterile conditions for hESC culture. 
Further dilutions were also made with DMSO in order to achieve the 
tested concentrations which are detailed later in the results and 
discussion section of this chapter. Likewise, the stock solutions were 
stored at -80⁰C. 
 
4.2.3 Sample preparation 
MEF-conditioned medium (MEF-CM) samples from batches 107, 115, 116, 
117, 118, 120, 121 and 122 were prepared three times using the protein 
precipitation method described in chapter 2. The preparation of the MEF-
CM batches has been described in section 3.2.3, chapter 3. 
 
4.2.4 Liquid chromatography and mass spectrometry methods 
The chromatographic conditions of all the experiments in this chapter 
were as described in section 3.2.6, chapter 3. Different mass 
spectrometry (MS) settings were employed for metabolite 
identification/confirmation and for metabolite quantification as described 
in sections 4.2.4.1 and 4.2.4.2. 
 
4.2.4.1 LC-MS for identity confirmation 
To compare exact masses and retention times, samples and standards 
were injected into the Exactive Orbitrap mass spectrometer via an Accela 
U-HPLC system (both from Thermo Fischer Scientific, USA) and were 
analysed maintaining the MS parameters detailed in section 3.2.7, 
chapter 3. 
To obtain MS/MS spectra both samples and standards were injected into 
an Accela U-HPLC system hyphenated to an LTQ Velos mass 
spectrometer (Thermo Fischer Scientific, USA) operated in data 
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dependent mode. The collision energy used was 35 eV. The MS settings 
were the same as those described in section 2.2.5. 
 
4.2.4.2 LC-MS for metabolite quantification 
For metabolite quantification slight modifications to the original MS 
settings (section 3.2.6, chapter 3) were made in order to increase the 
number of data points to measure more accurately the analyte peak 
areas. First, instead of analysing the samples in +ESI and –ESI modes 
simultaneously, the number of scan events was restricted to only that 
ionisation mode (+ve or –ve) in which the analyte was detected. Second, 
in addition to the original 2 Hz (50000 FWHM) scan rate of the method, a 
4 Hz (25000 FWHM) scan rate was also explored to compare the number 
of data points obtained with each scan rate. Metabolite quantification was 
performed using the Exactive Orbitrap mass spectrometer.  
 
4.2.5 Human embryonic stem cell culture 
The hESC line HUES7, between passages 26 and 30, was cultured on 
Matrigel with unconditioned medium (UM) as negative control, 
unconditioned medium supplemented with the small molecules (UM+sup) 
and with MEF-CM as positive control. Cells were passaged every three 
days by incubation with 0.05% accutase for 3 min at 37⁰C. Population 
doublings (PDs) were calculated at each passage with the formula 
[log10(cells harvested/cells seeded)/log10(2)], where the number of 
seeded cells was 2x106 cells/well. Proliferation rates were calculated by 
hours in test culture/cumulative PDs (Mahlstedt et al., 2010). The hESC 
culture was carried out by Dr James Smith, Wolfson Centre for Stem 
Cells, Tissue Engineering & Modelling, Centre for Biomolecular Sciences, 
University of Nottingham. 
 
4.2.6 Data analysis 
LC-MS data were quantified using QuanBrowser Xcalibur 2.2 software 
(Thermo Fischer Scientific, USA) and are expressed as mean ± SD.  
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4.3 Results and discussion 
4.3.1 Confirmation of chemical identity of increased metabolites 
found in MEF-CM 
The selected metabolites to be tested in hESC culture are shown in Table 
4-1 along with their m/z values and their possible isomers. The putative 
identity of these metabolites was confirmed by means of liquid 
chromatography and mass spectrometry as detailed below. 
 
Table 4-1. List of metabolites selected for hESC culture testing. 
Accurate 
mass (m/z) 
Ion Formula Putative identification 
275.2016 [M–H]– C18H28O2 Stearidonic acid 
329.2333 [M–H]– C18H34O5 9, 10, 13-TriHOME or 9, 12, 13-TriHOME 
333.2071 [M–H2O–H]
– C20H32O5 PGE2 or PGD2 or PGH2 
369.2282 [M–H]– C20H34O6 6-keto-PGF1α 
401.3414 [M+H]+ C27H44O2 7-Ketocholesterol 
417.3363 [M+H]+ C27H44O3 Calcitriol 
 
 
4.3.1.1 Chromatography and exact mass matching identification 
Initial identity confirmation started with the comparison of retention 
times and exact masses of the metabolites in the samples with those of 
the standards (Figure 4-1). The extracted ion chromatograms (EICs) of 
6-keto-PGF1α, stearidonic acid, and 7-KC in the samples matched 
perfectly the retention time and exact mass of their respective standards. 
Because the results of PGE2 (or its isomers PGD2 and PGH2), 9, 10, 13-
TriHOME (or its isomer 9, 12, 13-TriHOME) and calcitriol represented 
special cases, they will be discussed below in more detail. 
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Figure 4-1 Comparison of retention times and exact masses using extracted ion 
chromatograms (EICs) of metabolites in the samples (blue) and standards 
(black). Chromatographic confirmation of a) PGE2, b) 6-keto-PGF1α, c) 
stearidonic acid, d) 9, 12, 13-TriHOME and possibly 9, 10, 13-TriHOME and f) 7-
ketocholesterol in MEF-CM. e) calcitriol standard matched the retention time of 
the sample but failed to show the [M+H]+ ion. 
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PGE2, PGD2 or PGH2 
Since the ion at m/z 333.2071 matched the exact [M–H2O–H]
– ion mass 
of PGE2, PGD2 and PGH2, the standards of the three prostaglandins were 
injected in order to find out which of the three isomers was present in 
MEF-CM. Chromatographically, PGE2 standard was the only one that 
matched the retention time of the sample (Figure 4-1a). The peak at 
6.40 min of PGH2 standard is the result of its inherent instability that 
converts a proportion of PGH2 to PGE2 (Quraishi et al., 2002) and so 
likewise pairs up with the retention time of the sample and of PGE2 
standard; however, the actual retention time of PGH2 standard is the 
second peak at 7.57 min. As PGD2 standard clearly eluted at different 
retention time of the sample, then it can be concluded that PGE2 is the 
compound that is present in MEF-CM. 
 
9, 10, 13-TriHOME or 9, 12, 13-TriHOME 
The ion at m/z 329.2336 matched the exact mass of 9, 10, 13-TriHOME 
and 9, 12, 13-TriHOME. Both standards were injected but due to their 
high chemical structure similarity (Figure 4-2a,b) they were separated 
only by a small fraction of time (Figure 4-1d). When the EICs of the 
sample and standards were superimposed (Figure 4-2c), it was observed 
that 9, 12, 13-TriHOME was the most likely compound present in MEF-CM 
as its retention time matched better that of the sample, nevertheless, it 
was not ruled out the possibility that a small proportion of 9, 10, 13-
TriHOME was also present.  
 
OH
O
CH3
OH
OH
OH
OH
O
CH3
OHOH
OH  
Figure 4-2 Chemical structure of a) 9, 10, 13-TriHOME and b) 9, 12, 13-TriHOME. 
c) superimposition of the extracted ion chromatograms of the two standards and 
of the sample. 
G:\PhD\...\140408\140408-CM-107_A 09/04/2014 06:39:43
RT: 5.65 - 6.59
5.8 6.0 6.2 6.4
Time (min)
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
6.07 6.12
RT: 5.65 - 6.59
5.8 6.0 6.2 6.4
Time (min)
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
6.07 6.12
RT: 5.65 - 6.59
5.8 6.0 6.2 6.4
Time (min)
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
6.07
329.2340
6.11
329.2342
6.17
329.2341 6.43
329.2342
5.99
329.2338
5.81
329.2345
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
G:\PhD\...\140408\140408-CM-107_A 09/04/2014 06:39:43
RT: 5.65 - 6.59
5.8 6.0 6.2 6.4
Ti e ( in)
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
6.07 6.12
RT: 5.65 - 6.59
5.8 6.0 6.2 6.4
Time (min)
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
6.07 6.12
RT: 5.65 - 6.59
5.8 6.0 6.2 6.4
Time (min)
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
6.07
329.2340
6.11
329.2342
6.17
329.2341 6.43
329.2342
5.99
329.2338
5.81
329.2345
200 400
/
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0
48 .
200 400 600 8 0 1 0
m/z
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
. 260
401.0887
483.2523
714.6073 892.8324
2 0 400 600 800 1 00
m/z
0
20
40
60
80
1 0
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.12 4
329.2342
9.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
200 400 600 800 1000
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
267.1244
329.2342
99.9260
401.0887
483.2523
714.6073 892.8324
Sample 
9, 10, 13-TriHOME Std 
9, 12, 13-TriHOME Std 
a) 
b) 
c) 
111 
 
Calcitriol 
An interesting result was that obtained with calcitriol standard as it 
matched the retention time of the sample, but spectrometrically it 
behaved differently. As observed in Figure 4-1e, the most abundant ion 
of calcitriol standard was the [M–H2O+H]+ ion at m/z 399.3255 whereas 
that of the sample was the [M+H]+ ion at m/z 417.3360. When the m/z 
417.3360 ion of calcitriol standard was extracted, the peak was almost 
undetectable as it produced a very low intensity peak (data not shown). 
Therefore, these results suggest that the compound detected in MEF-CM 
was not calcitriol but possibly a structural isomer whose [M+H]+ ion is 
more stable. Further investigation was conducted with MS/MS 
experiments to confirm the false identity. 
 
4.3.1.2 Tandem mass spectrometry (MS/MS) confirmation 
Final metabolite confirmation was accomplished with tandem mass 
spectrometry by comparing the MS/MS spectra of both the metabolites in 
the samples and authentic standards (Figure 4-3 and Figure 4-4). With 
the exception of calcitriol, the rest of metabolites’ MS/MS spectra 
matched those of their standards, thus, confirming their presence in MEF-
CM. In the case of the ion at m/z 329.2336, the MS/MS spectrum of the 
sample presented characteristic fragment peaks of both standards (9, 10, 
13-TriHOME and 9, 12, 13-TriHOME). The specific peak of 9, 10, 13-
TriHOME was the fragment ion at m/z 171.1 whilst those of 9, 12, 13-
TriHOME were m/z 211.2 and m/z 229.2 (Figure 4-4). The presence of 
the three fragment ions in the MS/MS spectrum of the sample strongly 
suggests that both compounds are present in MEF-CM. On the other 
hand, the MS/MS spectrum of calcitriol standard did not match that of the 
sample, therefore the presence of calcitriol in MEF-CM was ruled out. 
Nonetheless, the matching in retention time and exact mass of the 
unknown compound still suggests that possibly a very close structural 
isomer of 1, 25-dihydroxyvitamin D3 (calcitriol) might be the one present 
in the sample. The most likely compound seems to be 24, 25-
dihydroxyvitamin D3 according to the human metabolome database 
(Wishart et al., 2009); however this requires further experimental 
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verification with the authentic standard which was beyond the scope of 
this thesis. 
 
 
      
      
      
 
Figure 4-3 Comparison of MS/MS spectra of standards (left panel) and samples 
(right panel). Tandem MS finally confirmed the presence of these metabolites in 
MEF-CM. 
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Figure 4-4 Comparison of MS/MS spectra of standards (left panel) and samples 
(right panel). The ion at m/z 329 in the sample showed the characteristic peaks 
of the standards 9, 10, 13-TriHOME and 9, 12, 13-TriHOME, suggesting that both 
compounds may be present in MEF-CM. MS/MS spectrum of calcitriol standard 
did not match that of the sample thus ruling out definitely that the m/z 417 ion 
in the sample is calcitriol. 
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4.3.2 Quantification of confirmed metabolites 
Having confirmed which of the selected metabolites were truly present in 
MEF-CM, it was decided to estimate their concentrations in several 
batches of MEF-CM so that the tested concentrations used in hESC 
culture experiments (described in section 4.3.3) resembled the levels at 
which these metabolites are normally present in MEF-CM. For this 
purpose a quantification method was developed. 
 
4.3.2.1 MS quantification method development 
Metabolite quantification was carried out in the Exactive Orbitrap mass 
spectrometer. Two scan rates (2 and 4 Hz) were investigated during the 
quantification method development in order to find out the scan rate that 
produced the largest number of data points per peak while maintaining 
high mass accuracy. Figure 4-5 indicates the number of data points and 
mass errors obtained at 2 and 4 Hz for selected peaks (PGE2 and 6-keto-
PGF1α).  
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Figure 4-5 Extracted ion chromatograms of PGE2 and 6-keto-PGF1α showing the 
number of data points obtained at 2 and 4 Hz scan rates as well as the mass 
accuracy across the peak. Each line represents one data point. 
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Because quantification selectivity with high resolution mass spectrometry 
(HRMS) is attained by the employment of EICs by centring a narrow 
mass window on the theoretical m/z value of the analyte (Xiao et al., 
2012), the scan rate with the highest mass accuracy will produce the 
most reliable results. In this experiment, the 2 Hz scan rate produced 
better mass accuracy (smaller mass errors) than the 4 Hz scan rate 
although at the expense of reduced number of data points per peak; 
however, since the number of points was still enough for precise 
quantification (>10) (Frank and McIntyre, 2009), the 2 Hz scan rate was 
selected for quantification of all the confirmed metabolites.  
The use of Orbitrap-based HRMS was preferred over the traditional triple 
quadrupole mass spectrometer (QqQ) (Lu et al., 2008) for quantification 
of the small molecules studied because the methodology was readily 
adapted from the untargeted metabolomics procedures already used. 
Using the Orbitrap Exactive method avoided the preoptimisation (collision 
energy, declustering voltage and collision cell exit potential) of target 
analytes which is a prerequisite for method development with QqQ. 
Furthermore, the quantitative capabilities of Orbitrap-based HRMS have 
been demonstrated to be similar to those of QqQ (Lu et al., 2010, 
Bateman et al., 2009); thus, offering a reliable and faster alternative to 
QqQ. 
 
4.3.2.2 Measurement of metabolites in MEF-CM 
Supportive MEF-CM batches 107, 115, 116, 117, 118, 120, 121 and 122 
were analysed using the method described to give targetted, quantitative 
measurements of the concentrations of all the confirmed metabolites of 
interest. The concentrations obtained for each metabolite in each batch 
are presented in Table 4-2. In spite of the fact that 9, 10, 13-TriHOME 
and 9, 12, 13-TriHOME may be both present in the conditioned medium, 
it was decided to use 9, 12, 13-TriHOME for quantification and 
subsequent test in hESC culture since it matched better the retention 
time of the sample and seemed to be the molecule at higher proportion in 
the sample as it covered a larger area of the sample peak (Figure 4-2c).  
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Table 4-2. Quantification results of the metabolites that were confirmed to be 
present in MEF-CM. 
   Prostaglandin E2 
 
6-Keto-prostaglandin F1a 
Range: 12.51 – 37.08 ng/mL 
 
Range: 0.93 – 2.67 ng/mL 
Batch # Mean ± SD, ng/mL RSD% 
 
Batch # Mean ± SD, ng/mL RSD% 
107 12.54 ± 0.14 1.09 
 
107 2.58 ± 0.19 7.33 
115 21.94 ± 0.76 3.48 
 
115 2.20 ± 0.10 4.54 
116 21.98 ± 0.51 2.34 
 
116 2.67 ± 0.10 3.62 
117 14.16 ± 0.27 1.87 
 
117 1.02 ± 0.06 5.75 
118 12.51 ± 0.17 1.39 
 
118 1.01 ± 0.07 6.69 
120 37.08 ± 1.50 4.05 
 
120 2.14 ± 0.07 3.20 
121 19.35 ± 0.44 2.30 
 
121 1.28 ± 0.05 4.18 
122 13.64 ± 0.44 3.19 
 
122 0.93 ± 0.10 10.96 
       7-Ketocholesterol 
 
Stearidonic acid 
Range: 38.47 – 48.65 ng/mL 
 
Range: 75.35 – 126.50 ng/mL 
Batch # Mean ± SD, ng/mL RSD% 
 
Batch # Mean ± SD, ng/mL RSD% 
107 46.94 ± 2.51 5.34 
 
107 124.66 ± 3.97 3.18 
115 48.65 ± 1.25 2.57 
 
115 97.08 ± 1.60 1.65 
116 43.96 ± 0.48 1.10 
 
116 126.50 ± 5.68 4.49 
117 43.08 ± 2.36 5.49 
 
117 75.35 ± 0.39 0.52 
118 46.35 ± 1.44 3.10 
 
118 90.32 ± 1.36 1.51 
120 48.00 ± 1.60 3.34 
 
120 92.19 ± 1.22 1.32 
121 41.28 ± 1.08 2.61 
 
121 89.48 ± 2.42 2.71 
122 38.47 ± 0.56 1.46 
 
122 95.13 ± 0.62 0.65 
       9, 12, 13-TriHOME 
    Range: 2.43 – 4.42 ng/mL 
    Batch # Mean ± SD, ng/mL RSD% 
    107 2.43 ± 0.10 4.26 
    115 4.42 ± 0.20 4.46 
    116 4.27 ± 0.11 2.66 
    117 3.27 ± 0.24 7.37 
    118 3.96 ± 0.07 1.65 
    120 4.24 ± 0.12 2.89 
    121 3.53 ± 0.26 7.34 
    122 3.45 ± 0.10 2.84 
    Results for each batch expressed as mean ± standard deviation (n=3)  
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High batch-to-batch variability was observed as judged by the wide range 
of concentrations found for each metabolite. Amongst all the metabolites 
quantified, PGE2 and 6-keto-PGF1α showed the highest variability with 
maximum concentrations 3-fold greater than the minimum 
concentrations. Other metabolites showed more constant levels, but still 
with considerable variations. On the other hand, as to the method 
performance, high reproducible measurements were obtained with 
precision variability (RSD%) below 15%, an acceptable criterion for LC-
MS methods (FDA, 2013). Furthermore, the calibration curves for all the 
analytes showed excellent linearity of response (R2 > 0.99) over the 
entire concentration range tested for each analyte (Table 4-3). What is 
more, at all concentration levels, the variability in the precision (RSD%) 
was also less than 15%. Although it is recognised that full validation of 
the method would be required for a greater degree of confidence on the 
results; for the purpose of this experiment, the results obtained with this 
quantification method offered a good estimate of the concentrations of 
the selected metabolites in MEF-CM.  
With the exception of PGE2 and 6-keto-PGF1α, no study had previously 
confirmed and reported concentrations of 7-ketocholesterol, stearidonic 
acid and 9, 12, 13-TriHOME in MEF-CM. Jones et al, by means of DNA 
microarray analysis, had identified in MEF-CM increased mRNA levels of 
cyclooxygenase-2 (COX-2) and prostaglandin I2 synthase (PGIS), two 
prostaglandin biosynthesis genes, whose downstream products are PGE2 
and 6-keto-PGF1α, respectively. Therefore, they quantified and reported 
levels of PGE2 and 6-keto-PGF1α at 9.1 and 4.3 ng/mL, respectively 
(Jones et al., 2010). They measured the prostaglandins’ levels using only 
one batch of MEFs (CF1 strain) to condition the medium and their 
quantification method was based on an enzyme-linked immunosorbent 
assay (ELISA). The differences in mouse strain and quantification 
methodology used by Jones et al and the ones employed here could 
explain the discrepancies between their results and those reported in this 
chapter. For example, it is known that antibody-based methods for 
quantification of prostaglandins suffer from cross-reactivity with related 
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Table 4-3. Linearity and precision of the calibration curves for metabolites 
measured in MEF-CM. 
Analyte Slope R2 
Concentration, 
ng/mL 
Peak area 
mean (n=3) 
Precision 
RSD% 
PGE2 y = 12390x 0.9933 1.0 12028 1.64 
   
2.5 28430 3.56 
   
5.0 71674 2.07 
   
10.0 133095 0.40 
   
20.0 241097 0.91 
      6-keto-PGF1α y = 50763x 0.9972 1.0 51665 0.86 
   
2.5 125245 0.77 
   
5.0 282409 1.58 
   
10.0 529747 1.79 
   
20.0 997211 0.69 
      7-Ketocholesterol y = 5850.87x 0.9947 2.6 14847 14.80 
   
5.2 26619 2.32 
   
6.9 38723 7.57 
   
10.4 59366 2.07 
   
20.8 123978 2.14 
      Stearidonic acid y = 5904.24x 0.9986 5.0 13527 14.64 
   
10.0 31000 1.74 
   
20.0 59254 1.38 
   
40.0 147126 0.39 
   
80.0 293176 2.68 
      9, 12, 13-TriHOME y = 58741.5x 0.9988 0.16 26371 4.12 
   
0.50 55048 2.15 
   
1.00 112017 0.97 
   
2.50 235465 0.29 
   
5.00 474904 2.71 
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compounds which results in reduced selectivity, producing ambiguous 
and possibly misleading results (Il'yasova et al., 2004). In contrast, mass 
spectrometry-based approaches have demonstrated to be more selective 
and reliable (Cao et al., 2008, Il'yasova et al., 2004). Consequently, 
given the number of batches analysed in this chapter, the results 
reported in Table 4-2 represent, with high degree of confidence, the 
typically secreted concentrations of PGE2, 6-keto-PGF1α, 7-
ketocholesterol, stearidonic acid and 9, 12, 13-TriHOME in MEF-
conditioned medium. 
 
 
4.3.3 Effect of medium supplementation with confirmed 
metabolites on proliferation of cultured hESCs 
Finally, to determine whether or not the small molecules found in MEF-
CM had an effect on hESC, HUES7 cells were cultured on Matrigel with 
UM supplemented with the compounds listed in Table 4-4 (UM+sup). 
Because of the wide range of concentrations found for each metabolite in 
MEF-CM batches (Table 4-2), the concentration chosen to be tested was 
the grand mean (mean of means) of the batches’ concentration means, 
also shown in Table 4-4. 
 
Table 4-4. Compounds tested in hESC culture. 
Compound name Concentration 
tested, ng/mL 
Stearidonic acid 98.84  
9, 12, 13-TriHOME 3.70  
PGE2  19.15  
6-keto-PGF1α 1.73  
7-Ketocholesterol 44.59  
 
Additionally, the cells were cultivated with UM and MEF-CM to be used as 
negative and positive control, respectively. Figure 4-6a shows the growth 
curves for each culture system.  
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Figure 4-6 a) Growth curves of HUES7 cells when cultured with UM, UM+sup and 
MEF-CM. b) Proliferation of HUES7 cells at passage number 3. When cultured 
with UM alone, the cells could no longer be expanded; however, when the small 
molecules were added (UM+sup) an enhancement in proliferation was observed, 
indicating that the mix of molecules had a proliferative effect. As expected, with 
MEF-CM, cells had the best growth rate. Scale bars = 250 µm. 
a) 
b) 
UM+sup 
UM 
MEF-CM 
Cells seeded Cells harvested 
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Whereas cells cultured with MEF-CM showed a continuous growth over 
the test period, cells cultivated with UM alone could no longer be 
expanded after passage 3. In contrast, when UM was supplemented with 
the small molecules (UM+sup), cells could still expand for one more 
passage. A significant increase in the cell number is observed at passage 
3 when cells are incubated in the presence of the small molecules than 
when the small molecules are absent (Figure 4-6a). Figure 4-6b shows 
the proliferation observed at passage number 3 with UM+sup as 
compared with the loss of expansion using UM alone. Cells appear to be 
more confluent when exposed to the compounds than when they are not. 
These results imply that the mix of compounds exerted a proliferative 
effect; however, as the proliferation observed was only in the short term, 
it is not clear yet whether the proliferative effect was indeed of 
undifferentiated cells or if some differentiation occurred. If long-term 
culture had been achieved then examination of pluripotency markers 
(e.g. Oct4, Sox2) would have determined if the cells still preserved their 
undifferentiated state. Nonetheless, the proliferative effect is a great 
achievement taking into account that the molecules were tested in the 
absence of MEF-derived growth factors. Therefore, it is very likely that if 
supplemented with growth factors that promote hESC survival, the tested 
small molecules could be beneficial for the long-term expansion of hESC. 
Furthermore, as none of these compounds have been reported in the 
formulations of more defined culture media like StemPro (Wang et al., 
2007) and mTeSR1 (Ludwig et al., 2006a), they represent potential 
candidates to enhance their efficiency.  
Although further research is needed, these results represent one more 
step towards the development of more defined and efficient culture 
systems. 
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4.4 Conclusions 
Based on retention time, exact mass and tandem mass spectrometry 
(MS/MS) it was possible to confirm the identity of PGE2, 6-keto-PGF1α, 7-
ketocholesterol, stearidonic acid, 9, 10, 13-TriHOME and 9, 12, 13-
TriHOME. To the best of the thesis author’s knowledge this was the first 
time that 7-ketocholesterol, stearidonic acid, 9, 10, 13-TriHOME and 9, 
12, 13-TriHOME were reported to be present in MEF-CM.  
The ion at m/z 417.3360 remained unidentified as it failed to match the 
MS/MS spectrum of calcitriol standard. Nevertheless, its exact mass and 
retention time matched those of calcitriol standard which suggested that 
a structural isomer of calcitriol (24, 25-dihydroxyvitamin D3) may be the 
one present in MEF-CM. However, because this was beyond the scope of 
this chapter the final identity of the ion at m/z 417.3360 could not be 
confirmed.  
A quantification method was developed using the Exactive Orbitrap mass 
spectrometer and it showed excellent linearity of response for all the 
analytes measured. Quantification of the compounds using different 
batches of MEF-CM showed great variability between batches.  
When PGE2, 6-keto-PGF1α, 7-ketocholesterol, stearidonic acid and 9, 12, 
13-TriHOME were finally tested in the in vitro culture of hESC they 
seemed to enhance the proliferation of hESC as compare to the negative 
control (UM alone). This demonstrated that metabolites secreted by MEFs 
are also important in the maintenance and proliferation of hESC. 
However, further research is required to identify more precisely which of 
the five molecules exerted the observed effect. 
 
 
 
 
CHAPTER 5 
Metabolomics analysis of 
the spent culture media of 
hESC when cultured with 
MEF-CM and StemPro 
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5 Metabolomics analysis of the spent culture media of 
hESC when cultured with MEF-CM and StemPro 
5.1 Introduction 
An alternative strategy to investigate the factors that allow hESC to 
proliferate and maintain an undifferentiated state is the study of their 
extracellular microenvironment; that is, the study of the culture medium 
that has been used to support their growth. It has been demonstrated 
that hESC can secrete a number of factors that also contribute to their 
own survival and proliferation (Dvorak et al., 2005, Przybyla and 
Voldman, 2012), in addition to the extrinsic growth factors added to the 
culture medium. The rich and complex set of small- and macro-molecules 
secreted from living cells is known as the secretome (Makridakis et al., 
2013). Furthermore, some of the factors released in the secretome have 
the ability to activate signalling pathways in an autocrine and/or 
paracrine manner. An autocrine mediator is that which binds and 
activates the receptors present on the surface of the same cell that 
produced it, whereas a paracrine mediator is released by one cell and 
subsequently interacts with receptors on neighbouring cells (Figure 5-1). 
Several autocrine and paracrine factors have been identified in hESC and 
will be described next. 
 
 
 
 
 
 
 
Figure 5-1 Schematic representing the autocrine and paracrine functions of a 
factor released into the extracellular microenvironment. 
 
 
Receptor 
Factor 
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Signal transduction 
autocrine 
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5.1.1 Known autocrine/paracrine signalling pathways in hESC 
Fibroblast growth factor 2, also known as basic fibroblast growth factor 
(bFGF), has been extensively added exogenously to the medium in 
feeder-free culture systems to support the proliferation of 
undifferentiated hESC (Levenstein et al., 2006, Amit et al., 2004, Xu et 
al., 2001, Inzunza et al., 2005). However, it has also been demonstrated 
that hESC can release bFGF to the medium and that this can activate the 
bFGF-receptors in an autocrine and/or paracrine fashion (Dvorak et al., 
2005), an activity which is thought to be reinforced by the exogenous 
bFGF (Greber et al., 2007). Members of the transforming growth factor β 
(TFG-β) superfamily have also been proposed as autocrine mediators (Xu 
et al., 2008a, Levine et al., 2009, Przybyla and Voldman, 2012). For 
example, when hESC were cultured at bFGF concentrations of 100 ng/mL 
but in the absence of exogenous TFG-β, only very minor effects on 
culture performance were observed; however, when additionally the TFG-
β/activin signalling was inhibited, a significant reduction in pluripotent 
cells was observed which suggested that autocrine/paracrine TFG-
β/activin signalling is important for the maintenance of hESC (Xu et al., 
2008a). Growth differentiation factor 3 (GDF3), also in the TFG-β 
superfamily, has been found to be secreted from hESC and helps to 
maintain their pluripotent state by blocking the bone morphogenetic 
protein (BMP) signalling (Levine et al., 2009, Levine and Brivanlou, 
2006). Finally, endogenous Wnts were also found to have an autocrine 
role in hESC by blocking neuronal differentiation; thus, maintaining the 
undifferentiated state (Wexler et al., 2009). 
With regard to small molecules, sphingosine-1-phosphate (S1P) has been 
suggested as a proliferative and pro-stemness autocrine factor in 
glioblastoma stem cells (Marfia et al., 2014); however, nothing is known 
about whether such activity occurs in hESC. To date, no small molecule 
with autocrine function in hESC has been identified, most probably 
because research has focussed more on the discovery of higher molecular 
weight factors (i.e. proteins) rather than the small molecule components 
of the secretome. 
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5.1.2 Study of the hESC secretome 
As with the search for the factors released from MEFs to maintain hESC in 
a pluripotent state (reviewed in chapter 3), most of the efforts into the 
investigation of the factors secreted by hESC have also focused on the 
protein components of the hESC secretome. For example, by employing 
an MS-based proteomics approach, Bendall et al reported the 
identification of 245 extracellular proteins in the culture medium obtained 
from hESC and amongst them 43 were growth factor-like proteins which 
represented potential hESC regulators (Bendall et al., 2009). 
A different strategy for the analysis of the secretome was adopted by 
Sarkar and colleagues (Sarkar et al., 2012). Instead of the analysis of the 
culture supernatant, they developed protocols to obtain subcellular 
fractions from hESC that were enriched in secretory pathway organelles, 
while preserving the secretory protein cargo. The MS analysis of the 
fractions revealed 99 putatively secreted proteins from hESC cultured in 
MEF-CM (Sarkar et al., 2012). The advantage of this strategy was that it 
did not require the use of customised media (i.e. serum free) as it is 
usually employed in other secretome analyses (Lim and Bodnar, 2002, 
Chin et al., 2007). However, one of its drawbacks was the potential 
cross-contamination of the secretory pathway organelle fractions during 
the extraction procedures. 
At present, the search for small molecule components of the hESC 
sectretome has been limited by the lack of application of suitable 
methods for comprehensive analysis. Some methods have been applied 
for the analysis of the extracellular metabolites (exo-metabolome) of 
pluripotent stem cells but these have targeted their measurements to a 
specific set of compounds (e.g. glucose, amino acids) (Rathjen et al., 
2014) or have addressed specific metabolic pathways (e.g. glycolysis) 
(Folmes et al., 2011, Folmes et al., 2013); thus, neglecting the rest of 
metabolites secreted by hESC. In this context, as the untargeted 
metabolomics approach developed in chapter 2 met the requirements for 
the comprehensive analysis of the low-molecular weight factors released 
by hESC in culture, it was applied here for this purpose. Additionally, the 
methodology could also detect the compounds that were potentially 
127 
 
consumed by the cells; thus, it also provided a better understanding of 
the metabolic processes occurring during the in vitro culture of hESC. 
The untargeted measurement of the exo-metabolome (known as 
metabolomics footprinting) was applied here for the investigation of the 
metabolites secreted and/or consumed by hESC cultured under feeder-
free conditions (Matrigel) using MEF-CM or StemPro™. A chemically 
defined medium such as StemPro™ (Wang et al., 2007) was also included 
because its less complex composition, in theory, would allow a better 
appreciation of the metabolites secreted into the medium. As far as the 
thesis author is aware, this is the first untargeted and most 
comprehensive LC-MS-based metabolomics study of the hESC small 
molecule secretome.  
 
 
5.1.3 Aims and objectives 
 To apply the untargeted metabolomics method developed in 
chapter 2 for the comprehensive analysis of low-molecular weight 
components of the hESC secretome. 
 
 To identify potential small-molecule autocrine/paracrine factors 
released by hESC during in vitro culture. 
 
 To analyse and compare the hESC exo-metabolome obtained with 
MEF-CM and the chemically defined medium StemPro™, when cells 
are cultured on Matrigel. 
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5.2 Material and methods 
5.2.1 Chemicals 
HPLC-grade acetonitrile and methanol were obtained from Fischer 
Scientific (Loughborough, UK). Deionized water (18.2MΩ) was prepared 
using an ELGA USF-Maxima water purification system (Marlow, UK). Mass 
spectrometry-grade formic acid was purchased from Sigma-Aldrich 
(Gillingham, UK) and the tissue culture reagents were obtained from 
Invitrogen. 
 
5.2.2 Human embryonic stem cell culture 
The hESC line HUES7, between passages 28 and 29, was cultured on 
Matrigel with two different culture media; namely, MEF-CM and the 
chemically defined medium StemPro™ (Life Technologies). Cells were 
seeded at 1.5x106 cells per flask and given 24 hours to adhere. 
Subsequently, cells were fed with fresh culture media that was collected 
24 hours after exposure to hESC (spent culture media). MEF-CM was 
prepared as described in section 3.2.3, chapter 3. The hESC culture was 
carried out by Dr James Smith, Wolfson Centre for Stem Cells, Tissue 
Engineering & Modelling, Centre for Biomolecular Sciences, University of 
Nottingham. 
 
5.2.3 Samples and sample preparation 
MEF-CM and StemPro™ culture medium samples were obtained before 
and after incubation with HUES7 cells as previously described. 
Samples were prepared by solvent protein precipitation using a 3:1 
MeOH-sample ratio as described in chapter 2. Briefly, 250 µL of sample 
were mixed with 750 µL of cold MeOH (kept at -20⁰C), vortexed for 1 min 
to precipitate the proteins and stored at -20⁰C for 20 min. After the cold 
storage period, samples were vortexed again for 15 s and centrifuged at 
17000 rpm for 10 min at 4⁰C. The supernatants were transferred to clean 
LC vials for analysis. Each type of culture medium (MEF-CM or StemPro, 
before and after hESC culture) was prepared six times and injected in 
triplicate into the LC-MS system. 
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As part of the system conditioning and quality control process, a pooled 
“quality control” (QC) sample was prepared by mixing equal volumes of 
the samples involved in each experiment (Gika et al., 2007, Want et al., 
2010). These QC samples were also prepared in exactly the same 
manner as the test samples. 
 
5.2.4 Sample analysis 
Ten QC samples were injected at the beginning of each experiment to 
condition the LC system and then intermittently once every 6 test 
samples to assess the stability of the analysis. All test samples were 
injected in a randomised order to eliminate any bias. 
 
5.2.5 Liquid chromatography and mass spectrometry  
The LC-MS methodology developed in chapter 2 was applied in the same 
manner here. Briefly, culture medium samples were injected into an 
Accela U-HPLC system hyphenated with an Exactive Orbitrap mass 
spectrometer (both from Thermo Fisher Scientific, USA) equipped with a 
heated electrospray interface (HESI-II) operating in positive and negative 
ion mode. Samples were separated using a ZORBAX Eclipse Plus C18 
column 1.8 µm (i.d. 2.1x100 mm) attached to a guard column (2.1x5 
mm) of the same chemistry and particle size (Agilent Technologies, 
Cheadle, UK). For a detailed description of the LC-MS parameters please 
refer to sections 2.2.5 and 2.2.6 in chapter 2.  
To obtain MS/MS spectra, samples were injected into an Accela U-HPLC 
system coupled online to an LTQ Velos mass spectrometer (Thermo 
Fischer Scientific, USA) operating in data dependent mode. The collision 
energy used was 35 eV. The electrospray and LC parameters were the 
same as those described in section 2.2.5 and 2.2.6 in chapter 2. 
 
5.2.6 Data processing and analysis 
The detailed methodology for data processing and data analysis has been 
previously described in section 3.2.8 (chapter 3) and in the same manner 
was applied here. Briefly, the LC-MS raw data files obtained from the 
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metabolomics analyses were imported to SIEVE software version 2.0 
(Thermo Fisher Scientific, USA) for data pre-processing. Positive and 
negative ion electrospray datasets were analysed separately with the 
following settings: ion intensity threshold, 10000; peak width, 10 ppm; 
frame time width, 2.50 min and normalised to the total ion current. 
Subsequently, the positive and negative ESI data sets obtained from 
SIEVE were merged in one file and exported to SIMCA version 13.0 
(Umetrics AB, Umea, Sweden) for multivariate analysis (MVA). The 
variables (ions) causing the class separation were searched against web-
based databases such as the Human Metabolome Database 
(www.hmdb.ca), Lipid Maps (www.lipidmaps.org) and METLIN 
Metabolomics Database (www.metlin.scripps.edu). For a greater degree 
of confidence in the identification of the ions, MS/MS analysis was carried 
out as previously described and the MS/MS spectra of the ions were 
compared with those registered in the databases aforementioned or with 
those published in the literature. For univariate statistics, data were 
exported to GraphPad Prism version 6.03 (GraphPad Software Inc., 
California, USA). Two-tailed Student’s t-tests with Welch’s correction 
were applied and differences were considered significant at p-values 
below those indicated in the text after correcting for multiple comparisons 
(Bonferroni’s correction). 
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5.3 Results and discussion 
5.3.1 Spent culture media chromatography 
Typical negative ESI mode base peak chromatograms of media exposed 
to hESC (referred to from here on as spent culture media) are shown in 
Figure 5-2a. Obvious differences between serum replacement-containing 
(MEF-CM) (black) and serum-free (StemPro) (blue) media are observed. 
As I (in chapter 2) and others (Frankland et al., 2007, Garcia-Gonzalo 
and Izpisua Belmonte, 2008) have reported, AlbuMAX I constituent of the 
knock out serum replacement (KOSR), used in the preparation of MEF-
CM, contains high levels of free fatty acids and lysophospholipids 
(including lysophosphatidylcholines (LPCs) and lysophosphatidyl-
ethanolamines (LPEs)) which are the main compounds responsible for the 
chromatographic peaks detected after minute 6 in MEF-CM and MEF-CM 
spent medium. For a more intuitive comparison of the differences 
between MEF-CM and StemPro spent media, Figure 5-2b shows extracted 
ion chromatograms (EICs) of selected peaks found in both spent culture 
media. Surprisingly, for the chemically defined medium StemPro, traces 
of the lipids shown in the EICs were found even before exposure to hESC, 
despite of the fact that StemPro formulation does not mention any other 
lipids apart from linoleic and lipoic acids (Wang et al., 2007). Although 
Life Technologies (StemPro manufacturer) uses the fatty acid-free 
(Cohn’s fraction V) bovine serum albumin (BSA) for medium 
manufacturing (Wang et al., 2007), BSA seems to be the most likely 
source for the presence of the not published fatty acids and LPCs of 
StemPro. In fact, free fatty acids have been reported to be present in 
albumin fraction V of several species, including bovine (Chen, 1967). 
Furthermore, at present, vendors like Sigma-Aldrich still report ≤ 0.02% 
fatty acid-impurities in fatty acid-free (Cohn’s fraction V) BSA 
(www.sigmaaldrich.com). As it will be shown later in the discussion, the 
unpublished lipids of StemPro may have an influence on hESC as they 
appear to be used by the cells; thus, implying that the unknown 
components of the so-called “chemically defined” medium StemPro are 
also important for the maintenance of hESC although they are not 
specified in its formulation. 
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Figure 5-2 a) Negative ESI base peak chromatograms of MEF-CM (black) and 
StemPro (blue) spent culture media. b) Differences in signal intensity of 
metabolites found in both spent culture media are illustrated by the extracted 
ion chromatograms of 1) LPC(16:0), 2) LPC(18:0), 3) palmitic acid and 4) 
stearic acid. 
 
5.3.2 Chromatography and mass spectrometry stability 
As in chapter 3, quality control (QC) samples were used here to assess 
the data quality (Gika et al., 2007) of the metabolomics studies carried 
out in this chapter. Fresh versus cell-exposed medium experiments, using 
MEF-CM or StemPro (SP), are respectively referred to as MEF-CM vs. 
MEF-CM-HUES7 or SP vs. SP-HUES7. Data from both experiments were 
evaluated by examining the retention time (RT) and signal intensity 
repeatability of a small subset of peaks (5 in +ESI and 5 in –ESI), 
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covering a range of times and intensities, in the QC samples injected 
throughout the LC-MS analyses, discarding the first 10 QC samples that 
were used for system equilibration. Table 5-1 presents the percentages of 
coefficient of variation (%CV) of RT and intensity of the selected peaks in 
each experiment. Results showed high LC-MS reproducibility with 
variations below 2% for RT and below 15% for signal intensity, 
demonstrating with this the validity of the data and the excellent stability 
of the method. Furthermore, exact mass variations were found to be less 
than 5 mDa. Based on these evaluations it was concluded that the quality 
of the metabolomics analysis was acceptable and the data sets from each 
experiment were investigated further as described below.  
 
5.3.3 Multivariate analysis 
Positive and negative electrospray data from each culture system (MEF-
CM or StemPro) were combined to perform multivariate analysis. In the 
first instance, PCA models were obtained to provide an overview of any 
patterns or groupings within the samples. Figure 5-3 shows the PCA 
scores plots of MEF-CM vs. MEF-CM-HUES7 and SP vs. SP-HUES7. In both 
cases clear differences in the metabolic profiles were observed between 
the cell-exposed and non-cell-exposed culture media. The class 
separation in the two PCA models was mainly depicted by the 1st 
principal component (t[1]) which accounted for approximately 30% of the 
explained variation of the data. The culture medium groups detected in 
the MEF-CM vs. MEF-CM-HUES7 model appeared more scattered than the 
culture medium groups of SP vs. SP-HUES7 which showed better 
clustering. Nevertheless, as described in the previous section and 
illustrated here with a tight cluster of QCs for each PCA model, both 
systems demonstrated sufficient stability throughout the LC-MS analyses. 
The datasets used to build the PCA models contained 2025 and 1223 
variables (ions) detected in the MEF-CM and StemPro culture medium 
systems, respectively. Not surprisingly MEF-CM showed the highest 
number of variables since it is the medium with the most complex small-
molecule composition as shown in Table 1-2, chapter 1 and demonstrated 
here with the base peak chromatograms presented in Figure 5-2. 
134 
 
 
Table 5-1. Variation in retention time and signal intensity of selected peaks in positive and negative ESI mode for MEF-CM vs. MEF-CM-
HUES7 and SP vs. SP-HUES7 metabolomics experiments. 
MEF-CM vs. MEF-CM-HUES7 
 
 
SP vs. SP-HUES7 
Negative ESI mode 
 
 
Negative ESI mode 
 
Retention time, min 
 
Intensity (arbitrary units)  
  
Retention time, min 
 
Intensity (arbitrary units) 
Peak (m/z) mean ± SD %CV 
 
mean ± SD %CV  
 
Peak (m/z) mean ± SD %CV 
 
mean ± SD %CV 
218.1035 1.14 ± 0.01 1.23 
 
898510 ± 64366 7.16  
 
130.0874 1.10 ± 0.02 1.86 
 
897892 ± 24159 2.69 
351.0336 4.31 ± 0.02 0.48 
 
314342 ± 16707 5.31  
 
371.0596 3.75 ± 0.01 0.38 
 
1724432 ± 55433 3.21 
313.0179 7.47 ± 0.03 0.39 
 
36467 ± 4278 11.73  
 
429.0805 7.42 ± 0.01 0.17 
 
42244 ± 2587 6.12 
558.3338 10.17 ± 0.02 0.15 
 
331804 ± 23973 7.23  
 
530.3021 9.30 ± 0.00 0.00 
 
20632 ± 627 3.04 
309.2803 13.29 ± 0.01 0.11 
 
79654 ± 5788 7.27  
 
457.2267 12.45 ± 0.01 0.10 
 
119031 ± 9769 8.21 
      
 
       
Positive ESI mode 
 
 
Positive ESI mode 
 
Retention time, min 
 
Intensity (arbitrary units)  
  
Retention time, min 
 
Intensity (arbitrary units) 
Peak (m/z) mean ± SD %CV 
 
mean ± SD %CV  
 
Peak (m/z) mean ± SD %CV 
 
mean ± SD %CV 
175.0341 1.67 ± 0.03 1.62 
 
622764 ± 54790 8.80  
 
240.0954 0.89 ± 0.01 1.64 
 
2653292 ± 44479 1.68 
226.1802 5.87 ± 0.01 0.25 
 
88220 ± 4596 5.21  
 
377.1456 2.59 ± 0.03 1.12 
 
309751 ± 11500 3.71 
304.2998 8.29 ± 0.02 0.18 
 
284966 ± 12904 4.53  
 
266.1722 5.86 ± 0.01 0.17 
 
57789 ± 3136 5.43 
270.2791 11.38 ± 0.01 0.12 
 
1117404 ± 107040 9.58  
 
455.3481 10.87 ± 0.00 0.00 
 
28040 ± 1961 6.99 
338.3416 13.63 ± 0.02 0.14 
 
1636368 ± 148094 9.05  
 
327.2280 12.08 ± 0.01 0.08 
 
37284 ± 2312 6.20 
Data expressed as mean ± standard deviation (n=8). 
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a) MEF-CM vs MEF-CM-HUES7 
      
 
b) SP vs SP-HUES7 
 
Figure 5-3 PCA scores plots of fresh vs. cell-exposed media using a) MEF-CM and 
b) StemPro (SP). In both cases, a clear separation between the culture medium 
classes was observed, indicating metabolic differences. The stability of the LC-
MS system in each case is illustrated by the tight clusters of QC samples. 
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5.3.3.1 OPLS-DA model building and validation 
In order to find out the variables (metabolites) responsible for the 
separation of the culture medium groups in each metabolomics 
experiment, orthogonal partial least squares-discriminant analysis (OPLS-
DA) was applied. The inherent properties of OPLS-DA modelling to 
maximise the separation of the groups while minimising within class 
variation, in addition to its interpretational benefits (Bylesjo et al., 2006), 
allowed the extraction of the metabolites that contributed most 
significantly to the corresponding culture media separation. OPLS-DA 
models (Figure 5-4) were built independently for each metabolomics 
experiment with 75% of the samples (n=27) randomly selected from 
each data set. The remaining 25% (n=9) in each case was used for 
external model validation as explained later in this section. Initially, the 
OPLS-DA models were evaluated using the R2Y(cum) and Q2(cum) 
parameters (Table 5-2). As stated before in chapter 3, these parameters 
indicate respectively the fitness and prediction ability of the models; that 
is, how well the model fits the data and how well it predicts new data. For 
biological models, Q2 values above 0.4 are empirically acceptable 
(Westerhuis et al., 2008), indicating good classification models. Overall, 
the results shown in Table 5-2 indicate that both OPLS-DA models 
showed good data fitness and good data predictivity with R2Y(cum) and 
Q2(cum) values superior to 0.4. 
 
Table 5-2. OPLS-DA model evaluation parameters 
Experiment R2Y(cum) Q2(cum) 
CV-ANOVA, 
p-value 
MEF-CM vs. MEF-CM-HUES7 0.996 0.990 1.55x10–21 
SP vs. SP-HUES7 0.998 0.995 1.37x10–24 
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a) MEF-CM vs MEF-CM-HUES7 
 
 
b) SP vs SP-HUES7 
 
Figure 5-4 OPLS-DA models of fresh vs cell-exposed media using a) MEF-CM and 
b) StemPro. In red, samples used to build the OPLS-DA models (training set) 
and in blue, samples used for class prediction (prediction set) during the 
external model validation procedure. 
 
 
 
Prediction set 
Training set 
Prediction set 
Training set 
R2X(cum), 0.530 
R2Y(cum), 0.996 
Q2(cum), 0.990 
R2X(cum), 0.517 
R2Y(cum), 0.998 
Q2(cum), 0.995 
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Because supervised multivariate methods like OPLS-DA have a tendency 
to over-fit models to data, validation is critical in ensuring model 
reliability as well as in assessing their predictive ability (Westerhuis et al., 
2008). Here, cross-validation and external validation were used to 
validate the models. To assess the significance of the models a cross-
validation-analysis of variance (CV-ANOVA) test was performed on each 
OPLS-DA model. The results of the tests are displayed in Table 5-2. A 
model is considered significant when the resulting p-value is lower than 
0.05 (Eriksson et al., 2008). Since the results showed p-values << 0.05, 
they indicate that the class separation observed in each culture system is 
not just the result of chance but of true experimental differences. 
Additionally, the two OPLS-DA models were further validated through 
external predictions. For this, the 25% of the samples that were initially 
excluded during model building were used to assess the predictivity of 
the models. Figure 5-4 shows in blue the 25% of the samples used in the 
prediction set. It is observed that in each case the OPLS-DA model was 
able to predict the class membership of the corresponding culture 
medium samples. Altogether, the results from the two diagnostics -CV-
ANOVA and external validation- denoted highly significant and highly 
predictive OPLS-DA models for both metabolomics experiments.  
 
5.3.3.2 Discovery and identification of discriminating metabolites in the 
MEF-CM and StemPro culture systems. 
To select the metabolites (ions) that contributed most significantly to the 
separation of the culture medium groups (fresh vs. cell-exposed medium 
samples) in each culture system, the variable importance for the 
projection (VIP) value of each metabolite was taken into account. Ions 
with VIP values above 1.5 were selected and subjected to Student’s t-
tests to validate their significance. To correct for the multiple testing 
problem Bonferroni’s correction was applied (Vinaixa et al., 2012), 
therefore, only those ions with p-values below 2.47x10-5 and 4.09x10-5 in 
the MEF-CM and StemPro culture system, respectively, were considered 
significant (for a detailed explanation of the Bonferroni’s correction in 
metabolomics please refer to section 3.3.2.2 in chapter 3).  
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When a metabolite was found to be significantly different, then 
identification was carried out. The detailed method of compound 
identification has been described in section 2.3.6 and in the same way 
was applied here. Table 5-3 and Table 5-4 indicate respectively the 
compounds that increased or decreased significantly in the cell-exposed 
medium of each culture system. Whenever possible authentic standards 
were used to confirm the identity of the compounds; however, in many 
cases, metabolites remained without a definitive identification. 
Consequently, the metabolites will be discussed based on their putative 
identities assigned with a greater degree of confidence after comparing 
their MS/MS spectra with those registered in the databases’ spectral 
libraries or with those reported in the literature. About 87% of the 
compounds were assigned a putative identity; however, the rest of ions 
remained unidentifiable due to insufficient intensity for MS/MS or 
limitations in the databases’ repositories. MS/MS spectra of the identified 
compounds are provided in appendix C at the end of the thesis. 
In electrospray ionisation, compounds are typically found in the form of 
their protonated [M+H]+ or deprotonated [M-H]– ion depending on the 
ionization mode utilized. Nevertheless, the formation of anion (Cl-) and 
cation (Na+, K+, NH4
+) adducts of polar analytes that lack ionisable 
groups is also observed (Cech and Enke, 2001). For example, in the case 
of glucose which was found here as the sodium adduct [M+Na+]+, that is 
22.9898 units more than its exact mass 180.0634 ( 
Figure 5-5). This observation is consistent with what has been reported in 
the literature (Koulman et al., 2009) and helps to confirm the identity 
assignment for the ion at m/z 203.0524 (Table 5-4). 
 
 
 
                           
 
Figure 5-5 Under electrospray ionisation, polar compounds like glucose (a) 
which lack ionisable groups form sodium adducts (b); thus, they are detected as 
the [M+Na+]+ rather than the typical [M+H+] +. 
O
OH
OH
OH
OH
OH Na
+
O
OH
OH
OH
OH
OH
a)            b) 
Exact mass 180.0634 m/z 203.0524 
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Table 5-3 Tentative compounds significantly increased in spent culture media after 24 h exposure to hESC. 
Putative identification Formula Ion 
RT 
(min) 
Accurate 
mass (m/z) 
Δ ppm 
Fold change Database 
reference MEF-CM StemPro 
L-Lactic acid C3H6O3 [M–H]
– 0.78 89.0245 -0.8 2.57 31.75 HMDB00190 
Unknown 
 
[M+H]+ 0.82 214.0060 
 
3.82 3.32 
 Pyruvic acid C3H4O3 [M–H]
– 1.09 87.0088 0.2 1.57 
 
HMDB00243
L-Alanine C3H7NO2 [M+H]
+ 1.12 90.0551 -0.7 2.11 7.13 HMDB00161 
2-Hydroxy-3-methylbutyric acid C5H10O3 [M–H]
– 1.72 117.0558 -0.5 N/A 
 
HMDB00407 
Unknown 
 
[M–H]– 2.17 188.0927 
 
N/A 
  (R)-3-Hydroxyhexanoic acid C6H12O3 [M–H]
– 3.05 131.0714 0.3 18.14 
 
HMDB10718
L-Acetylcarnitine C9H17NO4 [M–H]
– 3.37 202.1084 0.4 144.87 N/A HMDB00201 
Unknown 
 
[M–H]– 3.72 236.0928 
 
75.82 N/A 
 Unknown 
 
[M–H]– 3.84 204.0665 
 
2.02 
  Unknown 
 
[M–H]– 3.90 275.1041 
 
N/A 
  Unknown 
 
[M–H]– 4.30 327.0878 
 
1.40 
  9,12,13-TriHOME C18H34O5 [M–H]
– 6.05 329.2337 -1.3 1.78 
 
HMDB04708
LPC(14:0) C22H46NO7P [M+HCOO
–]– 8.33 512.2996 -1.5 
 
N/A HMDB10379 
LPC(16:1(9Z)) C24H48NO7P [M+HCOO
–]– 8.60 538.3155 -1.8 
 
N/A HMDB10383 
2-Hydroxymyristic acid C14H28O3 [M–H]
– 8.87 243.1965 0.2 1.65 50.53 HMDB02261 
(9S,10S)-9,10-dihydroxyoctadecanoate C18H36O4 [M–H]
– 9.01 315.2545 -1.1 1.50 
 
HMDB59633 
17-Hydroxylinolenic acid C18H30O3 [M–H]
– 9.06 293.2124 -0.7 2.60 
 
HMDB11108 
LPE(16:0/0:0) C21H44NO7P [M–H]
– 9.24 452.2784 -0.3 
 
N/A HMDB11503 
Unknown LPC 
 
[M+HCOO–]– 9.27 584.3577 
 
1.73 
  LPC(16:0/0:0) C24H50NO7P [M+HCOO
–]– 9.30 540.3307 -1.2 
 
12.73 HMDB10382
Unknown 
 
[M+H]+ 9.40 267.1716 
 
1.46 1.40 
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Table 5-3 continued 
        
Putative identification Formula Ion 
RT 
(min) 
Accurate 
mass (m/z) 
Δ ppm 
Fold change Database 
reference MEF-CM StemPro 
24-Oxo-1alpha,25-dihydroxyvitamin D3 C27H42O4 [M–H]
– 9.42 429.3011 -0.2 1.99 
 
HMDB60128 
LPE(18:1(9Z)/0:0) C23H46NO7P [M+H]
+ 9.46 480.3083 0.3 2.49 N/A HMDB11506 
PE(P-16:0e/0:0) C21H44NO6P [M+H]
+ 9.50 438.2980 -0.2 2.51 N/A HMDB11152 
LPC(18:1(9Z)/0:0) C26H52NO7P [M+HCOO
–]– 9.54 566.3463 -0.8 
 
27.64 HMDB02815 
Unknown 
 
[M+H]+ 9.64 417.3364 
  
N/A 
 Unknown 
 
[M–H]– 9.71 462.2991 
 
1.56 N/A 
 Myristoylglycine C16H31NO3 [M–H]
– 9.80 284.2231 0.2 3.17 N/A HMDB13250
2-hydroxy-heptadecanoic acid C17H34O3 [M–H]
– 9.86 285.2437 -0.6 1.40 
 
LMFA01050052 
20-HETE C20H32O3 [M–H]
– 9.97 319.2280 -0.4 2.44 
 
HMDB05998 
LPE(18:0/0:0) C23H48NO7P [M+H]
+ 10.06 482.3244 -0.6 
 
18.73 HMDB11130 
Monoacylglycerol (16:0/0:0/0:0) C19H36O3 [M–H]
– 10.16 311.2593 -0.3 2.41 
 
HMDB11564 
LPE(20:1(11Z)/0:0) C25H50NO7P [M+H]
+ 10.23 508.3399 -0.4 
 
N/A HMDB11512 
1alpha,22-dihydroxy-23,24,25,26,27-
pentanorvitamin D3 
C22H34O3 [M–H]
– 10.26 345.2437 -0.6 2.66  LMST03020011 
PE(O-18:1(9Z)/0:0) C23H48NO6P [M+H]
+ 10.36 466.3295 -0.6 
 
N/A LMGP02060004 
N-oleoyl ethanolamine C20H39NO2 [M+H]
+ 10.80 326.3053 0.1 2.34 
 
LMFA08040015 
2-Hydroxypalmitic acid C16H32O3 [M–H]
– 10.90 271.2281 -0.9 1.72 33.14 HMDB31057 
Myristic acid C14H28O2 [M–H]
– 10.85 227.2018 -0.9 
 
2.40 HMDB00806 
Linoleic acid C18H32O2 [M–H]
– 11.29 279.2329 0.1 
 
1.33 HMDB00673 
Docosapentaenoic acid C22H34O2 [M–H]
– 11.32 329.2488 -0.7 
 
N/A HMDB06528 
Hexadecenal C16H30O [M+H]
+ 11.34 239.2368 0.2 1.45 1.28 HMDB60482 
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Table 5-3 continued 
        
Putative identification Formula Ion 
RT 
(min) 
Accurate 
mass (m/z) 
Δ ppm 
Fold change Database 
reference MEF-CM StemPro 
3-hydroxystearic acid C18H36O3 [M–H]
– 11.49 299.2594 -0.8 2.06 6.64 HMDB10737 
14R-hydroxy-11Z-eicosenoic acid C20H38O3 [M–H]
– 11.62 325.2751 -1.0 2.81 
 
LMFA01050257 
Tetracosahexaenoic acid C24H36O2 [M–H]
– 11.64 355.2646 -0.7 3.68 
 
LMFA01030822 
Palmitic acid C16H32O2 [M–H]
– 11.91 255.2329 0.0 
 
3.95 HMDB00220 
Oleic acid C18H34O2 [M–H]
– 12.10 281.2487 -0.4 
 
18.77 HMDB00207 
Unknown 
 
[M+H]+ 12.42 381.2971 
 
1.47 1.55 
 Eicosadienoic acid C20H36O2 [M–H]
– 12.45 307.2644 -0.6 2.18 
 
HMDB05060
Eicosenoic acid C20H38O2 [M–H]
– 13.28 309.2802 -1.0 2.79 N/A HMDB02231 
 
Fold changes were calculated as the ratio of the average peak area (n=18) of the metabolites found in the cell-exposed medium and fresh culture 
medium either using MEF-CM or StemPro.  
Lyosophospholipids are highlighted with grey-shaded rows. 
LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamines; PE, phosphoethanolamine; TriHOME, trihydroxyoctadecenoic acid. 
N/A means that the metabolite was only found in the spent culture media. 
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Table 5-4. Tentative compounds significantly decreased in spent culture media after 24 h exposure to hESC.  
Putative identification Formula Ion 
RT 
(min) 
Accurate 
mass (m/z) 
Δ ppm 
Fold change Database 
reference MEF-CM StemPro 
L-Arginine C6H14N4O2 [M+H]
+ 0.70 175.1190 -0.3 -1.77 -2.34 HMDB00517 
L-Histidine C6H9N3O2 [M–H]
– 0.73 154.0623 -0.4 -1.32 -2.51 HMDB00177 
L-Lysine C6H14N2O2 [M–H]
– 0.74 145.0983 -0.5 -2.45 -5.21 HMDB00182 
L-Alanyl-L-glutamine C8H15N3O4 [M–H]
– 0.78 216.0990 0.0 -24.35 -33.30 HMDB28685 
D-Glucose C6H12O6 [M+Na]
+ 0.79 203.0524 4.2 -2.28 -2.62 HMDB00122 
Choline C5H14NO [M]
+ 0.81 104.1069 5.4 -1.86 -1.62 HMDB00097 
L-Glutamine C5H10N2O3 [M+H]
+ 0.88 147.0763 0.4 -2.77 -7.23 HMDB00641 
L-Valine C5H11NO2 [M–H]
– 0.91 116.0718 -0.5 -1.51 -7.04 HMDB00883 
L-Phenylalanine C9H11NO2 [M–H]
– 1.09 164.0718 -0.5 -1.59 -4.37 HMDB00159 
L-Tyrosine C9H11NO3 [M–H]
– 1.09 180.0667 -0.4 -2.05 -3.94 HMDB00158 
Pyridoxine C8H11NO3 [M–H]
– 1.10 168.0665 0.6 -2.83 -3.64 HMDB00239 
L-Leucine/Isoleucine C6H13NO2 [M+H]
+ 1.11 132.1019 0.0 
 
-1.72 HMDB00687 
L-Tryptophan C11H12N2O2 [M–H]
– 1.30 203.0826 -0.2 -1.16 -2.98 HMDB00929 
LPE(18:3(9Z,12Z,15Z)/0:0) C23H42NO7P [M–H]
– 8.40 474.2631 -1.0 -1.98 
 
HMDB11509 
LPC(18:3(9Z,12Z,15Z)) C26H48NO7P [M+HCOO
–]– 8.43 562.3155 -1.8 -1.86 
 
HMDB10388 
LPC(18:2(9Z,12Z)) C26H50NO7P [M+HCOO
–]– 8.92 564.3310 -1.6 -1.72 
 
HMDB10386 
LPC(22:5(4Z,7Z,10Z,13Z,16Z)) C30H52NO7P [M+HCOO
–]– 9.16 614.3469 -1.7 -2.40 
 
HMDB10402 
LPC(18:1(9Z)/0:0) C26H52NO7P [M+HCOO
–]– 9.54 566.3468 -1.8 -1.51 
 
HMDB02815 
LPC(P-16:0/0:0) C24H50NO6P [M+HCOO
–]– 9.58 524.3361 -1.8 -1.55 
 
HMDB10407 
Unknown 
 
[M+H]+ 9.65 492.3447 
 
-1.59 
  LPC(17:0) C25H52NO7P [M+HCOO
–]– 9.73 554.3467 -1.6 -1.60 
 
HMDB12108
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Table 5-4 continued 
        
Putative identification Formula Ion 
RT 
(min) 
Accurate 
mass (m/z) 
Δ ppm 
Fold change Database 
reference MEF-CM StemPro 
PS(O-20:0/0:0) C26H54NO8P [M–H]
– 9.90 538.3520 -1.1 -1.86 
 
LMGP03060001 
PE(P-20:0/0:0) C25H52NO6P [M+H]
+ 9.92 494.3604 0.1 -1.79 
 
LMGP02070004 
LPC(18:0) C26H54NO7P [M+HCOO
–]– 10.14 568.3619 -1.0 -1.71 -5.14 HMDB10384 
Stearidonic acid C18H28O2 [M–H]
– 10.29 275.2020 -1.4 -3.06 
 
HMDB06547 
LPC(20:0) C28H58NO7P [M+HCOO
–]– 10.45 596.3940 -2.2 -1.51 
 
HMDB10390 
Eicosapentaenoic acid C20H30O2 [M–H]
– 10.63 301.2173 0.1 -7.71 
 
HMDB01999 
Alpha-Linolenic acid C18H30O2 [M–H]
– 10.00 277.2175 -0.8 -2.54 
 
HMDB01388 
Docosahexaenoic acid C22H32O2 [M–H]
– 10.98 327.2332 -0.9 -2.54 
 
HMDB02183 
Palmitoleic acid C16H30O2 [M–H]
– 11.05 253.2175 -1.0 -1.72 
 
HMDB03229 
Arachidonic acid C20H32O2 [M–H]
– 11.17 303.2332 -1.0 -4.93 
 
HMDB01043 
Pentadecanoic acid C15H30O2 [M–H]
– 11.22 241.2175 -0.8 -2.34 
 
HMDB00826 
Docosapentaenoic acid C22H34O2 [M–H]
– 11.32 329.2484 0.5 -3.30 
 
HMDB06528 
Linoleic acid C18H32O2 [M–H]
– 11.33 279.2329 -0.0 -1.73 
 
HMDB00673 
(Z)-9-Heptadecenoic acid C17H32O2 [M–H]
– 11.58 267.2331 -0.8 -1.65 
 
HMDB31046 
Palmitic acid C16H32O2 [M–H]
– 11.90 255.2332 -1.1 -1.95 
 
HMDB00220 
Adrenic acid C22H36O2 [M–H]
– 11.91 331.2644 -0.5 -2.89 
 
HMDB02226 
Oleic acid C18H34O2 [M–H]
– 12.08 281.2488 -0.9 -1.36 
 
HMDB00207 
Heptadecanoic acid C17H34O2 [M–H]
– 12.44 269.2488 -0.9 -1.97 
 
HMDB02259 
Stearic acid C18H36O2 [M–H]
– 13.11 283.2645 -0.9 -1.50 
 
HMDB00827 
Fold changes were calculated as the ratio of the average peak area (n=18) of the metabolites found in the fresh culture medium and cell-exposed 
medium either using MEF-CM or StemPro. The sign was changed to indicate a decrease.  
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Another ‘atypical’ behaviour in electrospray ionisation is that of LPCs. Due 
to their zwitterionic molecular structure (Figure 5-6a), this group of 
phospholipids are commonly observed in the negative ESI mode as the 
demethylated ion [M–CH3]– or as the formate adduct [M+HCOO–]– (Fang 
et al., 2003). As an example, the full scan MS spectrum of LPC(18:3) is 
shown in Figure 5-6b. Although the chlorine ([M+Cl–]–) and the formic 
acid-sodium formate ([M+HCOONa+HCOO–]–) adducts are also observed, 
their abundance are considerably inferior to the [M–CH3]– or [M+HCOO–
]– ions. Therefore, in Table 5-3 and Table 5-4, LPCs are reported as the 
[M+HCOO–]– adduct since it was the ion that produced the most intense 
peak under the LC-MS conditions used in this study. It should be noted 
that LPCs can also be detected in the positive ESI mode as the 
protonated ion [M+H+]+ (as shown in Table 2-6, chapter 2); however, 
because in these metabolomics studies the positive ions of the LPCs 
provided less discriminatory power than their corresponding negative 
ones, they were not reported in Table 5-3 and Table 5-4. 
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Figure 5-6 a) Chemical structure and b) full scan MS spectrum of 
lysophosphatidylcholine (18:3). The table insert shows the m/z values of the 
most commonly found adducts of this LPC. 
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5.3.4 Biological significance of increased metabolites in spent 
culture media 
Fifty metabolites were found to be significantly increased in the culture 
media after exposure to hESC, ranging from very polar to non-polar 
compounds. Increased metabolites included glycolysis by-products such 
as lactate and pyruvate and some others like hydroxylated fatty acids, 
LPCs, LPEs, vitamin D3 derivatives and free fatty acids. The two culture 
systems (MEF-CM and StemPro) had in common 16 increased 
metabolites (Figure 5-7a), while 20 and 14 were found to be uniquely 
secreted in MEF-CM and StemPro spent media, respectively. In general, 
StemPro spent medium rendered larger fold changes than MEF-CM spent 
medium, but this was due to the absence (or low concentration) of those 
compounds in StemPro fresh medium (medium before cell exposure). On 
the contrary, the small fold changes observed with MEF-CM were due to 
the fact that the compounds were already present in MEF-CM fresh 
medium which made the ratios (metabolite in spent medium/metabolite 
in fresh medium) smaller. Nevertheless, in both cases, the changes were 
statistically significant following correction for multiple comparisions 
(Bonferroni’s correction), indicating that the increases were indeed the 
result of hESC metabolism. There were other metabolites however that 
showed more substantial changes in MEF-CM spent medium like the 
putatively identified 3-hydroxyhenanoic acid, L-acetylcarnitine, and the 
unknown ion at m/z 236.0928, the last two also found in StemPro spent 
medium, which could potentially be used as a metabolic signature of 
hESC in culture. 
              
Figure 5-7 a) Venn diagram of significantly increased metabolites found in spent 
culture media using MEF-CM (dark blue) and StemPro (light blue). 16 
metabolites were commonly identified in both spent culture media, while 20 and 
14 were uniquely identified in MEF-CM and StemPro spent media, respectively. 
b) Venn diagram representing the amount of increased lysophospholipids (LPLs) 
found in each culture system, again MEF-CM (dark blue) and StemPro (light 
blue). 
 
 2 
10 
  20 16 14 
a)     b) 
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Of particular interest were the range and abundance of lysophospholipids 
(LPLs) secreted by human embryonic stem cells when StemPro was used 
as culture medium. In total, ten LPLs (4 LPCs and 6 LPEs) were found to 
be significantly increased in StemPro spent medium compared to 2 in 
MEF-CM spent medium (Figure 5-7b). The reason of why fewer LPLs were 
increased when MEF-CM was used might be because LPEs and LPCs were 
already present in the medium, provided by the knock out serum 
replacement (as shown in chapter 2) used for the preparation of MEF-CM. 
Therefore, in case the cells require the use of these types of compounds 
(as it will be shown later in section 5.3.5), cells can simply take them 
from the medium and it might not be necessary to secrete them. In 
support of the increased levels of LPLs, phospholipase A2, the enzyme 
that hydrolyzes phosphatidylcholines to release fatty acids and LPCs, has 
been identified in H1 and H9 hESC cell lines (Sarkar et al., 2012), thus, 
providing evidence that LPLs can be produced and secreted by hESC.  
It was interesting to observe that when hESC were grown in the absence 
of LPLs as in the case of StemPro, cells were able to synthesise them and 
release them to the extracellular microenvironment, while when they 
were cultured in a lysophospholipid-rich medium like MEF-CM, cells 
seemed to incorporate them (Table 5-3 and Table 5-4). It has been 
widely demonstrated that LPLs are not simply metabolites for membrane 
phospholipid synthesis but also bioactive compounds that act as 
extracellular signalling molecules activating specific G-protein coupled 
receptors (GPCRs) (Rivera and Chun, 2008, Hla et al., 2001). The most 
widely studied LPLs are lysophosphatidic acid (LPA) and sphingosine-1-
phosphate (S1P) which have been shown to mediate a wide range of 
cellular processes such as proliferation, survival, adhesion, migration, 
morphogenesis and differentiation in a large number of cell types 
including T cells (Huang et al., 2002), neurons (Choi and Chun, 2013), 
vascular endothelial cells (Yatomi, 2006), lung cells (Brinkmann and 
Baumruker, 2006) and stem cells (Pebay et al., 2007, Avery et al., 
2008).  
In human embryonic stem cells, exogenous LPA does not appear to have 
any biological effect; however, S1P, in combination with platelet-derived 
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growth factor (PDGF), maintained hESC undifferentiated in the absence 
of serum (Pebay et al., 2005). Furthermore, in various mammalian cells 
(e.g. ovarian cancer cells, mast cells, glioblastoma stem cells) LPA and 
S1P have also been identified with autocrine and paracrine functions (Xie 
et al., 2002, Alvarez et al., 2007). Nonetheless, in the present study, 
neither LPA nor S1P were detected in the extracellular microenvironment 
of hESC with either culture medium.  
It should be noted however that potential precursors for LPA were indeed 
identified. For example, as shown in Figure 5-8, LPA can be formed by 
hydrolysis of phosphatidic acid or LPCs or by the phosphorylation of 
monoacylglycerol (Pages et al., 2001). In the current study, LPCs and 
monoacylglycerol both with a 16-carbon moiety (as LPA) were identified. 
Therefore, it is possible that the LPCs and the monoacylgycerol secreted 
to the medium might be transformed to LPA by the action of 
lysophospholipase D (lysoPLD) or monoacylglycerol kinase, respectively 
(Figure 5-8). Although there is no evidence of the existence of these 
enzymes in the hESC secretome (Bendall et al., 2009, Sarkar et al., 
2012), the possibility of extracellular LPA synthesis cannot be completely 
discarded, because as demonstrated by Bendall et al, in MS-based 
proteomics analyses, many low abundant proteins are masked by the 
most abundant ones thus suggesting that there may be many low 
abundant proteins that remain to be identified (Bendall et al., 2009). 
Even in the remote case that LPA could be synthesised extracellularly, it 
remains unknown whether obtained in this manner it would have an 
effect on hESC since when added exogenously LPA did not show any 
effect, in spite of the identification of LPA receptors on hESC (Pebay et 
al., 2005). Alternatively, the LPLs identified could mediate some 
biological activities by themselves as it will be described in section 5.3.5 
where LPLs were found to be significantly decreased in MEF-CM. 
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Figure 5-8 Biosynthetic routes of lysophosphatidic acid (LPA), a potent bioactive lysophospholipid. Different synthetic pathways for the 
formation of LPA have been identified (Pages et al., 2001) including the hydrolysis of LPCs by the action of lysophospholipase D and the 
phosphorylation of monoacylglycerol by monoacylglycerol kinase. In blue are depicted the potential precursors of LPA that were detected 
in hESC spent culture media. PLA, phospholipase. 
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Other compounds that were significantly increased in the media exposed 
to hESC were lactic acid, pyruvic acid, hydroxylated fatty acids (e.g. 3-
hydroxyhexanoic acid, 3-hydroxystearic acid) and L-acetylcarnitine, 
implicated in glycolysis and fatty acid metabolism, respectively, but with 
no function directly associated with hESC maintenance. Nevertheless, 
these metabolites provided valuable insights of the metabolic events 
occurring during the in vitro cultivation of undifferentiated hESC. Their 
increased levels in the spent media could be explained as follows. 
Undifferentiated hESC are characterised by a low mitochondrial mass, 
reduced mitochondrial reactive oxygen species (ROS) production and by 
a small number of mitochondria when compared to their more mature 
differentiated-derivatives which are characterised by an increase in 
mitochondrial mass and number as well as higher ROS activity 
(Armstrong et al., 2010, Rehman, 2010) (Figure 5-9). As a result, 
undifferentiated hESC rely more on glycolysis (occurring in the cytosol) to 
meet their energy demands than on the Kreb’s cycle and oxidative 
phosphorylation (OxPhos) metabolic pathways that take place in the 
mitochondria (Varum et al., 2011, Shyh-Chang et al., 2013). The end 
products of glycolysis are lactate and pyruvate which can exit the cell or 
be further metabolised. Particularly, pyruvate can be transformed in the 
mitochondria by pyruvate dehydrogenase (PDH) to acetyl-coenzyme A 
(Ac-CoA) and enter the Kreb’s cycle to be further oxidised by OxPhos to 
produce adenosine triphosphate (ATP), although at the expense of 
generating ROS in the process (Zhang and Gutterman, 2007). However, 
because undifferentiated hESC have low mitochondrial mass and reduced 
mitochondrial number, only a small portion of Ac-CoA could enter the 
Kreb’s cylce and the rest would start to accumulate. Therefore alternate 
routes may be required by the cells to dispose of the excess of Ac-CoA, 
otherwise, more Ac-CoA could be metabolised by the mitochondria and 
more ROS released to the cytosol which would increase the oxidation 
state of the cells and lead to differentiation (Yanes et al., 2010, Shyh-
Chang et al., 2013, Tsatmali et al., 2005, Smith et al., 2000). One 
possible route is to use Ac-CoA for fatty acid biosynthesis or alternatively 
transform Ac-CoA to L-acetylcarnitine which can then be transported to 
the cytosol (Schroeder et al., 2012, Pettegrew et al., 2000) where it 
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could finally be secreted to the extracellular space. These alternative 
metabolic pathways could explain the increased concentrations observed 
of fatty acid intermediates and fatty acid metabolites (both with hydroxyl 
groups in the carbon backbone) as well as the increase of L-
acetylcarnitine in the cell-exposed media. Nevertheless, metabolomics 
experiments targeting these metabolic routes and metabolites would be 
required to confirm these observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-9 Upper panel: undifferentiated hESC and mature (differentiated) cell. Pluripotent 
stem cells show high expression of pluripotency markers such as Oct4 and Sox2 but low 
mitochondrial mass and number as well as reduced production of reactive oxygen species 
(ROS) (Rehman, 2010). They rely on glycolysis for their energy needs. On the contrary, 
differentiated cells show reduced expression of pluripotency markers and increased 
mitochondrial activity (oxidative metabolism) associated with high production of ROS. 
Lower panel: Metabolic events occurring in undifferentiated hESC during in vitro culture 
explaining increases in the concentration of metabolites like pyruvate, lactate, L-
acetylcarnitine (L-Ac-carnitine) and hydroxylated fatty acids as well as the reduction of 
glucose in the spent culture media. PDH, pyruvate dehydrogenase; Ac-CoA, acetyl-
coenzyme A. 
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Interestingly, some of the compounds identified previously in chapter 3 
as significantly increased in MEF-CM, after the medium conditioning 
process, were further increased after exposure to hESC which suggests 
that they were not required by the cells; furthermore, that hESC also 
produced them. These compounds were 9, 12, 13-TriHOME and the ion at 
m/z 345.2437 putatively identified as 1alpha, 22-dihydroxy-23, 24, 25, 
26, 27-pentanorvitamin D3 (Table 5-3). The potential role of these 
metabolites in the maintenance of pluripotent hESC has been discussed 
in chapter 3 and 4, but since they seem not to be used by the cells, it is 
believed that these metabolites might be just excretion products of hESC 
metabolism. Furthermore, these metabolites were only observed when 
MEF-CM was used. 
As mentioned in chapter 3, the main source of 9, 12, 13-TriHOME is 
linoleic acid (Funk and Powell, 1983, Nording et al., 2010) which 
consistently appeared here in the list of significantly decreased 
compounds of MEF-CM (Table 5-4). However, when cells were cultured in 
StemPro, linoleic acid appeared significantly increased and no 9, 12, 13-
TriHOME was observed. A similar case occurred with docosapentaenoic 
acid (DPA). DPA decreased in MEF-CM but increased in StemPro spent 
medium. The reasons for these metabolic differences are not completely 
understood, but certainly indicate that hESC metabolism adjusts in 
response to the surrounding environment (i.e. culture medium).  
Due to limitations in the available databases repositories many 
metabolites that were observed to increase significantly in the spent 
culture media remain unidentified. Consequently, their relevance in hESC 
culture could not be assessed. Whether some of the unknown metabolites 
exert a biological effect on hESC, it still remains to be determined.  
 
 
 
 
153 
 
5.3.5 Biological significance of decreased metabolites in spent 
culture media 
Thirty nine compounds in MEF-CM and 14 in StemPro were significantly 
reduced after exposure to hESC (Table 5-4, Figure 5-10), suggesting that 
they were used by the cells; however, it is possible that they could have 
been adsorbed/absorbed by the culture substrate (Matrigel) too as it will 
be discussed later.  
 
 
 
 
 
 
 
 
Differences in the chemical composition between MEF-CM and StemPro 
(Table 1-2, chapter 1) are reflected here in the number of nutrients 
potentially consumed by hESC from each culture medium. Because 
StemPro is a serum-free medium, the cells are limited to a smaller 
number of nutrients; namely, amino acids and vitamins which are the 
major small-molecule components of StemPro (Wang et al., 2007). 
Therefore, it is not unexpected that most of the compounds that were 
significantly reduced in StemPro after culture with hESC were amino 
acids and vitamins (Table 5-4). Surprisingly, however, was the 
observation of a significant decrease of LPC(18:0), a compound not listed 
in the StemPro formulation and that most probably originated from the 
BSA used in StemPro manufacturing as it was discussed earlier in section 
5.3.1. To confirm that the LPC(18:0) observed in StemPro fresh medium 
was not part of the LC-MS system or any other contamination during 
sample preparation, extracted ion chromatograms of a blank and 
StemPro before hESC culture were compared (Figure 5-11). The results 
indicated that StemPro indeed contained traces of LPC(18:0) since there 
  26 13 1 
Figure 5-10 Venn diagram representing the compounds significantly decreased  
in MEF-CM (dark green) and StemPro (light green) after 24 h exposure to hESC.  
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were no signs of carryover or contamination in the blank (Figure 5-11). 
In the same manner, arachidonic acid (m/z 303.2329) and LPC(16:0) 
(m/z 540.3312), not listed in StemPro recipe (Wang et al., 2007), were 
also confirmed to be present. As a consequence, it could be said that 
StemPro is not a complete chemically defined medium and that its 
‘known’ composition is somewhat deceptive since there are compounds 
associated with BSA that are not published in its chemically defined 
formula. Furthermore, that some of these unpublished compounds may 
be relevant for hESC since, as demonstrated here, they appeared to be 
used by hESC in culture.  
 
 
Figure 5-11 Extracted ion chromatograms of the ion m/z 568.3622 (LPC(18:0)) 
in a) blank and b) StemPro before hESC culture confirming the presence of this 
lysophospholipid in StemPro culture medium, even though it does not appear in 
StemPro published formulation (Wang et al., 2007).  
 
 
As with StemPro, MEF-CM also showed reduced quantities of amino acids 
and vitamins. However, because MEF-CM is a complex, serum 
replacement-containing medium (which provides more nutrients to the 
cells), other MEF-CM components were also significantly reduced; 
amongst them, lysophospholipids and free fatty acids. Interestingly, most 
of the LPLs that were reduced contained 18-carbon length moieties, 
although entities of 16- and 20-carbon chains were also observed. It is 
still unclear however whether these LPLs were taken by the cells or if 
they were adsorbed to the substrate Matrigel. The most abundant 
constituents of Matrigel are laminin, type IV collagen, perlecan (a 
heparan sulfate proteoglycan) and entactin (Kleinman and Martin, 2005). 
As published by Roberts et al, these are a group of glycoproteins that 
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bind more specifically and with high affinity to sulphated glycolipids and 
show very low or null binding to phospholipids (Roberts et al., 1985); 
thus, strongly suggesting that the reduced LPLs were most likely used by 
the cells rather than being adsorbed to Matrigel, although there may be 
other unknown components of Matrigel that could have also sequestered 
the LPLs however this is unknown. Whether hESC used the LPLs, the next 
question would be, what could hESC have used LPLs for? It has been 
reported that LPLs, including LPCs, induce the expression of adhesion 
molecules such as vascular cell adhesion molecule-1 (VCAM-1) and 
intracellular adhesion molecule-1 (ICAM-1) in a wide variety of cells 
including prostate cells (YPEN-1 cell line), human embryonic kidney cells 
(293T cell line), leukocytes, human umbilical vein endothelial cells 
(HUVECs) and splenic B cells (Zou et al., 2007, Kume et al., 1992, Rieken 
et al., 2006, Lee et al., 2004). Therefore, it might be possible that hESC 
take the LPLs listed in Table 5-4 from the medium to enhance cell 
attachment and consequently their proliferation; however, no study has 
been published to support this notion. 
With regard to the fatty acids that were decreased in spent culture 
medium, it was observed that amongst them, the most highly consumed 
were mono- and poly-unsaturated fatty acids as compared to relatively 
few saturated ones (Table 5-4, Figure 5-12).  
 
 
Figure 5-12 Compounds significantly decreased in MEF-CM after 24 h exposure 
to hESC. Note the large proportion of unsaturated fatty acids potentially 
consumed by hESC as compared to the small proportion of saturated fatty acids. 
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In total, eleven unsaturated- and 4 saturated- fatty acids were 
significantly decreased in MEF-CM after exposure to hESC. In agreement 
with these results, Yanes and colleagues, by studying the intracellular 
metabolites of hESC (also cultured with MEF-CM), reported that 
undifferentiated hESC were characterised by abundant unsaturated 
molecules (Yanes et al., 2010) and that such compounds were important 
in the regulation of the cellular redox status since they are reactive and 
susceptible to oxygenation and hydrogenation reactions which ultimately 
can mediate the balance between self-renewal and differentiation (Yanes 
et al., 2010, Rehman, 2010). Examples of polyunsaturated fatty acids 
that were reduced in MEF-CM after hESC exposure are linolenic, 
docosapentaenoic, arachidonic and eicosapentaenoic acids (Figure 5-13) 
which consistently were found in the metabolite profile of hESC 
performed by Yanes et al (Yanes et al., 2010). 
 
OH
O
OOH
OH
O
OOH
 
 
Figure 5-13 Examples of unsaturated fatty acids potentially incorporated by 
hESC when cultured with MEF-CM.  
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5.4 Conclusions 
The chemical investigation of the hESC secretome has become of vital 
importance in the identification of the autrocrine and paracrine factors 
released by hESC. In this study, the untargeted LC-MS-based 
metabolomics method developed in chapter 2 was applied and proved to 
be successful in the identification of a number of low-molecular weight 
factors secreted by hESC in culture. To the best of the thesis author’s 
knowledge, this is the most comprehensive metabolomics analysis of the 
hESC secretome which complements the discoveries of other research 
groups aiming at the identification of the protein components. 
The use of a chemically defined medium such as StemPro, in addition to 
the traditional MEF-CM, allowed a better appreciation of the secreted 
metabolites. For example, increases in the lysophospholipids levels were 
more noticeable in StemPro than in MEF-CM. Furthermore, comparison of 
the increased and decreased metabolites in both spent culture media 
highlighted the importance of lysophospholipids in hESC since when cells 
were cultured in the absence (or low abundance) of lysophospholipids like 
StemPro, hESC were able to produce and secrete them to the 
extracellular space, whereas when they were cultured in a 
lysophospholipid-rich medium like MEF-CM, hESC seemed to 
incorporate/use them. What is more, amongst the increased metabolites 
in the spent culture media, lysophospholipids were the ones with known 
biological activity. These results suggest lysophospholipids as potential 
small-molecule autocrine/paracrine factors; however, their precise role in 
the maintenance of hESC still remains to be determined. 
Overall, the use of an untargeted metabolomics method for the study of 
the hESC secretome has provided valuable and complementary 
information in our understanding of the molecular mechanism governing 
hESC which ultimately will aid in the development of more efficient 
protocols for the large-scale expansion of undifferentiated hESC in vitro. 
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6 General conclusions 
 
Through a series of metabolomics experiments this thesis aimed to 
identify small-molecule factors with potential biological activity in the 
proliferation and/or pluripotency of hESC. To accomplish this, an 
untargeted metabolomics method was developed and applied to the 
analysis of culture media used in in vitro growth of hESC.  
 
The metabolomics method, based on the use of liquid chromatography 
and mass spectrometry, was developed aiming the comprehensive 
analysis of the small molecule components of the culture media. The 
initial application of the method was the identification of the unknown 
components of UM. The analysis revealed that AlbuMax I, the constituent 
of knock out serum replacement, was responsible for the peaks observed 
after minute 6 of the chromatographic run. Several classes of lipids were 
identified including lysophosphatidylcholines, lysophosphatidylethanol-
amines, cholic-acid derivatives, fatty-acid amides and free fatty acids. 
The characterisation of the UM constituents represented one of the major 
achievements of the methodology as it was possible to enhance the 
chemical definition of a widely used hESC culture medium revealing not 
previously reported information that could help cell biologist to get a 
deeper understanding of hESC behaviour in vitro. 
 
The ability of the LC-MS method to provide putative identities to the 
components of UM surpassed previous attempts (Frankland et al., 2007, 
Garcia-Gonzalo and Izpisua Belmonte, 2008) trying to characterise such 
components and that were only able to provide lipid classes rather than 
more defined identities. To date, the chemical characterisation achieved 
with the method developed in this thesis represents the most 
comprehensive chemical definition of UM. 
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The application of the methodology to the investigation of the 
metabolites secreted by MEFs into the conditioned medium successfully 
identified a number of compounds whose concentrations increased after 
the medium conditioning process. To the majority of these compounds a 
putative identity was assigned; however, due to limitations in the 
databases’ repositories some remained unidentified. Amongst the 
increased small molecules were compounds with known biological activity 
such as the prostaglandins PGE2 and 6-keto-PGF1α, 7-ketocholesterol 
and some polyunsaturated fatty acids like 9, 12, 13-TriHOME and 
stearidonic acid. The use of authentic standards finally confirmed their 
presence in MEF-CM. With the exception of PGE2 and 6-keto-PGF1α, the 
rest of molecules were for the first time identified in MEF-CM. 
 
In addition to the identification of increased metabolites in MEF-CM, the 
methodology was also able to detect those compounds whose 
concentrations declined after incubation with MEFs. Examination of the 
increasing and decreasing molecules led to the identification of some 
metabolic activities taking place during the conditioning of the medium. 
One of those metabolic activities identified was arachidonic acid 
metabolism. It was observed that while levels of arachidonic acid 
decreased, those of prostaglandins (PGE2 and 6-keto-PGF1α) increased. 
With the use of isotope labelled arachidonic acid, it was confirmed that 
MEFs, and not any enzyme present in the serum replacement, were 
responsible for the conversion of arachidonic acid into prostaglandins. 
 
The analysis of a series of MEF-CM obtained from different batches of 
MEFs or on different days employing the same batch of MEFs, showed 
chemical variability between MEF-CM batches and underscored the 
inconsistent and fluctuating conditions to which hESC are exposed to in 
routine culture. The information attained with these experiments might 
help understand the varying culture efficiencies reported in the literature 
(Villa-Diaz et al., 2009) when hESC are cultured with batches of MEF-CM 
obtained on different days. 
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Having successfully identified low-molecular weight factors in MEF-CM 
with potential biological activity, the compounds were investigated to test 
their effects on hESC. However, because it is unknown at what 
concentration they possibly exert their effects, it was decided to quantify 
the selected compounds in several batches of MEF-CM and use the grand 
mean in order to resemble the concentrations at which they are normally 
found in MEF-CM. PGE2, 6-keto-PGF1α, 7-ketocholesterol, 9, 12, 13-
TriHOME and stearidonic acid, previously confirmed with standards, were 
supplemented in combination to UM and tested for their effects. In spite 
of the stringent conditions (absence of growth factors) in which the 
compounds were investigated, it was observed that hESC cultivated in 
the presence of these chemicals could proliferate for at least one more 
passage compared to cells grown with UM alone (the negative control). 
For the first time it was demonstrated that small-molecule components 
identified in MEF-CM can mediate some proliferative effects. This 
represented another major achievement of the work undertaken in this 
thesis as the small molecules identified are potential candidates to the 
creation of more defined and efficient culture protocols or to the 
enhancement of others such as mTeSR1 or StemPro. Because of the lack 
of time, no further research could be done but some planned experiments 
derived from these results are proposed in the future work section. 
 
Due to the increasing evidence of the importance of autocrine and 
paracrine factors in the regulation of pluripotency and self-renewal of 
hESC, it was decided to study the hESC secretome. Employing the same 
methodology, the spent culture medium of hESC using MEF-CM or 
StemPro was investigated. The use of a less complex medium such as 
StemPro facilitated the identification of metabolites secreted by hESC 
under normal culture with Matrigel. Although all the identified metabolites 
provided insights into the metabolic activities of hESC in in vitro culture, 
the most relevant ones in terms of factors with potential biological 
activity were lysophospholipids. The importance of this class of lipids was 
identified due to the fact that when cells were cultured with StemPro (a 
lysophospholipid-free medium), hESC were able to secrete 
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lysophospholipids to their extracellular space, whereas when they were 
cultured in a lysophospholipid-rich medium like MEF-CM, they seemed to 
use them. Nevertheless, the precise biological activity of these 
compounds still remains to be determined and some proposed 
experiments towards this are described in the future work section. 
 
The work carried out with this thesis has demonstrated that the relatively 
unexplored small-molecule components of MEF-CM and hESC secretome 
can provide valuable information to understanding stem cell biology and 
the small-molecule requirements for their long-term expansion. At the 
same time, the information garnered with this metabolomics method 
complements the extensive work of other research groups aiming the 
identification of the protein components of MEF-CM and hESC secretome. 
 
The contribution of this work to the identification of potential low-
molecular weight factors that can mediate some biological activities in 
hESC may be important to the establishment of a more defined culture 
system for the full realization of hESC in clinic and other research areas. 
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FUTURE WORK 
 
Some proposed experiments derived from the results obtained in this 
thesis are detailed: 
 
Given that 9, 10, 13-TriHOME and 9, 12, 13-TriHOME are mainly 
produced by the oxidation of linoleic acid and that linoleic acid levels 
remain unchanged after medium conditioning in spite of the production of 
TriHOMEs, it is proposed to use deuterated LPC(18:2) to determine 
whether the levels of linoleic acid are being replenished by the hydrolysis 
of LPC(18:2). Similarly, the use of deuterated LPC (18:3) would confirm 
whether LPC(18:3) is used to replenish the levels of alpha-linolenic acid, 
the most likely substrate for the production of stearidonic acid, one of the 
PUFAs increased in MEF-CM. If the deuterated LPCs are indeed converted 
to the corresponding fatty acid, linoleic acid or alpha-linolenic acid, then 
it would be expected to observe the deuterated form of these fatty acids 
and possibly small quantities of deuterated TriHOMEs or stearidonic acid, 
respectively. These isotope labelling flux experiments would confirm 
some of the metabolic pathways occurring during the conditioning of UM 
and explain the unexpected high levels of linoleic and alpha-linolenic 
acids. 
 
In order to investigate more in depth how the age of MEFs influence the 
hESC growth efficiency of the MEF-CM they produce, it is proposed to 
perform PLS analysis where the X variables are the metabolites measured 
with the LC-MS methodology described in this thesis and the Y variables 
the percentages of cell viability, cell proliferation and percentage of 
undifferentiated cells observed with each batch of MEF-CM obtained on 
different days. The PLS model would reveal which X variables 
(metabolites) are correlated with the performance of the MEF-CM media. 
Likewise, this experiment can be repeated employing separate batches of 
MEFs in order to find out, in a more systematic way, which metabolites 
have major influence on the efficiency of MEF-CM batches. 
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With regard to the confirmation of metabolites present in MEF-CM, it 
would be necessary to test whether the structural isomer of calcitriol, 24, 
25-dihydroxyvitamin D3, matches the experimental data of the [M+H]+ 
ion at m/z 417.3360 in terms of full scan MS and tandem mass 
spectrometry since calcitriol failed to match them. Another experiment 
would be to improve the liquid-chromatography conditions of the current 
method in order to separate more efficiently the peaks of the standards 
9, 10, 13-TriHOME and 9, 12, 13-TriHOME and therefore verify with a 
greater degree of certainty which of the two TriHOMEs is present in the 
conditioned medium.  
 
It is also suggested to assess the biological activity of PGE2, 6-keto-
PGF1α, 7-ketocholesterol, 9, 12, 13-TriHOME and stearidonic acid in 
multiple ways. The first one, investigating each compound individually at 
varying concentrations and measuring cell viability and pluripotency 
markers to determine which one(s) exert a positive effect on the 
expansion of undifferentiated hESC. Another proposed experiment is to 
examine the compounds in a pairwise manner, also at varying 
concentrations, to look for any possible synergism. Once it has been 
determined which compound or mix of compounds (and the 
concentrations at which they perform the best) enhances the culture 
conditions, then it would be possible to add the selected compounds to 
defined culture media such as StemPro or mTeSR1 and subsequently 
determine whether the extra compounds improve the efficiency of such 
kind of media. In the first instance, the improved culture medium recipes 
would be tested with Matrigel as substrate. If successful, other synthetic 
substrates such as PE-TCPS, PMEDSAH and APMAAm would also be 
evaluated. 
 
For the analysis of the hESC secretome, it is recommended to repeat the 
experiment adding a second control which would consist in the incubation 
of StemPro and MEF-CM with Matrigel alone (without hESC) and 
consequently determine if the reduced concentrations of 
lysophospholipids observed with both media are due to their adsorption 
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or absorption to Matrigel or because they were indeed used by the cells. 
It would be expected that the levels of the lysophospholipids in the fresh 
media and in the media incubated with Matrigel alone would not differ 
significantly; therefore suggesting that hESC consume/use the 
lysophospholipids during their in vitro culture. In order to confirm this 
outcome, hESC would be cultured with isotope labelled lysophospholipids 
and then carry out a metabolomics fingerprinting experiment employing 
Yanes et al method (Yanes et al., 2010). It would be expected to find 
isotope labelled lysophospholipids or any related isotope labelled 
metabolites such as free fatty acids as result of lysophospholipids 
hydrolysis. 
 
Finally, in the event that the lysophospholipids were absorbed or 
adsorbed to Matrigel, then the following experiment would be to test 
hESC growth efficiency under two conditions. Firstly, cultivating hESC 
over Matrigel using the standard protocol; and secondly, preconditioning 
Matrigel with non-labelled lysophospholipids to allow their adsorption or 
absorption and then continue with the standard culture protocol. By 
measuring the percentages of cell viability, cell proliferation and the 
number of undifferentiated cells, it would be determine whether or not 
the lysophospholipids have an impact on hESC growth. 
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Appendix A 
MS/MS spectra of compounds identified in unconditioned medium. 
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NL: 5.06E7
TIC  M S 130509-QC_04
NL: 6.70E6
TIC F: FTM S {1,2}  - p ESI Full ms [70.00-1000.00]  
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NL: 5.06E7
TIC F: FTM S {1,1}  + p ESI Full ms [70.00-1000.00]  
M S 130509-QC_04
350 400 450 500 550 600 650 700 750 800
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
414.3
432.3
450.3
472.3
339.3 506.2 605.4 703.6 746.0538.4 784.6637.5371.1
411.3
350 400 450 500 550 600 650 700 750 800
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
414.3
432.3
450.3
472.3
339.3 506.2 605.4 703.6 746.0538.4 784.6637.5371.1
411.3
+ESI 500.3038 
Taurodeoxycholic acid 
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-ESI 464.3021 
Glycocholic acid 
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Glycocholic acid 
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Lithocholyltaurine 
-ESI 407.2805 
Cholic acid 
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Appendix B 
Experimental MS/MS spectra of significantly increased and decreased 
metabolites in MEF-CM. 
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Appendix C 
MS/MS spectra of putatively identified metabolites significantly increased 
in MEF-CM and StemPro spent culture media. MS/MS spectra of the 
significantly decreased metabolites have been previously provided in 
chapter 2 and are shown in appendix A. 
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-ESI 284.223  
Myristoylglycine 
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-ESI 319.2280 
20-HETE 
-ESI 311.26 
Monoacylglycerol (16:0/0:0/0:0) 
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-ESI 345.2437 
1a, 22-dihydroxy-23,24,25,26,27-
pentarnorvitamin D3 
-ESI 271.22281 
2-Hydroxypalmitic acid 
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